The Role of Resveratrol and Sirtuin1 in Skeletal Muscle Under a Nutrient Stress by Dugdale, HF
  
The Role of Resveratrol 
and Sirtuin1 in Skeletal 
Muscle Under a Nutrient 
Stress 
 
 
Hannah Fox Dugdale 
 
A thesis submitted in partial fulfilment of the requirements of 
Liverpool John Moores University for the degree of Doctor of 
Philosophy 
 
January 2017 
 
 
  
2 
Abstract 
Dietary restriction (DR) is the only known nutritional manipulation that can 
increase both lifespan and healthspan in a variety of species. Underlying 
these increases are improvements in metabolic health and reductions in 
cancer incidence. Despite these physiological improvements, the 
regulation of skeletal muscle mass is extremely sensitive to alterations in 
nutrients [reviewed in (Sharples et al., 2015)] and as such has been 
reported to reduce regenerative potential and increase atrophy in skeletal 
muscle cells and myotubes. Interestingly, the activation of Sirtuin1 (SIRT1) 
has been reported during DR and its reduction abrogates lifespan 
extension. Importantly, SIRT1 activation via resveratrol treatment has 
been indicated to be important in the presence of inflammatory stress 
(TNF-α) (Saini et al., 2012). Resveratrol supplementation has also 
improved survival and regeneration of skeletal muscle cells as well in 
muscle cell remodelling following oxidative stress (Bosutti and Degens, 
2015). We therefore sought to create an in-vitro physiological model of DR 
by mimicking levels of glucose in the circulation and interstitium in-vivo in 
response to DR (Chapter 3) as well as optimising the activation and 
inhibition of SIRT1 using resveratrol and SIRT1 inhibitor, EX-527 
respectively (Chapter 4). With our ultimate aim to investigate the potential 
role and mechanisms of the activation/inhibition of SIRT1 in ameliorating 
the degenerative/atrophic effect of DR in both differentiating myoblasts 
(Chapter 5) and mature myotubes (Chapter 6). Indeed, in Chapter 3 we 
present two models of reduced glucose; one reduced (medium/ MED) and 
the other blocked (LOW) differentiation and myotube hypertrophy. The 
former represented circulatory glucose blood levels (MED 1.13 g/L or 6.25 
mM) and the latter interstitial represented glucose levels (LOW 0.56 g/L or 
3.12 mM) of rodents under DR. In Chapter 4 we also suggest that within 
the in vitro muscle cell model, activation/inhibition of SIRT1 
phosphorylation (western blot analysis) was thought to be most effective at 
10 M of resveratrol and 100 nM of EX-527 respectively. In chapter 5, we 
observed that resveratrol treatment did not improve fusion when 
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administered to differentiating myoblasts. Resveratrol did however evoke 
increases in myotube hypertrophy under normal glucose conditions.  
Importantly resveratrol enabled improved myotube hypertrophy over an 
acute 24 h period when administered to existing mature myotubes in low 
glucose environments. If this finding translates to whole organisms and 
human populations it could provide healthspan improvements via 
reductions in fragility associated with loss of muscle mass in individuals 
undergoing dietary restriction. After this 24 h period resveratrol was unable 
to reduce myotube atrophy and the myotubes continued to atrophy, 
suggestive of a need for repeated resveratrol treatment to enable 
continued protection against muscle atrophy under low glucose conditions.  
SIRT1 activation increased Myogenic regulatory factor 4 (MRF4) gene 
expression under LOW glucose conditions which was associated with the 
observed improvements in myotube size at 24 h. Whereas, SIRT1 
activation via resveratrol treatment in normal glucose conditions 
modulated increased gene expression of Myosin heavy chain 7 (MYHC7) 
coding for the slow isoform while inhibition of SIRT1 (EX-527) lead to 
reductions in gene expression of MYHC 1, 2 and 4, coding for faster IIx, 
IIa, IIb isoforms respectively. Perhaps suggesting that elevated SIRT1 was 
important in the activation of genes coding for slower myosin heavy chain 
isoforms. Furthermore, while SIRT activation via resveratrol did modulate 
increases in IGF-I gene expression, it did not appear to modulate energy 
sensing AMP activated protein kinase (AMPK) vs. growth related Protein 
70 S6 Kinase (p70S6K) signalling pathways. However, SIRT1 inhibition 
increased AMPK activity in both low and normal glucose with 
corresponding mean reductions in p70S6K in normal glucose conditions. 
This indicates that perhaps normal SIRT1 activity was required for 
appropriate AMPK activation, which may therefore prevent the 
suppression of p70S6K and the corresponding reductions in myotube size 
observed in SIRT1 inhibitor conditions. Furthermore, during low glucose 
induced myotube atrophy resveratrol reduced gene expression of the 
negative regulator of muscle mass, myostatin and protein degradative 
ubiquitin ligase enzyme, MUSA1. Overall, SIRT1 activation via a single 
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dose of resveratrol appears to have a role in acutely negating the effect of 
low glucose induced myotube atrophy and promoting myotube 
hypertrophy when glucose is readily available.  
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1. Introduction 
1.1. Calorie restriction 
The strikingly simple intervention of calorie restriction (CR) originates from 
the 1935 publication by McCay et al. in which reduced energy intake 
extended both mean and maximum lifespan in rats. Despite its simplicity 
CR is often mistaken for a minimal or lack of dietary intake known as 
fasting, when literature actually describes CR as an absence of 
malnutrition, while maintaining meal frequency, neither of which are 
present during fasting (Selman, 2014).  CR is most accurately described 
as a 20-50% reduction in caloric energy intake in comparison to ad libitum 
(AL) counterparts (Longo and Mattson, 2014, Fontana and Klein, 2007, 
Mccay et al., 1935). Replication these initial findings have since been 
observed in yeast, worms and mice, with similar trends being observed in 
rhesus monkeys (Fontana et al., 2010, Masoro, 2005, Mattison et al., 2012, 
Colman et al., 2009, Harper et al., 2006, Weindruch et al., 1986, 
Kaeberlein et al., 2006, Mccay et al., 1939). Although compelling data 
suggests that humans display beneficial health improvements under CR 
conditions, the effect on human lifespan is inconclusive (Roth et al., 2002, 
Holloszy and Fontana, 2007), partly due to the lack of long term CR 
studies in humans perhaps due poor adherence/motivation to undertake  
long term CR.  
 
1.2. Dietary restriction  
Alternative investigations into CR involve manipulation of micro and/ or 
macro nutrients which differ from ad lib counterparts, in addition or 
independently to an overall changes in energy intake. For the purpose of 
this thesis the term dietary restriction (DR) will henceforth encompass both 
the traditional definition of CR and the aforementioned nutritional 
manipulations (Selman, 2014). Dietary restriction increases longevity 
(Longo and Mattson, 2014, Fontana and Klein, 2007, Mccay et al., 1935). 
Before establishing how DR is instrumental in delaying the onset of ageing 
it is important first to understand the ageing phenotype. Eukaryotic aging 
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is defined as increasing dysfunction in both tissue and organs as a whole 
and can be considered both as a chronological and biological process 
(Hekimi and Guarente, 2003, Tatar et al., 2003, Carter et al., 2007). A 
plethora of functional changes have been associated with this pathology 
including a reduction in tissue regenerative capacity, a decrease in 
endocrine response and increases in oxidative stress (Lightfoot et al., 
2014, Carter et al., 2007). Not only does DR reduces mortality via the 
reduction of these age related changes it also reduces the prevalence of 
morbidity. Disease risk reductions during DR include, but are not limited to, 
the prevalence of type II diabetes, hypertension and obesity, as well as a 
decline in some cancers and cardio-vascular disease (Longo and Mattson, 
2014, Lam et al., 2013, Carter et al., 2007). Therefore, regardless of the 
limited data to suggest that DR improves lifespan in humans, the 
implementation of DR reduces numerous physiological afflictions often 
associated with obesity and age and is therefore widely considered to 
improve healthspan. Skeletal muscle is one such tissue that maybe 
particularly susceptible to age related changes and DR.  
 
1.3. DR, muscle size regulation and regeneration 
During chronic DR, there may be an increased dependence on protein 
metabolism thus leading to reductions in skeletal muscle mass as a result 
of reductions in protein synthesis and increases in protein degradation 
(Ballor et al., 1988, Carter et al., 2007, Fulco et al., 2008). Indeed, 
pioneering work in 2003 suggested that cells prioritized maintenance/ 
survival over growth during starvation (Inoki et al., 2003). They reported 
increased AMPK activity and phosphorylated tuberous sclerosis 2 (TSC2) 
under starvation, TSC2 then inhibited mammalian target of rapamycin 
(mTOR) and other downstream substrates, including translation initiators 
and elongators P70S6K, 4EBP-1 and EIF2. This subsequently resulted in 
reduced cellular growth rates. Despite this, fascinatingly, but perhaps 
intuitively, the complex nature of skeletal muscle mass regulation has led 
to inconsistent adaptations following DR. Indeed, short-term DR has 
actually been shown to increased skeletal muscle stem cell availability and 
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repair following injury in young and old mice (Cerletti et al., 2012). And DR 
has been shown to reduce both the loss of total fibres as well as the 
atrophy of the remaining slow twitch fibres in a long-lived hybrid rat strain 
(Mckiernan et al., 2004).  DR also appears to delay or prevent age-related 
loss of SkM mass in rats and rhesus monkeys (Phillips and Leeuwenburgh, 
2005, Aspnes et al., 1997, Hepple et al., 2008, Mckiernan et al., 2011). 
These observations may be as a result of alleviating the production of 
chronically upregulated inflammatory cytokines during DR (Spaulding et al., 
1997a). When chronically upregulated, TNF-α regulates inflammatory, 
apoptotic and protein degradative pathways and is associated with 
reduced muscle size with age (Bruunsgaard et al., 2003a, Greiwe et al., 
2001, Bruunsgaard et al., 2003b, Brüünsgaard and Pedersen, 2003). 
However, the mediation of these pathways has been shown to be reduced 
following the attenuation of TNF-α due to the implementation of DR 
(Spaulding et al., 1997b, Phillips and Leeuwenburgh, 2005). In addition to 
the reduction of chronic inflammation, DR has also been documented to 
reduce apoptotic cell death (Cohen, 2004), as well as oxidative and DNA 
damage, among other factors (Carter et al., 2009).   
 
 In humans, chronic DR (by 30% of recommended daily intake) for an 
average period of 9.6 years, resulted in reduced growth factor expression 
of insulin-like-growth-factor I (IGF-I) levels. Additionally AKT 
phosphorylation was reduced by 35 - 50% under DR conditions, consistent 
with the observed reductions in transcription, an important finding due to 
the AKT pathways’ associated involvement in growth/ protein synthetic 
signaling. Furthermore, in the same study authors showed the reduction in 
AKT resulted in an increase in genes associated with protein degradation, 
including FOXO3a (Mercken et al., 2013). Yet with increased FOXO3a the 
authors also observed increased genes associated with stress resistance 
and DNA repair (Mercken et al., 2013) as suggested above (Carter et al., 
2009).  Therefore, it is worth noting that with DR, this decrease in protein 
synthetic signaling, increase in protein degradation and shift from growth 
towards stress resistance, would potentially reduce protein synthesis and 
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increase degradation over time (Sandri et al., 2004, Edström et al., 2006) 
It is also worth noting that despite some unintuitive findings with respect to 
the influence of DR on muscle mass regulation some in-vivo studies that 
investigate the impact of DR on skeletal muscle mass provide muscle 
mass relative to fat mass or total mass, with DR animals reportedly 
possessing higher lean mass to fat mass and/ or total mass ratio, 
therefore perhaps underestimating the influence of DR on lean mass. 
(Colman et al., 2008, Mckiernan et al., 2011) (Mckiernan et al., 2011). 
Furthermore, even if muscle mass is maintained during a specific DR 
regimen, the ability of skeletal muscle to undergo hypertrophy may also be 
limited. This was observable within combined diet and resistance exercise 
training studies, where the loss of muscle mass experienced with DR in 
human cohorts was diminished when undertaken alongside resistance 
exercise in comparison to DR alone (Larson-Meyer et al., 2006, Ballor et 
al., 1988, Weiss et al., 2007, Ross et al., 2000, Janssen and Ross, 1999).  
 
As aluded to above, in addition to the reductions in AKT activity (Mercken 
et al., 2013) a reduction in the insulin/IGF signaling pathway is also 
present and has been previously associated with increased lifespan and 
healthspan in model organisms (Clancy et al., 2001, Holzenberger et al., 
2003, Barbieri et al., 2003, Tatar et al., 2003, Giannakou and Partridge, 
2007, Piper et al., 2008, Selman et al., 2008, Vallejo et al., 2009, Kenyon, 
2011, Selman et al., 2011). With ageing however, where considerable 
muscle loss occurs, there is a paradoxical reduction of approximately 33% 
in circulating IGF-I (Benbassat et al., 1997) and a 45% decline in SkM-
derived IGF-I mRNA in older (70 ± 0.3 years) vs. younger (20 ± 0.2 years) 
human males (Léger et al., 2008). These observations indicate that 
although DR may reduce IGF-I to evoke improvements in lifespan and 
healthspan, reduced IGF-I is associated with reductions in muscle mass 
with age.  Indeed, this is demonstrated in insulin receptor substrate 1 
(IRS1) knockout mice (required for intracellular signalling following 
successful IGF-I/IGFI receptor binding), where despite having increased 
lifespan, have reduced body weight and fat mass compared to age-
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matched controls (Pete et al., 1999, Selman et al., 2008) and importantly 
have reduced gastrocnemius skeletal muscle weight that is proportionately 
greater than the decrease seen in total body weight (Pete et al., 1999). 
 
 
DR therefore may be a successful intervention at improving lifespan and 
healthspan and evidence suggests in animal models that DR does not 
affect muscle mass possibly due to a reduction in inflammation 
Contradictory evidence suggests however that DR evokes a reduction in 
IGF-I and related signalling associated that is also observed with muscle 
loss in older age. Finally, the loss of cellular differentiation capabilities in 
myoblasts have been observed in low glucose conditions (Elkalaf et al., 
2013, Khodabukus and Baar, 2014). Fulco et al. (2008) suggested that 
increased activation of Sirtuin 1 (SIRT1) was responsible for the observed 
impaired differentiation in low glucose conditions.  Fulco et al. (2008) 
further suggests that this mediated via activation of the energy dependent, 
AMPK pathway, in which the expression of downstream genes such as 
FOXO, atrogin1/ MAFbx and MuRF1 associated with protein degradation 
are up regulated (Nakashima and Yakabe, 2007) an observation 
discussed later in this introduction under section 1.6, however suggests 
that further SIRT1 activation may be important under DR in skeletal 
muscle cells.  
 
1.5. SIRT1 and DR 
Indeed, Sirtuin 1 (silent information regulator/ SIRT1) is a nicotinamide 
adenine dinucleotide (NAD+) dependant class III histone deacetylase, the 
closest homologue of all seven mammalian Sirtuins to the yeast Sir2 
enzyme (Boily, 2008, Inoue et al., 2007). Both SIRT1 and Sir2 are 
activated via an increase in the NAD+: NADH ratio (Canto and Auwerx, 
2008, Bk, 2006). This reliance on nutrient sensing has led to extensive 
research on the involvement of Sir2 in yeast and more recently SIRT1 in 
mammalian longevity experienced during DR (Baur et al., 2012, 
Brenmoehl and Hoeflich, 2013, Gurd et al., 2011, Mercken et al., 2014a). 
Sir2 overexpression improves lifespan in budding yeast and similar trends 
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have been recorded regarding SIRT1 in mammalian models (Kaeberlein et 
al., 1999, Herranz et al., 2010).  
 
The effect SIRT1 has on lifespan is demonstrated by Boily (2008), in 
which the maximal survival of SIRT1 null mice is 24 months compared to 
approximately 32 months in similar wild type counterparts (Harper et al., 
2006). This suggests that adequate SIRT1 is required for normal lifespan. 
Furthermore, this reduced lifespan is further exacerbated by the 
employment of DR in these mice (Boily, 2008). These findings are 
indicative of SIRT1 knockout mice being unable to adapt to reduced 
calorie intake, thus highlighting the importance of SIRT in longevity during 
DR. Also, administration of the SIRT1 activator, STR2104 in murine 
populations has resulted in lifespan improvements similar to that observed 
during DR (Mercken et al., 2014b). Additionally, the use of an alternate 
SIRT1 activator, resveratrol has also shown improvements in age related 
diseases and ultimately lifespan in mice, albeit the most prominent 
research suggests this phenomenon is more likely to occur on a 
background of a high fat diet (Baur et al., 2006, Pearson et al., 2008, 
Barger, 2008). Short-term resveratrol supplementation in humans also 
elicits similar metabolic and inflammatory adaptations as those observed 
during DR (Timmers et al., 2011). Unfortunately, there are inconsistencies 
in the literature regarding overexpression of SIRT1 not always leading to 
lifespan improvements, however in these instances where longevity is not 
experienced, age-related disease prevalence appears to decline similarly 
to DR (Mercken et al., 2014b, Herranz et al., 2010), suggesting an 
important role in healthspan. Overall, it is evident that SIRT1 plays a 
significant role in both the life and health span experienced during DR.  
 
1.6. SIRT1 and skeletal muscle mass 
Although there is limited data regarding the effect of SIRT1 on skeletal 
muscle mass per se, its role in metabolism has been studied more 
extensively. Overexpression of SIRT1 in murine models has led to 
improved glucose uptake in skeletal muscle. In addition, the age-
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associated accumulation of nuclear foci of DNA damage proteins have 
been shown to be suppressed in comparison to wild type (WT) 
counterparts. Both these outcomes suggest a slowing in metabolic 
damage (Herranz et al., 2010). Bordone et al. (2007) implemented a 
transgenic mouse model (overexpresses SIRT1) and observed an 
increase in metabolic activity via increased oxygen and food consumption 
relative to body weight compared to their controls. SIRT1 may 
consequently play an important role in increasing metabolic activity, 
possibly preventing accretion of metabolic damage and ultimately inducing 
a reduction in overall pathological incidence. In some tissues, 
overexpression of SIRT1, despite no further improvements in lifespan, 
reduces pathological incidence such as eye infections and abnormal 
growths by 13% (Mercken et al., 2014a).  
 
There is also now emerging evidence that SIRT1 could also be involved in 
muscle mass regulation under stressful environments (see below). 
Overexpression of SIRT1 via the administration of SRT2014, during the 
employment of a 2 week hind-limb unloading protocol, has reportedly 
maintained skeletal muscle mass compared with unsupplemented controls, 
in addition to increasing rodent lifespan (Mercken et al., 2014b). Despite 
this, it has been observed that aged mice had a blunted hypertrophic 
response following synergistic ablation with a lower satellite cell 
content }and not as large an increases in in type II fibres vs. young adult 
mice (Ballak et al., 2015). However, resveratrol did not rescue the blunted 
hypertrophic response and actually even reduced, rather than increased, 
the number of satellite cells in the hypertrophied muscles. These findings 
indicate that SIRT1 may play an important role in stressful environments 
such as disuse and disease, yet perhaps not in basal ageing and warrants 
further investigation.  
 
1.6 Role of SIRT1 and DR in skeletal muscle cells in vitro:  
Adult skeletal muscle fiber number is set in-utero and adult fibers are post-
mitotic (incapable of cellular division) (Buckingham et al., 2003).. Despite 
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these phenomena, adult skeletal muscle is highly adaptable, readily 
responding environmental cues. Much of this adaptability (growth and 
repair) is achieved via resident adult stem cells, termed satellite or muscle 
precursor cells that have mitotic potential (Once activated these cells are 
termed myoblasts) (Brown and Stickland, 1993, Rudnicki et al., 2008, 
Charge and Rudnicki, 2004). 
 
Despite the sparse literature involving the role of SIRT1 in whole skeletal 
muscle maintenance, in vitro studies involving mouse skeletal muscle 
satellite cells, primary myoblasts and myoblast cell lines have also begun 
to be conducted. As previously discussed, the loss of differentiation 
capabilities in myoblasts, have been observed in low glucose (DR) (Elkalaf 
et al., 2013, Khodabukus and Baar, 2014). Also, as discussed above, 
Fulco et al. (2008) suggested that increased SIRT1 activity was 
responsible for impaired differentiation, mediated via activation of the 
energy dependent, AMPK pathway, in which the expression of 
downstream genes such as FOXO, atrogin1/ MAFbx and MuRF1 
associated with atrophy are up regulated (Nakashima and Yakabe, 2007).  
 
Contrary to this finding research by our group were first to demonstrate 
(Saini et al., 2012), with replication by Wang et al. (2014), a survival and 
regenerative effect of SIRT1 on myoblast differentiation when the SIRT1 
activator, resveratrol is administered together with an inflammatory 
cytokine known to induce an inhibition of myoblast differentiation, TNF-α 
(Saini et al., 2012). This is important given that TNF-α increases 
chronically in both the circulation and skeletal muscle tissue of elderly 
humans, and correlates with loss of muscle function, morbidity and 
mortality (Greiwe et al., 2001) (Greiwe et al., 2001, Bruunsgaard and 
Pedersen, 2003, Bruunsgaard et al., 2003a, Bruunsgaard et al., 2003c), 
Saini et al. (2012) observed an increase in SIRT1 mRNA associated with 
TNF-α induced cell death, which was further exacerbated through SIRT1 
inhibition by siRNA. However, death was rescued through SIRT1 
activation via resveratrol. These findings imply that SIRT1 is important in 
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cell survival. Furthermore, TNF-α induced reductions in differentiation 
were restored with SIRT1 activation via resveratrol administration also an 
indication that SIRT1 may actually be important in maintaining myoblast 
differentiation in stressful catabolic environments (Saini et al., 2012). 
Furthermore, resveratrol has been shown to improve myoblast migration 
(albeit not differentiation) in the presence of oxidative stress via hydrogen 
peroxide (Bosutti and Degens, 2016). Overall suggesting that SIRT1 
activation via resveratrol administration may mediate survival, remodelling 
and differentiation in muscle cells.  
 
1.7. Summary  
Despite the dramatic improvements in health observed under dietary 
restricted environments the chronic reduction in caloric intake may lead to 
impaired growth related signaling causing a potential breakdown in muscle 
protein over time. The activation of SIRT1 via resveratrol treatment in the 
presence of inflammatory and oxidative stress, has been previously shown 
to protect myoblasts from a loss of myotube formation and improve muscle 
cell remodelling, therefore the activation of SIRT1 under the alternate 
stress of DR may provide a similar protective effect.  
 
1.8 Aim 
The overall aim of this thesis was to determine whether the 
supplementation of resveratrol via activation of SIRT1 was able to 
ameliorate the potential losses in myoblast differentiation and myotube 
hypertrophy observed under DR conditions.  
  
1.9 Thesis Overview 
Following this introduction, we first documented the methodology used to 
carry our aims in the following four data chapters, this information can be 
found in Chapter 2. A physiological model of glucose restriction in vitro 
was then established in Chapter 3. Glucose concentrations that mimic 
both the circulating/ interstitial levels in rodents following DR where 
assessed for skeletal muscle cells differentiation capacity via 
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morphological (myotube number, diameter, area) and biochemical 
analysis (CK activity). In addition gene expression analysis was also 
performed for fundamental genes related to myogenisis, the differentiation 
program, myotube maturation and protein degradation (MyoD, MRF4, 
Myogenin, MYHC 1, 2, 4 and 7, IGFBP2, ID3, MUSA1 and SIRT1). In 
Chapter 4 the most appropriate doses of SIRT1 activator resveratrol and 
inhibitor (EX-527) was determined as to evoke increased/ decreased 
SIRT1 activity via western blot analysis, respectively.  Both Chapter 5 and 
6 utilised the findings from both chapter 3 and 4 and carried out glucose 
restriction in the presence of the SIRT1 activator and inhibitor. Chapter 5 
addressed the role of altering SIRT1 activity in differentiating myoblasts 
under glucose restriction via morphological, biochemical and gene 
expression analysis (as in chapter 3) to determine whether SIRT1 had a 
role in ameliorating the effect of low glucose on myoblast regeneration 
capacity. Finally, data from chapter 5 led us to believe SIRT1 activation 
may play a role in later myotube hypertrophy and therefore in Chapter 6 
we addressed the role of SIRT1 activation/ suppression in fully 
differentiated formed myotubes. This was carried out through extensive 
morphological analysis and gene expression of important genes identified 
above in this introduction and those associated with late differentiation and 
myotube maturation (MRF4, MYHC1, 2, 4 and 7) myotube hypertrophy 
(IGF-I, IGF-IR, IGF-II, IGF-IIR, IGFBP2, mTOR) and myotube atrophy 
(TNF-, myostatin, MuRF, MAFbx, MUSA1, FOXO1, 3, NF-kB, p53). 
Furthermore, we assessed protein activity of energy sensing (AMPK) vs. 
growth cellular signalling (P70S6K) identified in this introduction above to 
be important in DR in muscle cells Fulco et al. (2008) and other cell types 
(Inoki et al., 2003). Finally, Chapter 7 provides the final discussion and 
conclusions that can be drawn from the work, as well potential future 
directions. 
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Chapter 2 
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2. Materials and Methodology  
2.1 General equipment and specialized 
software  
2.1.1 Cell Culture 
All cell culture experiments were performed in a certified class II cabinet 
(BioULTRA, Telstar, Terrassa, Spain).  All liquid handling was performed 
using a portable pipet aid (Drummond, PA, USA) and waste liquid was 
vacuum pump aspirated (Capex 8c, Charles Austen pump Ltd. U.K.). The 
cells were incubated in a CO2 incubator (CB 150, Binder, Germany), 
maintained at 37°C and 5% CO2.  
 
2.1.2 Biochemical Assays 
A CLARIOstar plate reader (BMG Labtech, Germany) was used for both 
total protein and CK at 540-590 nm and 340 nm respectively. The BCA 
protein assay kit was purchased from Thermoscientific (IL, USA) and the 
DiscretPak™ Creatinine kinase Reagent kit from Catachem (CT, USA). 
 
2.1.3 Real Time, Reverse Transcription quantitative Polymerase 
Chain Reaction (RT-qPCR) 
A Spectrophotometer (Nanodrop 2000, ThermoScientific, IL, USA) was 
used at absorbency ratios of 260/ 280 nm and 260/ 230 nm to measure 
quantity and quality of each RNA isolation. Samples were prepared for 
PCR using an automated pipetting system (QIAgility, Qiagen, Venlo, 
Netherlands). The prepared samples where then placed in a qPCR cycler 
(Rotor-gene Q®, Qiagen, Venlo, Netherlands). Reagents, reaction tubes 
and pipette tips used for q-PCR (Syber green, RT master mix and RNA 
free water) were all supplied by Qiagen (Venlo, Netherlands). 
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2.1.4 SDS-Page and Western Ligand Blotting 
Mini Protean Tetra stands with clamp kit (Bio-Rad Laboratories, Inc. CA, 
USA) were used for gel casting, a Powerpac Basic Power Supply used 
for electrophoresis and Trans-blot Turbo Blotting system (Bio-Rad 
Laboratories, Inc. CA, USA) for transfer from gel to nitrocellulose 
membrane. Protein detection was carried out using Pierce Fast Western 
Kit, Supersignal West Pico, Rabbit (Thermofisher scientific, MA, USA) and 
enhanced chemiluminescence (ECL) detections were performed using the 
Chemidoc MP system  (Bio-Rad Laboratories, Inc. CA, USA). 
 
2.1.5 Plastic ware 
Plasticware used during cell culture procedures were acquired from 
Falcon (Thermofisher scientific, MA, USA), this included; 75 cm2 Straight 
neck cell culture flask and 6 well plate cell culture plate. Biochemical 
assays used Falcon (Thermofisher scientific, MA, USA) 96 Well plates. 
Cryotubes used for cryopreservation where purchased from Nunc 
(Sigma-Aldrich, MO, USA). Differentiation media was filtered using 
Stericup Filter units (0.2 m) and collected into receiver flask produced 
by Merck Millipore (Darmstadt, Germany). Filtering of media components 
was performed using 0.2 m syringe filters originally produced by 
Corning (MA, USA) and purchased from Thermofisher scientific (MA, 
USA). Preparation of liquid for cell dosing and Biochemical assays was 
performed in either a 5, 10 and 25 ml Falcon tube (Thermofisher 
scientific, MA, USA). Extraction of samples from cell culture was aided 
using Fisherbrand cell scrapers (Thermofisher scientific, MA, USA) and 
the sample was collected into tubes originally produced by Eppendorf 
(Hamburg, Germany) of either 2, 1.5 or 0.5 ml. During RNA extraction and 
isolation Applied Biosystems 1.5 ml RNA free tubes were used, 
purchased from Thermofisher scientific (MA, USA). Reaction tubes for q-
PCR where purchased from Qiagen (Crawly, UK). Pipette tips used for cell 
culture, biochemistry and western blotting as well as filter tips for RNA 
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isolations were purchased from Fisherbrand (Thermofisher scientific, MA, 
USA). 
 
2.1.6 Cell Culture Reagents 
The purchase of sterile cell culture reagents is listed below: Dulbecco’s 
modified eagle’s medium (DMEM) from Sigma-Aldrich (MO, USA). Heat 
inactivated (hi) New Born Calf Serum (NBCS), hi Foetal bovine serum 
(FBS) and hi horse serum (HS) were originally produced by Gibco 
(Paisley, UK) and purchased from Sigma-Aldrich (MO, USA). Powdered 
DMEM with no glucose was also purchased from Sigma-Aldrich (MO, 
USA), the reconstitution of which was performed using Hyclone water, 
cell culture grade (endotoxin free) purchased from Thermofisher scientific 
(MA, USA). L-Glutamine 200 mM, Penicillin-Streptomycin solution 5000 
U/ml (Pen-strep), Trypsin EDTA (0.05%) and phenol red were produced 
by Gibco (Paisley, UK) and purchased from Thermofisher scientific (MA, 
USA). These items where purchased unsterile and where filtered using the 
above mentioned syringe filters. Porcine gelatine was reconstituted using 
1 g in 500 ml of D2O. Phosphate buffered saline (PBS) was reconstituted 
using 1 tablet per 100 ml of D2O. Both gelatine type A (from porcine skin 
(cat no. G2500-100G) and PBS were purchased from Sigma-Aldrich (MO, 
USA). The distilled water was produced using a Milli-Q direct 8 
purification system from (Merck Millipore, Darmstadt, Germany). These 
reagents were reconstituted in glassware bottles. These were then 
autoclaved. Items that where bought in large quantities e.g. Pen-strep and 
Trypsin were aliquoted into smaller volumes ready for use, this reduced 
the number of freeze thaw cycles. 
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2.2. Methodology- Principles and 
procedures 
2.2.1. C2C12 Skeletal Myoblasts 
The C2C12 cell line were used in both the cell and myotube studies (Blau, 
1993). These cells were purchased from the American type culture 
collection (ATCC). Once these cells arrive they are categorized as P0, the 
first passage is subsequently known as P1. Each additional passage 
increases the P number by 1. C2C12 and C2 myoblasts undergo 
spontaneous differentiation into myotubes on serum withdrawal, and do 
not require growth factor addition to stimulate the process (Blau, 1993, 
Tollefsen et al., 1989). 
 
2.2.2 Cell Culture of C2C12 Skeletal Myoblasts 
 T75 flasks were prepared using 8 ml of 0.2% gelatine left at room 
temperature for 10 min and then incubated at 37 °C for 10 min. The 
excess gelatine was removed and 14 ml of Growth Media (DM) (DMEM, 
10% hiFBS, 10% hiNCS, 1 % pen-strep) was added. Cryovials were 
brought up from liquid nitrogen containing 1-2 ml of cell solution consisting 
of 1-2 ml of growth media (GM) suspending 1 x106 cells per ml. The cells 
were then thawed at 37 °C, 1 ml cell solution was added to one pre-
prepared T75 and incubated at 37 °C and 5% CO2 for 72 hr. 
 
Following the 72 h incubation, cells were visually assessed in order to 
ensure confluency. Once achieved the GM was aspirated and the cells 
were washed twice using 8 ml of Phosphate Buffered Saline (PBS). Pre-
warmed Trypsin (1 ml per T75) was then applied for 5 min at 37 °C. Once 
cells were no longer adhered to the dish (assessed by looking at the cells 
under an Olympus CKX31 inverted microscope (Olympus Corporation, 
Japan) the Trypsin was neutralized by adding 4-8 ml of GM. The solution 
containing Trypsin, cells and GM was then removed into a 50 ml tube and 
homogenized gently using a 19G needle BD Microlance 3, (Becton, 
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Dickinson and Company, UK) to reduce cell clumps thus increasing the 
accuracy of the cell count (section 2.2.3). 
 
Prior to use, 6-well plates were pre-treated with 1 ml, 0.2% porcine 
gelatine per well and incubated for 10 min at room temperature (RT) and 
10 min in a humidified incubator at 37°C with 5% CO2. The excess 
gelatine was aspirated and cells were seeded at 8 x 104 cells per ml in 2 
ml of GM per well, these were then incubated until 80% confluency. High 
serum (20%) GM was removed and the cells were washed once with 2 ml 
PBS, 2 ml of low serum Differentiation Media (DMEM, 2% horse serum, 
1% pen-strep) was then added to each well. It is during this change in DM 
that the cells were treated in various conditions specific to individual 
chapters detailed below (Section 2.2.5.). 
 
2.2.3. Cell Counting via Trypan Blue Method 
The Trypan blue method of cell counting was originally devised to 
determine cell viability of the cell population by differentiating between 
trypan incorporated (blue non-vivable) and non-coloured (viable) cells. 
Here the Trypan blue dye infiltrates perforated cells, a characteristic of the 
impaired membrane integrity of non-viable cells, thus making them appear 
blue under a microscope where cell death occurs. A haemocytometer was 
used for manual counting; this consists of a thick glass microscope slide 
with two chambers. Each chamber can contain a total of 10 μl of liquid. 
(Fig.2.1).  
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Preparation of the cell solution consisted of a 1:1 dilution, produced using 
a 50 μl Trypan blue solution 0.4% (Thermofisher scientific, MA, USA) and 
50 μl cell solution, once removed from a confluent T75. The solution was 
applied in 10 μl to both chambers of the Bright-line haemocytometer 
(Sigma-Aldrich, MO, USA) and the coverslip was placed over the 
chambers. After leaving the solution to settle for 1-2 min the 
haemocytometer was placed under a CKX31 inverted microscope 
(Olympus Corporation, Tokyo, Japan) at a 10 x magnification. Each 
chamber was divided into 4 segments; A-D, the viable cells were counted 
in all of the segments and an average was calculated across all 4 
segments in both chambers. If one cell was situated across the singe line 
edge then it was not counted, if it was across the multiple lines (closest to 
the centre) then these were counted (Fig.2.1).  
 
Fig. 2.1. The original, unedited image was obtained from www.microbehunter.com/the-
hemocytometer-counting-chamber. Viable cells and dead cells are represented by grey 
and blue dots respectively. The red lines indicate a magnification of the area. 
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To obtain the number of cells per ml the average cell number was 
multiplied by 2. This is because the cell solution was diluted 1:1 with the 
Trypan blue. As each grid section in which the average cell count was 
obtained has a volume of 0.1 mm3 it must therefore contain 0.1 μl of 
solution. The value obtained above (following the x 2 multiplication) was 
therefore multiplied by 104 to obtain the number of cells ml-1. The same 
cell solution was used across both chambers as a duplicate and an 
average of these was also taken to ensure accurate cell numbers were 
obtained.   
 
2.2.4. Cell Cryopreservation and Resurrection 
Cells at densities above or below 1 x 106 cells/ml were diluted in GM or 
centrifuged (5 minutes at 2500 rcf) and resuspended in GM respectively to 
provide a concentration of 1 x 106 cells/ml. To prevent the formation of ice 
crystals cells were treated with 10% Dimethyl sulfoxide (DMSO). The 
treated solution was then aliquoted into labelled cryotubes (Sigma-Aldrich, 
MO, USA) and stored in a Mr FrostyTM Freezing container (Thermofisher 
scientific, MA, USA) at -80°C for 24 h. The cryotubes were then moved 
into a labelled holder and stored in liquid nitrogen until required for future 
experimentation. 
 
2.2.5. Dosing Cells 
2.2.5.1. Reconstitution of powdered cell culture media  
The powdered DMEM (Sigma, Cat no D5030) was reconstituted according 
to manufacturers instructions (8.3 g/L of DMEM) supplemented with 0.58 
g/L L-Glutamine, 3.70 g/L Sodium Bicarbonate, 0.11 g/L, Sodium Pyruvate, 
0.02 g/L, Phenol red and either 0 g/L or 4.5 g/L (25 mM) D-Glucose in 
HyPure™ Molecular grade water (Hyclone, Thermofisher scientific, MA, 
USA). This was to ensure the composition matched the more generally 
used liquid DMEM.  
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2.2.5.2 Procedure for Dosing Cells at various glucose concentrations 
Media of varying glucose concentrations are implemented in Chapters 3, 5 
and 6. To obtain the different concentrations of glucose containing media 
powdered glucose (4.5 g/L) media was diluted using powdered glucose 
free media (0 g/L) detailed above, by creating the following concentrations; 
24.90, 18.75, 12.50, 6.24, 3.12, 0.00 mM.  
 
2.2.5.3. Reconstitution of Resveratrol 
Resveratrol, cat no. 554325 (Calbiochem, USA) was purchased in from 
Merck Millipore, (Darmstadt, Germany) in powder form and was 
reconstituted using 1 ml DMSO per 25 mg (25 mg/ml). Once reconstituted 
the resveratrol was frozen at -20°C. Concentrations of 5, 10 and 15 μM 
where used in Chapter 4.  Chapter 5 used 10 μM only. 
 
2.2.5.4. Reconstitution of SIRT1 inhibitor 
SIRT1 inhibitor, EX-527 (Merck Millipore, Darmstadt, Germany) was 
reconstituted using 500 μl DMSO per 5 mg (concentration of 10 mg/ml). 
Once reconstituted aliquots of 15 and 10 μl were stored at -20°C for up to 
6 months. Concentrations of 30 μM and 60 μM and 100 and 200 nM were 
used on C2C12 cells in the dose response study (Chapter 4) and 100 nM 
was carried forward for use in the co-incubation studies (Chapter 5 and 6).  
Molarity calculations for each compound were first carried out based on 
the equation in Equation 2.1. The dilution equation, Equation 2.2, could 
then be used depending on the amount of media needed for the specific 
experiment.  
 
Equation 2.1. Resveratrol and SIRT inhibitor (EX-527) molarity 
calculation 
Molarity x Volume (L) = Amount of powder (g) / Molecular weight (kD) 
 
Molarity = Amount of powder (g) / Molecular weight (kD) 
    Volume (L) 
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Resveratrol:  
 
Molarity= 0.025 g / 228.2 MW 
  0.001L 
 
Molarity= 0.109 M 
 
SIRT1 inhibitor:  
 
M= (0.005 g /248.7 MW) 
   0.001L 
 
M= 0.0201 M 
 
Equation 2.2 Resveratrol and SIRT1 inhibitor dilution  
 
M1 x V1 = M2 x V2 
 
V1 = M2 x V2 
      M1  
e.g. Resveratrol (10 μM) in 50 ml of media: 
 
V1 = 0.000010 M x 50000μl (50 ml) 
                     0.109 M 
 
V1 = 4.59 μl in 50 ml of media 
 
e.g. SIRT1 inhibitor (100 nM) in 50 ml of media: 
 
V = 0.0000001M x 50000 μl 
                 0.0201 
 
V = 0.248 μl in 50 ml of media 
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2.2.6. Muscle cell morphological measures by microscopy  
2.2.6.1. Principle 
The assessment of myotube number using microscopy is a morphological 
measure of the myoblasts differentiating and forming myotubes. Myotube 
diameter and area can be used to assess if myotubes have increased in 
size (i.e. undergone hypertrophy or decreased (undergone atrophy).  
 
2.2.6.2. Procedure 
Following media aspiration and 2× PBS washes (1 ml/well), cells were 
fixed by adding 1 ml methanol/ acetone (1:1) to 1 ml PBS per well in a 
drop-wise manner and incubated for 10 min at room temperature. 
Following aspiration, 2 ml methanol and acetone (1:1) were added to each 
well and incubated for a further 10 min. Finally, PBS (2 ml/well) was added 
after removal of the methanol and acetone solution and plates were stored 
at 4 °C until further analyses. This fixing process allowed nuclei to become 
discernible under light microscopy alone, without the need for additional 
nuclear staining. A total of 6 fields per well in duplicate, thus 12 per 
experimental condition for each time point were captured with a cell 
imaging system at x10 magnification on a microscope (DM6000 FS, Leica, 
Germany). Automated mark and find setting on the microscope allowed 6 
images per well to be taken in the same position in each well automatically, 
with the 6 locations chosen equally spread around the well. Images were 
analysed using Image J (Java) software (National Institutes of Health, 
USA). Morphology was assessed by determination of myotube number of 
myotubes per view, diameter and area. A myotube was defined as 
containing 3+ nuclei encapsulated within cellular structures, so to avoid 
counting of single cells undergoing mitosis. Myotube diameter (μm) was 
determined by measuring the diameter of 3 equidistant points on each 
myotube (left end, middle, right end) and determining the mean of the 3 
values as previously described (Trendelenburg et al., 2009, Deane et al., 
2013, Hughes et al., 2016). Myotube area (μm2) was determined by 
carefully tracing around myotube structures using Image J software and 
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converting pixel length to the known distance in μm taken from the scale 
bar on each image produced on each image automatically by the 
microscope. 
 
2.2.7. Cell Lysis for total Protein and Creatine Kinase Assays 
Following the intended incubation time for cells under various conditions 
(see specific detail in each chapter) cells were washed once using 2 ml 
PBS per well and PBS aspirated. The cell lysis buffer: Tris/ MES Triton 
(TMT; 50 mM Tris-MES, pH 7.8, 1% Triton X-100). A volume of 300 μl 
TMT was applied to each well of a 6 well plate and was then left at room 
temperature for 5 min to allow lysis to take place. The cells where scraped 
and the solution was collected into a 1.5 ml eppendorf tube and vortexed. 
Tubes were labelled with experiment name and number, time point and 
condition. These samples where kept at -80°C until further analysis was 
performed.  
 
2.2.8. Total Protein Assay 
2.2.8.1. Principle 
Total protein measurements where carried out using the Bicinchoninic acid 
(BCA) assay, originally devised by Smith et al. (1985). This colorimetric 
detection, similar to the previously popular Lowery method, implements 
the biuret reaction which states that Cu2+ is reduced to Cu1+ in the 
presence of protein under alkaline conditions (Fig 2.2.).  
 
 
Fig. 2.2. Simplified diagram of the Biuret reaction. 
The sensitivity of the biuret reaction alone is approximately 100 times less 
accurate than the additional BCA step. This addition allows one atom of 
Cu1+ produced during the biuret reaction to chelate with two molecules of 
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BCA (Fig. 2.3.). Following a 30 min incubation at 37°C, this reaction 
creates a purple colour when protein is present. This colour is proportional 
to the number of peptide bonds utilized during the reaction. Following the 
colour analysis at a wavelength of 540-590 nm, linear response curves of 
known standards were produced with an r2 >0.95 (Fig. 2.5.).  
 
 
 
2.2.8.2. Procedure 
Ultimately this protocol will consist of comparing the obtained samples to a 
known set of standards. These standards were produced in house using 
the same TMT used for lysis of the experimental samples. Here 4 mg/ml of 
bovine serum albumin (BSA) was serially diluted to produce eight 
standards: 4.00, 2.00, 1.00, 0.50, 0.25, 0.13, 0.06 and 0.00 mg/ml. These 
standards along with an additional blank (0.00 mg/ml standard) were then 
pipetted (in duplicate) into the first 18 wells in a non-UV, 96 wellplate. 
Each standard and the blank were then pipetted in a volume of 10 μl per 
well in duplicate. The experimental samples were pipetted into the 
remaining wells in duplicate using the same volume of 10 μl as the 
standards (Fig 2.4.)  
Fig. 2.3. One molecule of Cu1+ produced from the Biuret reaction chelating with two 
molecules of BCA. 
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Both reagents needed for the BCA assay were purchased from Pierce (IL, 
USA). Reagent A consisted of sodium carbonate, sodium bicarbonate, 
bichoninic acid and sodium tartrate in 0.1 M of sodium hydroxide and 
reagent B consisted of 4% cupric sulphate. To calculate the amount of 
reagent A required in total, the number of standards and samples in 
duplicate were multiplied by 200 μl (the volume of reconstituted reagent A 
required per well). The calculation for working reagent in a full plate would 
therefore be: 96 x 200 μl = 19,200 μl or 19.2 ml. Then reagent B was 
mixed with Reagent A (19.2ml) in a 1:50 ratio to produce the reaction 
solution e.g.19,200 μl reagent A / 50  = 384 μl of reagent B. 
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2.2.8.3. Analysis 
The plate was incubated for 30 min at 37°C following the above 
preparation of the samples. After this time the plate was inserted into a 
CLARIOstar plate reader (BMG Labtech, Germany) and absorbance was 
measured at 540-590 nm. Background was removed through blank 
correction (0.00 mg.ml-1 and reagent). Absorbance of the BSA standards 
where plotted against their known concentrations thus creating a standard 
Fig. 2.4. Total Protein assay, 96 Well Plate layout. Depiction of the position of the 
standards, samples and their accompanying duplicates. 
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curve. (Fig 2.5.). Sample concentrations where then derived through 
comparison to this curve.    
 
 
 
2.2.9. Creatine Kinase Assay 
2.2.9.1. Principle 
Creatine Kinase (CK) in vitro is used to mark the withdrawal from the cell 
cycle when myoblasts are fusing/differentiating. Where CK activity 
increases are detectable 3 h after induction of differentiation and serum 
withdrawal and 6 h before fusion occurs, where at 48 h of 
differentiation/fusion CK can be over 400 fold higher in myoblasts 
(Chamberlain et al., 1985). Furthermore, CK gene expression is a 
transcriptional target of MyoD the muscle-specific protein that is able to 
induce myogenesis (Lassar et al., 1989) and therefore investigating its 
biochemical activity at the protein level can help to indicate 
increased/decreased differentiation/fusion between experimental 
conditons and together with myotube morphology (myotube number, 
Fig.2.5.  BCA standard graph produced for the sample values to be obtain following 
comparison. r value = 0.99 and r
2
 = 0.98.  
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diameter, area and gene expression of myoD/myogenin) enables a 
complete picture of changes in differentiation in myoblasts. 
2.2.9.2. Procedure 
Cells were lysed according to the above protein procedure (Section 2.2.6). 
As described above, the samples were kept at -80°C until further analysis 
was carried out. Samples were thawed at room temperature and vortexed. 
A TMT blank was pipetted into the first two wells of 96 well UV plate in a 
volume of 10 μl. Each sample was then pipetted in duplicate into the 
remaining wells at the same volume as the blank. 
 
In order for each reaction to take place a working reagent was created. 
These reagents included two reagents purchased in a specific CK kit from 
Catachem, Inc. (Connecticut, NE, USA). According to manufacturers 
instructions these were combined as follows: 5 ml of liquid from bottle A 
with 0.118 g of powder from bottle B. The amount of reagent required was 
calculated according to the following equation. Reagent from bottle A (μl) 
= Reagent needed for each reaction per well (200 μl) x number of wells in 
use.  
 
Because 0.118 g bottle B was required per 5 ml of bottle A, the amount of 
powder required per ml was calculated as follows: 0.118 ÷ 5 = 0.0236 g. 
This is summarised in the equation below (Equation 2.3.). Once 
thoroughly mixed the working reagent were poured into a mixing trough 
and 200 μl working reagent was added to each well (except the blanks) 
using a multichannel pipette.  
 
Amount of Reagent of Bottle A (μl) = 200 μl x number of samples in 
duplicate 
Amount of powder from Bottle B (g) = Amount of Reagent of Bottle A (μl) x 
0.0236 
 
Therefore the calculation for working reagent in a full plate would read: 
 Amount of reagent from Bottle A (μl) = 200 μl x 96  
  
45 
                   = 19,200 μl (or 19.2 ml) 
 Amount of powder from Bottle B (g)    = 18.8 ml x 0.0236 g 
                 = 0.45312 g 
 
Equation 2.3. Calculation to determine quantities of reagents A and B 
needed for the CK assay. 
 
2.2.9.3. Analysis 
The 96 well plate was inserted into a CLARIOstar plate reader (BMG 
Labtech, Germany) and readings were taken every minute for 15 minutes 
allowing a linear enzymatic relationship to be observed to carry out further 
analysis. The absorbance level of every sample in the plate per minute 
was read at 340 nm. A change in absorbance over time was used to 
calculate CK activity, Equation 2.4. was applied to the change in 
absorbance values. This was normalised to total protein content 
established using the BCA protein assay protocol above (Section 2.2.8). 
 
ΔA.min-1 = (Final A - Initial A) ÷ (Final Reading Time – Initial Reading time 
(min))  
CK activity was then determined using the following calculation: 
CK (U.l-1)  = (ΔA.min-1 × TV × 1000) ÷ (6.22 × SV) 
 
Where: 
ΔA.min-1 = Change in absorbance per minute at 340 nm 
TV  = Total volume (ml) 
1000  = Conversion of units per ml to units per litre.    
6.22  = Millimolar absorptivity of NADH at 340nm 
SV  =  Sample volume (ml) 
 
Therefore, using 10 μl of sample and 200 μl of reagent the following 
equation applies: 
CK (U.l-1) =  (ΔA.min-1 × 0.21 × 1000) ÷ (6.22 × 0.01)            
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Equation 2.4. Calculation of CK activity 
 
2.2.10. SDS Page and Immunoblotting 
2.2.10.1. Principle 
Separation of proteins according to their molecular weight (kilo Daltons 
(kDa)) is performed using discontinuous sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970). Bis-
Acrylamide at different concentrations allows for the polymerisation of the 
gel by forming cross-links between the acrylamide polymers and the 
differentiation of the protein of interest by size e.g. 7% bis-acrylamide gels 
for a protein of high molecular weight versus 12% gel for proteins of low 
molecular weight. The process of polymerisation is catalysed by mixing 
ammonium per sulphate (APS) and N, N, N’, N’-
Tetramethylethylenediamine (TEMED) and two stacking gels are 
generated for each SDS page: i) the resolving gel (10%) which separates 
the protein by size and ii) the stacking gel (5%) which enables large 
volume of dilute sample to be loaded into lanes and thus align at the gel 
interface, prior to separation occurring in the resolving gel. 
 
2.2.10.2. Procedure 
The procedure consists of: Sample preparation, SDS-page Gel production, 
Electrophoresis, Transfer of proteins to nitrocellulose membranes, 
Immunoblotting and Enhanced chemiluminescence (ECL).  
 
2.2.10.3. Sample Preparation 
Cell lysis buffer (10 mM TrisHCL, 5 mM EDTA, 50 mM Sodium Chloride, 
30 mM Sodium Pyrophosphate, 50 mM Sodium Fluoride, 100 μM Sodium 
Orthovanadate, 1 mM PMSF and 1% Triton X-100.) was supplemented 
with commercial protease and cOmplete™, Mini, EDTA-free Protease 
Inhibitor Cocktail (Roche, Switzerland). Following analysis of total protein 
via BCA assay as above (2.2.7) 30 μg of protein was reconstituted in a 5th 
volume of the loading buffer (5 x Laemmli buffer, made up of: 3 ml 1M 
TRIS-HCl (pH 6.8.), 1 g Sodium dodecyl sulphate, 5 ml glycerol and 1 ml 
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DH2O, 25 mg Bromophenol blue). 
 
2.2.10.4. SDS-Page Gel production 
The SDS-Polyacrylamide (SDS-Page) gels were cast in a Mini- 
PROTEAN® Tetra cell casting stand (Bio-Rad Laboratories, Inc. CA, USA). 
Glass plates were aligned and clipped into place with gaskets below 
sealing the opening. A 10% resolving gel solution (4 ml 30% acrylamide 
1% BIS solution, 3.4 ml d2H2O, 2.5 ml 1.5M Tris Base, 100 μl 10 % SDS, 
50 μl 10% APS and 5 μl TEMED) was syringed between the plates. A 
layer of butanol was then syringed across the top of the resolving solution. 
Once removed this created a straight line on the resolving gel. Following a 
30 min incubation the butanol was removed and a 5% stacking gel 
solution (1.7 ml 30% acrylamide 1% BIS solution, 5.7 ml D2H2O, 2.5 ml 
0.5M Tris Base, 100 μl 10% SDS, 50 μl 10% APS and 10 μl TEMED) was 
applied, again using a syringe. A comb was carefully inserted at this point 
to prevent any bubbles forming in the gel. The comb selected was 
dependant on the number of samples, this ranged between 10 and 15 
wells.  
 
2.2.10.5. Electrophoresis  
The prepared gels where removed from their casting stand and inserted 
into a Mini- PROTEAN® Tetra vertical electrophoresis cell (Bio-Rad 
Laboratories, Inc. CA, USA.). These gels were run at 200 V until the 
bromophenol blue dye line reached the bottom of the gel (approximately 1 
h). The gels were closely monitored to ensure the sample did not run off 
the bottom of the gel. In addition these gels were also monitored to ensure 
the Amps did not exceed 3 A as this causes overheating of the gels.  
 
2.2.10.6. Transfer 
Following fractionation of the protein based on molecular weight, the 
protein was transferred onto a nitrocellulose membrane. Originally 
described by Towbin et al. (1979) the polyacrylamide gel was stacked 
against nitrocellulose paper and scotch-brite pads. The scotch brite pads 
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where replaced with extra thick filter paper for these experiments (Fig 2.6).  
The construction of the gel stack was carried out within semi-dry Trans-
blot Turbo Blotting system (Bio-Rad Laboratories, Inc. CA, USA) 
cassette. This stack began with the extra thick filter paper (Bio-Rad 
Laboratories, Inc. CA, USA.), which had been pre-soaked in transfer buffer 
(20 ml 10 x Tris Glycine, 40 ml methanol and 140 ml DH2O) followed by a 
nitrocellulose membrane, the SDS-Page gel and a final sheet of pre-
soaked filter paper. Care was taken to remove bubbles using a roller. The 
cassette lid was firmly and evenly pressed against the sandwiched gel and 
locked into place. The transfer protocol was run at 200 V for 30 min. The 
gel was then disposed of and the nitrocellulose membrane was either 
used in the immunoblotting stage (see below) or stored in plastic wrap at 4 
°C until needed. 
 
 
 
 
 
 
 
Figure 2.6. Construction of transfer stack located within the cassette of the Trans-blot 
TurboBlotting system (Bio-Rad Laboratories, Inc. CA, USA). The specific order is 
required to perform accurate transfer of protein from SDS page gel to nitrocellulose 
membrane. 
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2.2.10.7. Immunoblotting 
The nitrocellulose membrane was prepared for detection using a Pierce 
Fast Western Kit, Supersignal West Pico (Rabbit) (Thermofisher scientific, 
MA, USA). The membranes were incubated using the wash buffer 
provided in these kits for 10 min, during all incubations caution was taken 
to ensure the membrane were covered. Following the wash buffer (which 
includes an unspecified blocking agent) the membrane was incubated in a 
primary antibody, the manufacturer, catalogue number and concentration 
of primary antibodies (all of which were raised in a rabbit) used in the data 
chapters are available in Table 2.1. The membrane was then washed 
twice for 5 min using TBS-Tween at 0.1% (TBS-T) (100 ml TBS, 900 ml 
DH2O, 1 ml Tween-20) followed by the secondary rabbit antibody, raised 
in mouse, provided in the fast western kit. Finally, the wash buffer from the 
Pierce Fast Western Kit was used again for 2 x 5 min washes before 
ECL detection (see details below).  
 
 
 
Antibody Catalogue Number Dilution Factor 
Phosphorylated AMPK 2535S 1:1000 
Total AMPK 2532 1:1000 
Phosphorylated P70S6K 9205S 1:1000 
Total P70S6K 9202 1:1000 
Phosphorylated SIRT1 2314L 1:2000 
Total SIRT1 07-131 * 1:2000 
GAPDH 5174 1:4000 
Table 2.1. Dilution factors and product information for Primary antibodies used during 
immunoblotting. All antibodies were raised in rabbits. All antibodies were purchased 
from Cell Signalling Technology (MA, USA) except the one marked * which was 
purchased from Merck Millipore (Darmstadt, Germany).  
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2.2.10.8. ECL detection 
The Peirce™ fast western blot kit (Thermofisher scientific, MA, USA) also 
provided the enhanced chemiluminescence (ECL) detection reagents, 
these were used in a 1:1 dilution and incubated over the membrane for 5 
min. The membrane was then placed in the Chemidoc™ MP System (Bio-
Rad Laboratories, Inc. CA, USA.) where the band images where detected 
by densitometry in which the first image was taken at 5 sec and intervals 
of 30.5 sec thereafter until either the bands where overexposed, appearing 
red in colour or a maximum of 46 images had been taken (25 min in total). 
  
2.2.10.9. Analysis 
Following imaging, the band volumes were detected using Image lab™ 
(Bio-Rad Laboratories, Inc. CA, USA.). The bands for the phosphorylated 
protein were normalised to its own total protein counterpart before 
determining changes between experimental groups. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was detected on all membranes prior 
to further detection. To establish whether loading of protein was 
comparable, we determined the volume values for GAPDH, following 
determination that no change was present independent of loading when 
glucose concentration is changed. If GAPDH was significantly different 
following t-test, the samples were also relativized to the GAPDH before 
continuing with further analysis.  
 
2.2.11. RNA Extraction 
2.2.11.1. Principle 
The role of mRNA is to act as a chemical messenger to carry the genetic 
information from specific genes contained within the DNA to the protein 
factory, the ribosome, in order to produce functional proteins. As a result, 
there is usually an association between an increase in mRNA leading to 
an increase in a particular protein. The production of mRNA is also more 
rapid than changes in protein abundance due to the time it takes for 
proteins to be translated. Therefore, by assessing mRNA we are therefore 
able to assess important temporal changes following experimental 
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manipulation that provide information for potential alterations at the protein 
level. Furthermore, due to past literature characterising strong association 
between the alterations in gene expression with subsequent alterations in 
morphology or function (e.g. myogenin gene expression and myoblast 
differentiation), gene expression can be an important tool to establish the 
underlying molecular mechanisms to muscle cell adaptation. Prior to 
analysis of mRNA expression, extraction of RNA is required using the 
method below. 
 
2.2.11.2. Procedure 
RNA isolation was performed using the TRIzol method, as previously 
described by Simms et al. (1993). At specific time points, following 
relevant cell incubations current media was aspirated and the cells were 
washed once with 1ml PBS, which was then aspirated prior to the 
administration of 250 μl TRI Reagent® per well of a 6 well plate (Sigma-
Aldrich, MO, USA).  TRIzol was left at room temperature for 5 min and 
cells were scraped using Fisherbrand™ cell scrapers (Thermo Fisher 
Scientific, MA, USA). Wells containing the same sample conditions were 
pooled and collected into a 1.5 ml RNAfree tube and stored at -80 °C until 
RNA isolation was performed.  
 Samples were thawed at room temperature and vortexed 
thoroughly. Once fully defrosted 0.2 ml of chloroform was added per 1ml 
TRI Reagent®. Samples were then mixed via shaking vigorously and 
centrifuged for 15 min at 12,000 x g and 4 °C, with all tube hinges facing 
upwards. During centrifugation, separation of the solutions occurs, in 
which the colourless, aqueous phase resides on the top  (containing the 
RNA), the white interphase (where the DNA and protein reside) and finally 
the red, phenol-chloroform phase (cell debris) residing on the bottom (Fig. 
2.7.). The aqueous phase was carefully removed to avoid contamination 
with DNA from the milky interphase and collected into a new 1.5 ml RNA 
free tubes. Precipitation of RNA was performed via the addition of 0.5 ml 
of isopropanol, per ml of TRI Reagent® initially used. The samples were 
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vortexed and left at room temperature for 10 min and then centrifuged at 
12,000 x g for 10 min at 4°C.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
The centrifugation produced an RNA pellet at the bottom of the tube (Fig. 
2.8.), for which the surrounding supernatant was removed. A wash of 1 ml 
of 75% molecular grade ethanol was added to the pellet, gentle shaking 
then removed the pellet from the side of the tube and the sample was 
centrifuged at 7500 x g for 8 min at 4°C. Ethanol was removed and 
allowed to air dry and then dissolved in 30 μl RNA storage solution 
(Ambion®, Thermo Fisher Scientific, MA, USA). 
  
 
 
 
 
 
 
Aqueous phase; RNA 
Milky, DNA and protein phase 
Phenol-chloroform phase; cell 
debris 
Fig.2.7. Graphic representation depicting the three phases present following addition 
of chloroform and the first centrifugation of the RNA isolation protocol. 
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2.2.11.3. RNA quantification 
RNA purity and concentration was assessed using 1 μl of sample on a 
NanoDrop 2000c, UV-Vis (Ultraviolet–visible spectroscopy) 
spectrophotometer (Thermo Fisher Scientific, MA, USA) using ODs 
(Optical Density) of 260 and 280 nm. A ratio of these OD values was 
calculated for each sample with 1.8-2.2 being accepted as high RNA 
quality and were carried forward for reverse transcription and PCR 
amplification.  
 
2.2.12. PCR 
2.2.12.1. Principle  
Real-time Polymerase chain reaction analysed the extracted mRNA by 
first converting it to a double strand of complementary DNA (cDNA) using 
reverse transcriptase. This cDNA then undergoes a series of approx. 40- 
45 cycles of heating and cooling to allow denaturation of the cDNA, 
annealing of gene specific primers and extension of the new cDNA 
products using free nucleotides and the enzyme DNA polymerase. This 
process produces a doubling of the template cDNA at each cycle, with a 
fluorescent dye (e.g. SYBR green) incorporated into every double 
  
 
 
 
Supernatant  
RNA Pellet 
Fig.2.8. Graphic representation depicting the RNA pellet in the supernatant following 
addition of isopropanol and centrifugation. 
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stranded product. Therefore, as the product begins to accumulate above 
background levels, this allows quantification of the cDNA at the end of 
each cycle.  
 
2.2.12.2. Sample Preparation 
First, samples were all diluted to 7.3 ng/μl using RNA free water. This 
normalisation allowed the same amount of starting RNA to be present in 
all samples. The samples were added to the PCR reaction in a volume of 
9.5 μl, making a total concentration per reaction 70 ng per reaction/sample. 
Sample reactions where produced in optically clear strip tubes (Qiagen, 
Crawly, UK). The components of the aforementioned reactions consisted 
of: 
- 10 μl of 2x Quantifast SYBR green (Qiagen, Crawly, UK), 
- 0.2 μl Quantifast RT Mix (Qiagen, Crawly, UK), 
- 0.15 μl of both a forward and reverse primer (Sigma-Aldrich, MO, USA) 
of a specific stock/starting concentration of 100 μM. 
This process was carried out using a QIAGility automated pipetting system 
(Qiagen, Crawly, UK). 
 
2.2.12.3. PCR cycles  
One step RT-q-PCR (reverse transcription, quantitative PCR) was 
performed using a Rotorgene 3000 (Qiagen, Crawly, UK) and consisted of: 
10 min at 50°C (reverse transcription, cDNA production), 5 min at 95°C 
(transcription inactivation and initial denaturation), followed by 10 sec at 
95°C (denaturation), and 30 sec at 60°C (annealing and extension) for 40 
cycles. Melt curve analysis (Fig.2.9.) was performed as a final stage to 
identify non-specific amplifications and/or primer-dimer issues. Following 
initial characterisation and redesigning of primers where melt curves 
produced multiple peaks, all of the genes using the primers in table 2.2. 
produced a single melt curve peak suggestive of amplification of one 
single product. Average Efficiency of PCR reaction per sample (e.g. 100% 
is perfect doubling at every cycle) was determined by the software. All 
efficiencies for the primers of genes listed in table 2.2 were within 10% of 
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each other and therefore satisfied the MIQE guidelines (Lassar et al., 1989) 
for relative gene expression analysis (described below under section 
2.2.12.5.) where efficiency particular of the gene of interest and the 
calibrator gene should be within 10% of each other.  
 
2.2.12.4. Primer design 
Primers (Table 2.2.) were identified using a genome browser at 
www.genome.ucsc.edu or PubMed Gene 
(https://www.ncbi.nlm.nih.gov/gene/) and designed using web-based 
OligoPerfect™ Designer (Invitrogen, Life Technologies, Pasiley, U.K) or 
Primer Blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers 
were purchased from Sigma-Genosys (Suffolk, UK) without the 
requirement of further purification. Sequence homology searches against 
the Genbank database ensured specificity to ensure the primers only 
matched the sequence and therefore gene that they were designed for. 
Where possible, the primers were ideally designed to yield products 
spanning exon-exon boundaries to prevent any non-specific amplification 
of genomic DNA. Three or more GC bases in the last 5 bases at the 3’ end 
of the primer were avoided as stronger bonding of G and C bases can 
cause nonspecific amplification. Searches for secondary structure or 
inter/intra- molecular interactions (hairpins, self-dimer and cross-dimer) 
within the primer were also performed which would potentially lead too 
poor or no yield of the product. All primers designed were between 17 and 
24 bp and amplified a product of between 76-353 bp (Table 2.2.). GC 
content ranged between 38% and 60% (Table 2.2.). 
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Target 
Gene 
Primer Sequence (5’-3’) Reference 
number 
Amplicon 
length (bp) 
GC% 
 
MyoD F: CATTCCAACCCACAGAAC 
R: GGCGATAGAAGCTCCATA 
NM_010866.2 125 50.00 
50.00 
MRF4 F: GGCTCTCCTTTGTATCCAGGG 
R: CGATCTGTGGGGGCAGATTT 
NM_008657  
 
194 57.20 
55.00 
Myogenin F: CCAACTGAGATTGTCTGTC 
R: GGTGTTAGCCTTATGTGAAT 
NM_031189.2 173 47.37 
40.00 
MYHC1 F: CGGTCGAAGTTGCATCCCTA 
R: TTCTGAGCCTCGATTCGCTC 
NM_030679.1 145 55.00 
55.00 
MYHC2 F: GCGAAGAGTAAGGCTGTCCC 
R: GGCGCATGACCAAAGGTTTC 
NM_001039545.2 76 60.00 
55.00 
MYHC4 F: AGGAGGCTGAGGAACAATCC 
R: TTCTCCTGTCACCTCTCAACA 
NM_010855.3 192 55.00 
47.62 
MYHC7 F: TGTGCTACCCAGCTCCAAG 
R: CTGCTTCCACCTAAAGGGCTG 
NM_080728.2 77 57.89 
57.14 
ID3 F: AGCGTGTCATAGACTACATCCTC 
R: TCCTCTTGTCCTTGGAGATCAC 
NM_008321 135 47.82 
47.82 
MUSA1 F: CCTTGAGGCTCCCGGCAAAT 
R: ACTGCTCCACAAACCAATGGA 
NM_001168297 
 
189 60.00 
47.70 
SIRT1 F: ACAATTCCTCCACCTGAG 
R: GTAACTTCACAGCATCTTCAA 
NM_001159589.2 124 50.00 
38.10 
Myostatin F: TACTCCAGAATAGAAGCCATAA 
R: GTAGCGTGATAATCGTCATC 
NM_010834.3 194 36.36 
45.00 
IGF-I 
 
F:GCTTGCTCACCTTTACCAGC 
R:TTGGGCATGTCAGTGTGG 
NM_001111276.1 280 55.00 
55.56 
IGF-IR F:TGCGGTGTCCAATAACTAC 
R: TGTTGATGGTGGTCTTCTC 
NM_010513.2 110 47.40 
47.40 
IGF-II F: GTACAATATCTGGCCCGCCC 
R: GTATGCAAACCGAACAGCGG 
NM_010514.3 198 60.00 
55.00 
IGF-IIR F: GGAACTCCTGAATTTGTAACT 
R: CTACCAGATAGCCACCATT 
NM_010515.2  
 
181 38.00 
47.00 
IGFBP2 F: AGTGCCATCTCTTCTACAA  
R:  GCTCAGTGTTGGTCTCTT 
NM_008342.3 197 42.20 
50.00 
Table 2.2. Real qPCR primer sequences 
IGF-I mature and MGF were not designed by use and were taken from(Yang et al., 
1996)  
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2.2.12.5. Analysis 
Using RotorgeneQ 3000 software (Qiagen, Manchester, UK) a threshold 
line was positioned manually where there was an exponential rise in 
fluorescence above background levels on the lower third of the 
exponential increase (Bustin et al., 2009) (Fig. 2.9.). 
IGF-IEa F:GCTTGCTCACCTTTACCAGC 
R:AATGTACTTCCTTCTGGGTCT 
NM_010512.4 300 55.00 
50.00 
MGF F: GCTTGCTCACCTTTACCAGC 
R:AAATGTACTTCCTTTCCTCTC 
NM_184052.3 353 55.00 
38.10 
mTOR F: CACTCCACTATCCTGTTACCT 
R: GAGATCCTTGGCACACCT 
NM_020009.2 190 47.62 
55.56 
MuRf1 CCAAGGAGAATAGCCACCAG  
R: CGCTCTTCTTCTCGTCCAG 
NM_001039048.2 
 
84 55.00 
58.00 
MafBx F: GTCGCAGCCAAGAAGAGAA 
R: CGAGAAGTCCAGTCTGTTGAA 
NM_026346.3 156 53.00 
47.00 
FoxO1 F: AGTGGATGGTGAAGAGCGTG 
R: GAAGGGACAGATTGTGGCGA 
NM_019739.3 
 
96 55.00 
55.00 
FoxO3 F: CGGACAAACGGCTCACTTT 
R: TCGGCTCTTGGTGTACTTG 
NM_019740.2 
 
272 52.63 
52.63 
TNF-α F: TCAACAACTACTCAGAAACAC 
R: AGAACTCAGGAATGGACAT 
NM_001278601.1 130 38.10 
42.11 
TNFRS1b F: GTTGCTCTGTTATAGGATGGT 
R: TGCTGTCTGCTGTCTACT 
NM_011610.3  
 
113 42.00 
52.94 
NFκβ F: ACACGAGGCTACAACTCTGC 
R: GGTACCCCCAGAGACCTCAT 
NM_008689 
 
164 60.00 
55.00 
RPIIβ (a.k.a: 
pol2rb) 
F:GGTCAGAAGGGAACTTGTGGTAT 
R:GCATCATTAAATGGAGTAGCGTC 
NM_153798.2 197 47.82 
43.47 
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From this, the CT values (defined as the cycle at which the samples 
fluorescence trace crosses the threshold line) for all genes were compiled 
in table format imported into Excel to perform a relative analysis. Here a 
spreadsheet was formulated to apply the Delta Delta CT (ΔΔCT) equation 
Figure 2.9. A) Displays the output and threshold applied to actual data output. B) 
Shows an enlarged example of RT-PCR fluorescence (relative fluorescent units) at 
incrementing cycles of an experimental sample (exp) and a control sample. The 
threshold is positioned on the lower third of the exponential rise in fluorescence on the y 
axis above background levels of fluorescence vs. cycle number axis (x axis) and the 
threshold cycle (Ct) is calculated by reading of the cycle number on the x axis. Imaged 
acquired from http://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_5990.pdf 
A 
B 
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(Equation 2.5. otherwise known as the Livak Method (Schmittgen and 
Livak, 2008)) 
 
Equation 2.5. Delta Delta CT (ΔΔCT) equation otherwise known as the Livak Method 
(Schmittgen and Livak, 2008).  
Equation 1: ΔCT = Mean CT (Target gene, test e.g. MyoD) – Mean CT  (Reference gene, test 
e.g. GAPDH   ) 
Equation 2: ΔCT = Mean CT (Target gene, calibrator) – Mean CT (Reference gene, calibrator) 
Equation 3: ΔΔCT= ΔCT of Equation 1 - ΔCT of Equation 2 
Equation 4: 2-ΔΔCT (gives a normalised expression ratio) 
 
Where:  
Mean CT (Target gene, test) = The average CT value (sample and duplicate) of 
targeted gene (e.g. myoD) in the experimental condition e.g. RNA isolated 
from C2C12 after 72 h in DM. 
 
Mean CT Reference gene, test = The average CT value (sample and duplicate) of 
reference housekeeping gene (e.g. RPII β/polr2b) in the experimental 
condition e.g. RNA isolated from C2C12 cells after 72 h in DM. 
 
Mean CT (Target gene, calibrator) = The average CT value (sample and duplicate) 
of targeted gene (e.g. myoD) in the calibrator condition e.g. RNA isolated 
from C2C12 cells after 0 h in DM (0 h being the calibrator condition in all of 
the experiments in this thesis). 
 
Mean CT (Reference gene, calibrator) = The average CT value (sample and 
duplicate) of  reference housekeeping gene (e.g. RPII β) in the calibrator 
condition e.g. RNA isolated from C2C12 cells after 0 h in DM. 
 
For Example: 
Equation 1: ΔCT = 22.18 (myoD, 72 hrs DM) – 20.69(RPII β, 72 hrs DM) 
then: 
Equation 2: ΔCT = 26.86 (myoD, 0 hrs DM) – 20.49 (RPII β, 0 hrs DM) 
Equation 3: ΔΔCT= ΔCT of Equation 1 (1.49) – ΔCT of Equation 2 (6.37) 
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Equation 4:  2-(-4.88) (gives a normalised expression ratio of 29.45) 
 
Therefore, in this example (which is hypothetical data and corresponds to 
no true analysis) the expression ratio of MyoD between C2C12 cells that 
have placed in DM for 0 h and 72 h is 29:1. Therefore, in this hypothetical 
example MyoD is highly expressed (29 fold higher) after 72 h in C2C12 
cells compared with the 0 h time point, and after being normalised to the 
housekeeping gene of RPII β. 
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3. Determining Physiological 
Glucose Concentrations in vitro: 
A Model to investigate the 
impact of dietary restriction on 
muscle cell differentiation. 
3.1. Introduction  
Dietary restriction administered in vivo is calculated as a reduction in 
calories and/ or macronutrients in comparison to control ad libitum (AL) 
counterparts. Mimicking this model in culture however is more problematic. 
Firstly the assessment of calories consumed requires a more complex 
assessment in vitro than in vivo. Secondly, the current glucose 
concentration implemented in both rodent (Sharples et al., 2011, Stitt et al., 
2004, Dimchev et al., 2013, Hao et al., 2011, Staiger et al., 2004, Hao et 
al., 2006) and human culture (Steitz et al., 2001, Clempus et al., 2007) is 
24.9 mM or 4.5 g/L (NOR), which is much higher than has been detected 
physiologically. Despite this the concentration will therefore be carried 
forward as a reference control, allowing comparison with the existing 
literature and future glucose manipulation studies, however a more 
physiologically relevant dose needs to be established that mimics dietary 
restriction. 
 Various studies have compared changes in glucose 
concentration in both rodent and human studies, both determining a drop 
in serum/ blood glucose concentration during DR. Murine models have 
reported 30 – 40% reductions in glucose both acutely over a 3 week 
period from 2.79 to 1.63 g/L (15.5 to 9.1 mM) (Mahoney et al., 2006) and 
chronically over a 20 month period from 1.5 to 1 g/L (8.3 to 5.6 mM) 
(Cartee et al., 1994). Walford et al. (1992) suggested a 30% calorie 
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reduction decreased human serum levels from 0.92 g/L to 0.74 g/L (5.1 to 
4.1 mM) over 6 months. Whereas an average of 6.9 years calorie 
restriction in humans compared to western diet counterparts displayed a 
12.6% reduction in fasted glucose concentration (0.95 vs. 0.83 g/L and 5.2 
vs. 4.6 mM) (Fontana et al., 2006). 
 
 Although this data is indicative of the systemic effect of decreased calorie 
intake will have on the body it is not necessarily the concentration that 
skeletal muscle is exposed to due to the change in concentration from the 
blood and interstitial space. Glucose values in the muscle interstitium have 
been reported to be 30% lower than those found in the blood of both 
rodents (Aussedat et al., 2000) and humans (Maggs et al., 1995). To our 
knowledge, muscle interstitium values have unfortunately, not yet been 
reported during chronic DR, therefore using the above information we may 
only produce an approximation, as follows. The previously reported values 
for blood glucose during DR consisted of approximately 0.74 g/L (4.1 mM) 
in humans (Walford et al., 1992) and 1 g/L (5.6 mM) in murine models 
(Cartee et al., 1994). Therefore applying the aforementioned 30% 
reduction to represent the differences between interstitium and blood 
would estimate DR interstitium at nearly 0.5 and 0.7 g/L (2.8 and 3.9 mM) 
for humans and rat respectively.  
 
Fulco et al. (2008) initially assessed the effect of glucose deprivation on 
muscle in vitro, whose findings of reduced muscle differentiation was 
confirmed later by Elkalaf et al. (2013) and Khodabukus and Baar (2015). 
None of these studies reported the rationale behind the glucose 
concentration administered, which varied from 1 g/L (5.6 mM) (Elkalaf et 
al., 2013, Khodabukus and Baar, 2015) to 0.1 g/L (0.6 mM) (Fulco et al., 
2008). The former appears to be similar to the previously reported fasted 
blood glucose level and the latter is much lower than the predicted value 
for the interstitium during DR. Ideally we would aim to implement a 
physiologically relevant glucose concentration found in the interstitium, 
however, when undertaking studies in proliferating muscle cells the 
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viability of these cells must also be taken into account. Consequently, prior 
to carrying out any studies utilizing glucose concentrations in conjunction 
with other variables we will implement various percentage reductions in 
glucose concentration from the NOR, 4.5 g/L (25 mM) due to its 
widespread use in the literature (despite its lack of physiological relevance) 
in a dose response manor and assess the impact of these varying doses 
on growth and differentiation of muscle cells. These doses are as follows: 
4.50 g/L (NOR), 3.38 g/L, 2.25 g/L, 1.13 g/L (MED), 0.56 g/L (LOW) or 
0.00 g/L (25.00 mM (NOR), 18.75 mM, 12.50 mM, 6.25 mM (MED), 3.12 
mM (LOW) or 0.00 mM) where LOW, MED and NOR are closest to 
glucose levels expected during DR in the interstitium, circulation and in 
‘normal’ basal myoblast media respectively. 
 
We aimed initially to assess the impact on muscle cell differentiation via 
morphological analysis of myotube number, diameter and area and non-
subjective biochemical analysis (CK activity). Additionally molecular 
analysis of gene expression (mRNA) was performed to determine changes 
in genes that have been extensively characterised to be highly correlated 
with fusion/differentiation (IGF-1, myoD, myogenin, ID3 and IGFBP2), 
myotube maturation (MRF4, MYHC1 (IIx), 2 (IIa), 4 (IIb) and 7 (slow type I) 
and protein degradation (MUSA1) and survival (SIRT1). 
 
3.2. Methods 
3.2.1. Cell culture 
C2C12 murine myoblasts (Blau et al., 1985) at passage 12 were incubated 
in separate T75 flasks in a humidified, 37°C with 5% CO2 in Growth media 
(GM) containing: Dulbecco’s Modified Eagle Serum (DMEM) (D6429-6, 
Sigma-Aldrich, UK), 1% Penicillin Streptomycin (Pen Strep), 10% New 
born calf serum (NBCS) and 10% Fetal Bovine Serum (FBS) until 80% 
confluency was attained. 
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Experiments were initiated by removing GM (as described in the general  
methods, chapter 2, section 2.2.2), washing once with phosphate buffered 
saline (PBS) followed by the addition of differentiation media (DM). Two 
media forms were implemented for use in control DM conditions, 1) liquid, 
commercially available and ready to use with a 4.5 g/L glucose 
concentration (D6429, Sigma-Aldrich, UK) supplement with 2% horse 
serum (HS) and 1% PenStrep (PS) to allow a control that would be 
comparable to existing literature and 2) a powdered form (D5030, Sigma-
Aldrich, UK). The chosen powered DMEM was reconstituted according to 
manufactures instructions (8.3 g/L of DMEM) supplemented with 0.5840 
g/L L-Glutamine; 3.7000 g/L Sodium Bicarbonate; 0.1100 g/L, Sodium 
Pyruvate; 0.0159 g/L Phenol red and either 0 g/L or 4.5 g/L D-Glucose in 
order for the composition to match that of the more generally used liquid 
DMEM. This media was also supplemented with 2% HS and 1% PS. The 
powered DM supplemented with glucose was comparable to the liquid 
DMEM in section 3.3.1, thus making this DMEM a relevant control as well 
as being used to produce the dosing conditions described below under 
section 3.2.2. The reduction in serum content, causing the C2C12 
myoblasts to undergo spontaneous differentiation without requiring the 
addition of growth factors to initiate the process (Blau et al., 1985). Cells 
were seeded following trypsinization of the adherent cells, counts were 
preformed using haemocytometer in the presence of Trypan Blue dye as 
described in general methods (section 2.2.3).  
 
3.2.2. Cell dosing 
6Well plates where pre-treated with 0.2% porcine gelatine for 10 min at 
room temperature (RT) and 10 min in a humidified incubator at 37°C with 
5% CO2. The excess gelatine was aspirated and cells were seeded at 8 X 
104 cells/ml in 2 ml of GM, and incubated until 80% confluence. Cells were 
washed in PBS and transferred into 2 ml of DM at 37°C with 5% CO2 for 
up to 7 days (7D). Time point zero was defined as an incubation of 30 min 
after transfer to DM and is denoted as 0 hours (0 h). To assess the effect 
of glucose restriction on myoblasts the cells where incubated in 
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reconstituted powdered media as described above with either: 4.50 g/L, 
3.38 g/L, 2.25 g/L, 1.13 g/L, 0.56 g/L or 0.00 g/L or 25.00 mM, 18.75 mM, 
12.50 mM, 6.25 mM, 3.12 mM, 0.00 mM of glucose respectively. All 
experiments were carried out as N = 3, each N consisting of a different cell 
set brought out of liquid nitrogen at the same time.  
 
3.2.3. Morphology 
Myotube parameters including; number, diameter and size were assessed 
using a live imaging light microscope (AF600 modular system, Leica, 
Germany) cell imaging system at x10 magnification at time points; 0, 48 
and 72 hours and 7 days. Experiments were replicated three times (N=3), 
each experiment consisted of each time point and experimental condition 
being performed in duplicate with 6 images taken per well providing a total 
of 12 images per condition per timepoint. Analysis was performed on the 
images acquired at 72 h and 7D using ImageJ software (NIH, USA) (See 
general methods chapter 2, section 2.2.6.) 
 
3.2.4. Total protein content 
Protein was measured using BCA™ (Pierce, Rockfored, IL) according to 
instructions and detected using CLARIOstar® plate reader (BMG labtech, 
Germany) at a wavelength of 540-590 mM to quantify total protein 
concentrations prior to relative comparison of CK samples (See general 
methods chapter 2, section 2.2.8.). 
 
3.2.5. Creatine Kinase  
Assessment of creatine kinase activity was measured using an assay kit 
(Catachem, Inc, Connecticut, NE) according to manufactures instructions 
and detected using a CLARIOstar® plate reader (BMG labtech, Germany) 
at a wave length of 340 nm. See general methods chapter 2, section 2.2.9. 
 
3.2.6. RNA Extraction and analysis 
RNA extraction was performed using the TRIzol method (See method 
chapter 2, section 2.2.11.), following the manufactures instructions 
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(Invitrogen, Life technologies, Carlsbad, CA). RNA purity and 
concentration was assessed using 1 μl of sample on a NanoDrop 2000c, 
UV-Vis (Ultraviolet–visible spectroscopy) spectrophotometer (Thermo 
Fisher Scientific, MA, USA) using ODs of 260 and 280 nm. A ratio of these 
OD value was calculated for each sample with all samples possessing 
260/280 ratios of between 1.8-2.2 and therefore accepted as high RNA 
quality. 
 
3.2.7. Primer design 
Identification of target sequences were carried out via Gene 
(http://www.ncbi.nlm.nih.gov/gene). Primers (Chapter 2, section 2.2.12.4 
table 2.2.) were designed using Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer details can be 
found under 2.2.12.4. 
 
3.2.8. RT-PCR and analysis 
RT-PCR was carried out using Quantifast SYBR green RT-PCR kit 
(Qiagen, Manchester, UK) on a Rotor-Gene® (Qiagen, Manchester, UK) 
supported by Rotor-Gene® Q Software, version 2.1.0.9 (Qiagen, 
Manchester, UK). The RT-PCR cycles consisted of; 48°C, 30 min (reverse 
transcription/ synthesis of cDNA), 95°C, 10 min (transcriptase inactivation 
and initial denaturation) followed by 40 cycles at 95°C, 15 sec 
(denaturation), 60°C, 1 min (annealing and extension in 1 step). 
Disassociation melt-curve analysis was performed to reveal and exclude 
non-specific amplification and primer dimer issues. All gene products 
yielded a single melt peak/temperature suggesting one product was 
amplified. Relative gene expression analysis was carried out using ΔΔCt 
equation, otherwise known as the Livak method (Schmittgen and Livak, 
2008), to establish normalised expression ratios, where the relative 
expression is calculated as 2-ΔΔCt and Ct represents the threshold cycle. 
RPIIβ was extremely stable between experimental conditions (mean Ct 
15.62 ± 0.11) and therefore used as the housekeeping gene in all RT-PCR 
assays and the pooled mean used in the ΔΔCt calculations. All RT-PCR 
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figures are presented as a relative gene expression in comparison to the 0 
h cell incubated in “Normal” glucose (4.5g/L or 25 mM). This sample was 
used as a calibrator condition in the subsequent equations in order to 
compare expression values across glucose concentrations. 
 
3.2.9. Statistical analysis 
All data was performed using three separate cell populations thus 
performed N=3. Analysis was then carried out using Minitab® 17 (Minitab 
Ltd, Coventry U.K). Outliers where removed using Grubbs outlier test. All 
data was parametric, assessed using the Anderson-Darling test for 
normality. General linear models where carried out for morphological data 
CK (3 x 3, time (48, 72 h and 7D) x glucose concentration (NOR, MED and 
LOW) and gene expression (3 x 3, time (0, 72 h and 7D) x glucose 
concentration (NOR, MED and LOW). Post hoc tests where performed 
using Bonferroni, Tukey and Fisher. The results produced through the 
Bonferroni tests are reported throughout the results as this test is more 
stringent. Use of Tukey and Fisher is stated within the text if no 
significance was observed using Bonferroni.  
 
3.3. Results 
3.3.1. Preliminary morphological analysis to eliminate irrelevant 
glucose concentrations from further analysis  
Two 25.00 mM concentrations were implemented and appeared to 
produce similar results regardless of DMEM used (reconstituted powder vs. 
commercially bought liquid) (Fig. 3.1.). Therefore, as the glucose dose 
response media was created using the reconstituted powder DM and there 
was no morphological difference between this media and the liquid form 
the reconstituted (powdered) DMEM was used as the control condition 
(NOR) for all subsequent studies (Fig. 3.2.). Glucose dose response 
(25.00, 18.75, 12.50, 6.25, 3.12, 0.00 mM) initially investigated 
morphological analysis only, as some of the lowest concentrations we 
expected to have few viable cells. 
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Following 72 h in 0 mM glucose it was determined that the majority of cells 
had died and were no longer adherent to the plate (Figure 3.2. top left 
image). As such, this concentration could not be utilized as a suitable 
model for DR in myoblasts and was therefore not carried forward for 
further investigation. A morphological reduction in differentiation was 
present in the 3.12 mM glucose concentration. This concentration was 
similar to the glucose levels observed in interstitial concentrations during 
DR and was therefore carried forward for further morphological, 
biochemical and molecular analysis below. The apparent morphology 
between the remaining concentrations (6.25, 12.50, 18.75 mM) did not 
appear to differ appreciably between conditions. However, as the 6.25 mM 
(MED) concentration was also the most reflective of serum concentrations 
of glucose in fasted (but not dietary restricted) rodents this dose was also 
carried forward. It should be noted that morphological images only (Fig. 
3.2) were conducted for this wide range of dosing in order to initially 
narrow the focus to more relevant dosing conditions. Based on these initial 
observations further analysis degrading myotube number, diameter and 
size, as well as CK activity and transcriptional response was performed on 
doses of 25 mM (NOR), 6.25 mM (MED) similar to fasted serum levels and 
3.12 mM (LOW), similar to predicted interstitial concentration during DR. 
 
Fig 3.1. Images displaying similar number and size of myotubes within two 
different types of DMEM. Two 25 mM glucose conditions, the first created using a 
powered DMEM and supplementing with glucose, this is denoted as “reconstituted”. 
The second created using a commercially available DMEM denoted as “liquid”.  
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3.3.2. Morphological and biochemical analysis for differentiation 
capacity was reduced in LOW and MED glucose conditions.  
Following a brief time course experiment (data not shown) we determined 
that myotube formation was slightly delayed in the cell population used in 
comparison to other groups utilizing C2C12 cell lines. As a result there 
were a limited number of myotubes present at the 72 h time point and a 
much greater number was present following 7D within the NOR condition. 
The end time point was therefore extended to 7D for future studies 
allowing late differentiation and myotube maturation to take place. We 
investigated differentiation via myotube imaging (Fig. 3.3.), this allowed 
Fig 3.2. Initial dose response for glucose concentrations following 72 h. Doses include 
the readily used 25.00 mM (NOR) and a serial dilution of 18.25 mM, 12.50 mM, 6.25 mM 
(MED), 3.13 mM (LOW) and 0.00 mM. The 25.00 mM is the control glucose condition 
this condition contained larger and more plentiful myotubes than the glucose restricted 
conditions. Compared to the control condition both 0.00 and 3.12 mM displays an 
increase in cell death, whereas 6.25 mM displayed a reduction in myotube 
differentiation, observed via reduced number of myotubes.  Glucose conditions 12.50 
and 18.75 mM appeared unchanged in comparison to the control  
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analysis of myotube number and these results were confirmed with a 
biochemical assay for CK (marker of differentiation). Finally, myotube 
hypertrophy was analysed via measurement of myotube area and 
diameter.  
 
 
 
 
 
 
 
 
No myotubes were formed in either the MED or LOW glucose conditions 
following 72 h as such no further morphological analysis was carried out. 
Following 7D myotubes had formed in MED and NOR conditions however 
the number was greatly diminished in MED glucose conditions following in 
comparison to the NOR glucose condition (NOR vs. MED: 21.72  1.22 vs. 
1.44  0.30, p < 0.001). Again no myotubes were observed in the LOW 
glucose condition (Fig 3.4.) As a result following ANOVA analysis there 
was a significant main effect for glucose condition (F(2,105)= 281.33, p < 
0.001).  
 
Fig 3.3. 10X magnification images of: 25.00 mM (NOR), 6.25 (MED) and 3.12 (LOW) 
glucose concentrations. Images taken following 72 h and 7D. No myotubes have been 
formed following 72 h in any condition. After 7D there are no myotubes formed in LOW 
glucose conditions and there is a large amount of cell death. In MED and NOR conditions 
myotubes have formed (only counted as a myotube when 3 or more nuclei were present) 
however there are a much greater number and area in NOR compared to MED.  
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To confirm morphological analysis of myotube number, CK activity a 
biochemical marker of fusion/ differentiation and early myotube formation 
was assessed (Fig 3.5.). Following an ANOVA test there was an 
interaction for CK activity between time and glucose dosing (F(4,99) = 2.43, 
p = 0.053) and as predicted there was also a significant main effect for 
glucose alone (F(2,99) = 49.23, p < 0.001). Post hoc tests revealed that the 
NOR glucose conditions exhibited higher CK activity than both the MED 
and LOW conditions at both 72 h (NOR: 208.20  84.00 vs. MED: 86.20  
68.90, p < 0.001 vs. LOW: vs. 37.21  26.03 mU.mg.ml-1, p < 0.001) and 
at 7D (NOR vs. MED vs. LOW: 281.50 101.50 vs. 84.03  32.63 vs. 
40.50  29.90 mU.mg.ml-1, p < 0.001, respectively, Fig 3.5). NOR was also 
significantly higher at 48 h than the LOW glucose condition (130  104 vs. 
46  13 mU.mg.ml-1, p = 0.042 (tukey)) with a definite trend towards 
significance between NOR and MED (130  104 vs. 79  21 mU.mg.ml-1, p 
= 0.055 (fisher)). Although not significant it is worth noting MED glucose 
LOW MED NOR
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Fig 3.4. Myotube number is dramatically reduced at 7D in cells undergoing MED 
glucose restriction with no observable myotubes in LOW glucose conditions. Data was 
displayed as mean and SD values of following experimentation to three cell populations 
(n =3). Significant difference (p<0.05) is denoted using a *.  
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showed a trend towards an increased CK expression when compared to 
LOW at 72 h (86.20  68.90 vs. 37.21  26.03, mU.mg.ml-1, p = 0.061 
(fisher)) and 7D (84.03  32.63 vs. 40.50  29.90 mU.mg.ml-1, p = 0.096 
(fisher)).  
 
 
No myotubes were formed following 7D in the LOW condition therefore 
measurement of myotube size and diameter was only carried out on the 
MED and NOR conditions (Fig. 3.6.). The total size of the myotubes was 
established via measurements of myotube area. There was a significant 
reduction in size of myotubes between NOR and MED conditions (NOR vs. 
MED: 7395  4544 vs. 4805  2732 μM2, p < 0.001). Myotube diameter 
however displayed no significant difference between NOR and MED 
Fig 3.5. CK is relativized to total protein. The NOR dose indicates differentiation is 
occurring more rapidly between 48 h and 7D compared with MED and LOW glucose 
conditions. There is also significantly higher CK activity in NOR vs. MED and LOW 
conditions at 72 h and 7D and between NOR and LOW at 48 h. Significant 
differences (p<0.05) are denoted using a *. If approaching significance p value is 
stated. 
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conditions (NOR vs. MED: 15.55  5.14 vs. 16.80  6.51 μM, p = 0.103). 
Overall there was a significant reduction in number and size of myotubes 
in MED glucose conditions compared with NOR. Additionally myotube 
formation was completely inhibited under LOW conditions. 
 
 
3.3.3. Impaired expression of the myogenic regulatory factors (MRF) 
during LOW glucose. 
Myogenic regulatory factors (MRF’s) are involved in the lineage 
commitment of myoblasts, myoblast fusion and differentiation as well as 
Fig 3.6. Graphs depicting myotube size (A) and myotube diameter (B). As described 
above there are no myotubes observed under LOW conditions and as such there are no 
measurements to report and therefore this glucose concentration was removed from 
analysis. There are no significant difference present between MED and NOR glucose for 
diameter, Myotube size is significantly higher in the MED condition than in the NOR. 
Significant difference (p<0.05) is denoted using a *. 
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the maintenance of differentiation. MyoD underpins myoblast 
determination and the onset of fusion (Buckingham et al., 2003, Cooper et 
al., 1999), whereas myogenin regulates formation and executes the 
differentiation program (Berkes and Tapscott, 2005) Analysis of MyoD 
gene expression suggested a significant main effect for time (F(2,17) = 4.64, 
p = 0.025). No change in MyoD expression was observed over time for 
NOR glucose (0 h vs. 72 h: 0.98  0.53 vs. 0.70  0.21, p = 0.480, 0 h vs. 
7D: 0.98  0.53 vs. 0.90  0.66, p = 0.836, 72 h vs. 7D: 0.70  0.21 vs. 
0.90  0.66, p = 0.600). Compared to 0 h, LOW glucose displayed a 
reduced MyoD expression at 72h, (0 h vs. LOW: 0.98  0.53 vs. 0.08  
0.03, p = 0.020) and 7D (0 h vs. LOW: 0.98  0.53 vs. 0.22  0.04, p = 
0.044) whereas MED did not (0 h vs. 72 h MED: 0.98  0.53 vs. 0.38  
0.46, p = 0.107, 0 h vs. 7D MED: 0.98  0.53 vs. 0.37  0.20, p = 0.100). 
There is no significant difference at 72 h between NOR and both MED and 
LOW (NOR vs. LOW: 0.70  0.21 vs. 0.08  0.03, p = 0.135, NOR vs. 
MED: 0.70  0.21 vs. 0.38  0.46, p = 0.435). There is also no significant 
difference between MED and NOR following 7D (NOR vs. MED: 0.90  
0.66 vs. 0.37  0.20, p = 0.145), however for LOW in comparison to NOR 
there is a trend towards a decrease in MyoD expression under LOW 
conditions (NOR vs. LOW: 0.90  0.66 vs. 0.22  0.04, p = 0.066) This 
data suggests that LOW may have a reduced capacity to produce 
myotubes, a previously documented in the morphological data (Fig 3.7,A).   
 
MRF4 (myf6) activates differentiation so an early time point should see an 
increase in MRF4. There are no interactional or main effects for MRF4 
(Fig 3.7,B).  Despite the lack of significance across all time points and 
conditions the data was reduced on average between certain experimental 
conditions. The high stringency in our chosen post hoc tests led us to 
implement these to determine the pairwise comparisons. Following these 
post hoc tests there was a significant increase in gene expression in MED 
glucose at 72 h in comparison to both LOW and NOR (MED vs. LOW: 
3.66  4.76 vs. 0.09  0.06, p = 0.022, MED vs. NOR: 3.66  4.76 vs. 0.10 
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 0.01, p = 0.038). These findings suggest there is a difference between 
LOW and MED and these concentrations are not simply replicas. 
 
Myogenin promotes terminal differentiation and as such is observed in late 
differentiation. There was also no significant interaction or main effect 
present for myogenin (Fig 3.7,C), as with MRF4 despite this lack of 
significance we chose to assess the pair wise comparisons using post hoc 
tests due to their stringency. There is no significant difference between 0 h 
and NOR at 72h (0 h vs. NOR: 1.88  1.31 vs. 5.62  4.12, p = 0.069) 
which is indicative of the late activation of myogenin required for 
differentiation to take place. There is however a significant increase in 
myogenin expression at NOR 7D in comparison to 0 h (NOR vs. 0 h: 10.61 
 4.81 vs. 1.88  1.31, p = 0.010). Although there is no difference between 
LOW and MED concentrations at 72 h (LOW vs. MED: 1.48  1.53 vs. 
1.60  1.51, p = 1.00) there is a reduction in expression under MED 
conditions from NOR (MED vs. NOR: 1.60  1.51 vs. 5.62  4.12, p = 
0.053 (fisher)) as well as a significant reduction under LOW conditions 
(LOW vs. NOR: 1.48  1.53 vs. 5.62  4.12, p = 0.047 (fisher)). 
Additionally there is a significant reduction in LOW and MED compared to 
NOR at 7D (LOW vs. NOR: 0.68  0.76 vs. 10.61  4.81, p = 0.002, MED 
vs. NOR: 4.52  0.55 vs. 10.61  4.81, p = 0.006 (fisher)). Additionally 
there is a trend between LOW and MED (LOW vs. MED: 0.68  0.76 vs. 
4.52  0.55, p = 0.064 (fisher)), which suggests that LOW may reduce 
myogenin expression to a greater extent. This suggests that terminal 
differentiation is inhibited in both glucose-restricted conditions but more 
severely under LOW conditions. 
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 Fig 3.7. Graphs depicting means and SD’s for gene expression for: MyoD (A), MRF4 
(B) and Myogenin (C). LOW glucose is reduced compared to NOR or MED in at least 
one time point for all MRF’s studied. Significant difference (p<0.05) is denoted using a 
* . If approaching significance p value is stated. 
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3.3.4. Myosin Heavy Chain (MYHC) expression is impaired under 
MED and LOW glucose conditions compared to NOR. 
 Slow twitch fibres (MYHC7) have been observed to increase expression 
earlier during maturation whereas fast twitch fibres; MYHC: 1 (IIx), 2 (IIa) 
and 4 (IIb) tend to increase gene expression as myotubes become even 
more mature(Brown et al., 2012). No main or interactional effects are 
present for MYHC7. As with MRF4 and myogenin previously discussed, 
despite no significant main effect or interaction we still obtained pairwise 
comparisons using post hoc tests due to their stringency. These post hoc 
tests revealed an early increase in in MYHC7 in the NOR glucose 
condition at 72 h compared to 0 h, (NOR vs. 0 h: 5.54  2.40 vs. 1.46  
1.23, p = 0.027 (fisher)). We also see a significant difference between the 
0 h baseline and NOR glucose at 7D (0 h vs. NOR: 1.46  1.23 vs. 5.46  
4.94, p = 0.030 (fisher)). More importantly, we observed a main effect for 
glucose (F(2,18)  = 6.57, p = 0.007). This is readily observable at 7D where a 
significant difference is present between NOR and both the LOW (NOR vs. 
LOW: 5.46  4.94 vs. 0.61  0.27, p = 0.011 (fisher)) and MED (NOR vs. 
MED: 5.46  4.94 vs. 1.23  0.87, p= 0.023 (fisher)) conditions (Fig. 3.8, 
A). MYHC2 also displays no significant difference across time points or 
glucose concentrations in addition to no significant pairwise comparisons 
(data not reported, see figure 3.8, B). 
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MYHC4 displays a significant main effect for glucose (F(2,18) = 6.57, p = 
0.007), evidenced by the large increase under NOR conditions between 0 
h to 7D (0 h vs. NOR: 1.38  1.19 vs. 10.04  10.30, p = 0.016). There 
was no significance over time in the MED condition overtime (0 h vs. MED: 
1.38  1.19 vs. 2.30  1.53, p = 1.000). Importantly there was a significant 
difference in MYHC4 between NOR and both MED and LOW glucose 
conditions at 7D (NOR vs. MED: 10.04  10.30 vs. 2.30  1.53, p = 0.028 
(fisher), NOR vs. LOW: 10.04  10.30 vs. 0.91  0.06, p = 0.012 (fisher)) 
(Fig. 3.9, A). 
Fig. 3.8. Graphs depicting means and SD’s for gene expression for: A) MYHC7 B) 
MYHC2. MYHC7 is effected by restricted glucose whereas MYHC2 is not. Significant 
difference (p<0.05) is denoted using a * . If approaching significance p value is stated. 
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Finally, for MYHC1, a significant main effects for glucose (F(2,17) = 4.48 , p= 
0.027) and time (F(2,17) = 3.78, p = 0.044) as well as a significant 
interaction between the two (F(4,17) = 2.95, p = 0.051), was observed for 
MYHC1 (Fig. 3.9, B). Post hoc tests elucidated a significant increase in 
MYHC1 gene expression between NOR at 7D and 0 h (NOR vs. 0 h:  
386.00  333.00 vs. 1.13  0.77, p= 0.028). A significant difference was 
also present at 7D between NOR and LOW (NOR vs. LOW: 386.00  
333.00 vs. 3.37  1.71, p = 0.029). With fisher comparisons observing a 
significant difference between NOR and MED (NOR vs. MED: 386.00  
333.00 vs. 31.70  40.90, p= 0.002). These findings are similar to both 
MYHC4 and 7. Overall lowing glucose availability clearly affected early 
differentiation (MyoD) and myotube formation (myogenin) in line with the 
reduced myotube number and CK activity. This is in addition to impaired 
myotube maturation and hypertrophy demonstrated by a reduction in 
myotube size and gene expression of MYHC 1,4 and 7. 
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3.3.5. LOW and MED glucose do not have an increased atrophic gene 
expression.  
Work from our lab has previously documented a reduction in Insulin like 
growth factor binding protein 2 (IGFBP2) expression across the 
differentiation timecourse, when expression increased differentiation 
reduced (Fig 3.10, A) (Sharples et al., 2013a). There was a significant 
main effect for time for IGFBP2 in these experiments (F(2,17) = 15.29, p < 
0.001). Fisher posthoc tests then confirmed a significant reduction in 
IGFBP2 expression between the 0 h baseline compared to NOR, MED 
Fig. 3.9. Graphs depicting means and SD’s for gene expression for: A) MYHC4 B) 
MYHC1. Both MYHC4 and 1 display an increase in NOR at 7D compared to 0 h. 
Additionally there is a significant increase in expression for both MYHC4 and 1 between 
NOR and both MED and LOW. Significant difference (p<0.05) is denoted using a *.  If 
approaching significance p value is stated. 
 
CON LOW MED NOR LOW MED NOR
0
200
400
600
800
M
Y
H
C
1
 Δ
Δ
C
T
 e
x
p
re
s
s
io
n
 v
a
lu
e
0 h 72 h 7D
*
*
*
*
CON LOW MED NOR LOW MED NOR
0
5
10
15
20
25
M
Y
H
C
4
 Δ
Δ
C
T
 e
x
p
re
s
s
io
n
 v
a
lu
e
0 h 72 h 7D
*
*
*
A B
  
82 
and LOW for both 72h (0 h vs. NOR: 1.25  0.82 vs. 0.38  0.31, p < 0.046, 
0 h vs. MED: 1.25  0.82 vs. 0.04  0.02, p = 0.017, 0 h vs. LOW: 1.25  
0.82 vs. 0.02  0.01, p = 0.008) and 7D (0 h vs. NOR: 1.25  0.82 vs. 0.07 
 0.06, p = 0.012, 0 h vs. MED: 1.25  0.82 vs. 0.09  0.05, p = 0.013, 0 h 
vs. LOW: 1.25  0.82 vs. 0.02  0.01, p = 0.008). This surprisingly 
suggests that all conditions are reducing IGFBP2 across the differentiation 
timecourse as a decrease over the timecourse has been previously 
correlated with improved differentiation (Sharples et al., 2013a).  
 
As inhibitor DNA binding protein 3 (ID3) inhibits differentiation. A 
significant reduction in ID3 is needed following proliferation in order to 
allow myotube formation to take place (Jen et al., 1992). By measuring 
ID3 we aimed to establish whether the reduction in MRFs, particularly 
MyoD, was driven by an increase in ID3 (Chen et al., 1997). There is a 
main effect for time present for ID3 expression (F(2,17) = 9.21, p = 0.002 
(fisher)). As expected this was due to the reduced expression in 
comparison to the 0 h for LOW and NOR at both 72 h (0 h vs. LOW: 1.11 
 0.63 vs. 0.04  0.01, p = 0.022, 0 h vs. NOR: 1.11  0.63 vs. 0.32  0.10, 
p = 0.055 (all fisher comparisons)) and 7D (0 h vs. LOW: 1.11  0.63 vs. 
0.12  0.08, p = 0.022, 0 h vs. NOR: 1.11  0.63 vs. 0.28  0.05, p = 0.043 
(all fisher comparisons)) signifying the end of proliferation (Fig 3.10, B). 
There was no difference between 72 h and 7D (NOR, 72 h vs. 7D: 0.32  
0.10 vs. 0.28  0.05, LOW, 72 h vs. 7D: 0.04  0.01 vs. 0.15  0.13, p > 
0.05). Nor was there a significant difference between glucose 
concentrations at either 72 h (NOR vs. MED: 0.32  0.10 vs. 0.46  0.68, 
vs. LOW: 0.04  0.01, MED vs. LOW: 0.46  0.68 vs. 0.04  0.01, p > 0.05) 
or 7D (NOR vs. MED: 0.28  0.05 vs. 0.44  0.41, vs. LOW: 0.15  0.13, p 
= 0.736, MED vs. LOW: 0.44  0.41 vs. 0.15  0.13, p > 0.05).  
 
Muscle ubiquitin ligase of SCF complex in atrophy-1 (MUSA1) is a 
Forkhead box O (FoxO) dependant ubiquitin ligase with a role in the 
tagging of proteins to undergo ubiquitination (Bodine and Baehr, 2014). An 
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increase in MUSA1 expression has been documented in muscle atrophy, 
particularly denervation (Bodine and Baehr, 2014) and fasting under the 
regulation of FoxO3 (Milan et al., 2015). Throughout the time course none 
of the glucose concentrations differed significantly form the 0 h (0 h: 1.35  
0.81 vs. LOW, 72 h: 0.84  0.01, vs. LOW, 7D:. 1.54  1.05, , vs. MED, 72 
h: 1.35  0.81 vs. 0.63  0.43, vs. MED, 7D: 1.35  0.81 vs. 0.45  0.25 vs. 
NOR, 72 h: 1.41 v 1.39, vs. NOR, 7D:. 0.83  0.54, p > 0.05). There was 
also no significant difference present between glucose restriction and 
NOR conditions at 72 h (NOR vs. MED: 1.41 v 1.39 vs. 0.63  0.43, NOR 
vs. LOW: 1.41 v 1.39 vs. 0.84  0.01, All p > 0.05) or 7D (NOR vs. MED: 
0.83  0.54 vs. 0.45  0.25, NOR vs. LOW: 0.83  0.54 vs. 1.54  1.05, All 
p > 0.05) (Fig 3.10, C). This data taken alone suggests that under glucose 
reduction there is no increase in atrophic gene expression, this is in direct 
conflict with the morphological and biochemical data. The reduction in 
myotube formation observed here may therefore be due to a reduction in 
hypertrophic gene expression only or MUSA1 is playing a different role in 
differentiating muscle cells than the previous observations in mature 
muscle fibres in-vivo, described above (Milan et al., 2015).  
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Fig. 3.10. Graphs depicting means and SD’s for gene expression for: A) IGFBP2 B) 
ID3 and MUSA1 C). All experimental conditions are significantly reduced in 
comparison to 0h. The same is true for LOW and NOR conditions for ID3 gene 
expression. There are no significant differences present for MUSA1. Significant 
difference (p < 0.05) is denoted using a * . If approaching significance p value is 
stated. 
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 3.3.6. SIRT1 expression increases following LOW glucose conditions  
We have previously observed increases in SIRT1 mRNA expression under 
the stress induced by the presence of the inflammatory cytokine TNF-α. 
This increase promoted cell survival in muscle cells as confirmed via SIRT 
siRNA in which further cell death was promoted, Furthermore SIRT1 
activation via resveratrol administration aided the maintenance of 
differentiation under the aforementioned TNF-α condition (Saini et al., 
2012). For SIRT1 gene expression we observed significant main effects 
for glucose (F(2,17) = 9.62, p = 0.002) and time (F(2,17) = 6.60, p = 0.008) as 
well as an interaction between glucose dose and time (F(4,17) = 5.40, p = 
0.005). Interestingly the changes over time for the NOR group consisted of 
a decrease between 0 h and both 72 h (0 h vs. NOR: 1.41  0.54 vs. 0.55 
 0.23, p = 0.046 (fisher)) and 7D (0 h vs. NOR: 1.41  0.54 vs. (Fig 3.11). 
There is however no significant difference for NOR glucose between these 
time points (72 h vs. 7D: 0.55  0.23 vs. 0.58  0.44, p > 0.05).  
 
The observation above in which the NOR condition is decreased in 
comparison to the 0 h time point is not detected following 72 h in MED 
glucose (0h vs. MED, 72 h: 1.41  0.54 vs. 1.27  0.01, p > 0.05). At 72 h 
there is no significant reduction in SIRT1 present and the expression 
remained the same as 0 h. A trend similar to the abovementioned 
reduction in SIRT1 under NOR conditions is instead observed at 7D 
compared to 0 h (0 h vs. MED, 7D: 1.41  0.54 vs. 0.65  0.25, p = 0.075 
(fisher)).  
 
Importantly, initial changes in SIRT1 expression under LOW glucose 
conditions display an opposing pattern to NOR conditions (Fig 3.11). A 
large significant increase in SIRT1 expression is observed under LOW 
conditions following 72 h in comparison to 0 h (0h vs. LOW: 1.41  0.54 vs. 
2.97  0.84, p = 0.038). LOW glucose causes a significantly larger 
expression of SIRT1 than both MED and NOR following 72 h (LOW vs. 
MED: 2.97  0.84 vs. 1.27  0.01, p = 0.047, LOW vs. NOR: 2.97  0.84 
vs. 0.55  0.23, p < 0.001). This observation is similar to that previously 
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documented under an alternative stress, the presence of TNF-α (Saini et 
al., 2012). After this initial increase, we observed a dramatic significant 
decrease at 7D (LOW, 72h vs. LOW, 7D: 2.97  0.84 vs. 1.10  0.33, p = 
0.007). This decrease brings SIRT1 levels back to a similar level of the 0 h 
control (0 h vs. LOW, 7D: 1.41  0.54 vs. 1.10  0.33, p > 0.05). At this 
timepoint there was no longer a significant difference between any of the 
glucose conditions (LOW vs. MED: 1.10  0.33 vs. 0.65  0.25, LOW vs. 
NOR: 1.10  0.33 vs. 0.58  0.44, MED vs. NOR: 0.65  0.25 vs. 0.58  
0.44, All p > 0.05). The complete loss of myotube formation observed 
during the LOW glucose conditions may therefore be closely related to this 
initial increase in SIRT1 (Fig 3.11). where the cells are attempting to 
survive rather than differentiate. Importantly, by activating SIRT1 in LOW 
glucose conditions, as in TNF-α administration, we may be able to 
promote maintenance of differentiation under nutrient stress.  
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Fig. 3.11. Graphs depicting means and SD’s for gene expression for SIRT1. LOW 
glucose is significantly increased in comparison to NOR and MED following 72 h. 
Significant difference (p<0.05) is denoted using a * . If approaching significance p 
value is stated. 
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3.4. Summary 
Following reductions from the normal in vitro glucose concentration (NOR) 
we established that two concentrations were more physiologically relevant 
than the other possibilities.  The morphological and biochemical data 
determined that there was a reduced ability to differentiate under MED 
glucose conditions evidenced through the reduction in myotube size. 
Under LOW conditions no myotubes where formed. This provided us with 
models of reduced (MED) and impaired (LOW) differentiation which where 
also physiologically relevant to muscle interstitium levels under regular 
calorie consumption (MED) and restricted levels (LOW). Gene expression 
of the MRF’s was impaired in both concentrations in comparison to NOR, 
however the restricted concentrations did not differ from each other in 
MyoD nor Myogenin. There was, however a significant difference between 
the two for MRF4 suggesting that the gene expression for these two 
concentrations are not simply replicas.  
 
MYHC 4 and MYHC 1 expression was reduced in both LOW and MED 
compared to the NOR glucose condition. As these isoforms are 
prerequisites to fast and slow twitch fibres respectively it suggests that a 
change in composition is not present, instead the expression is reduced 
possibly due to the reduction in both size and number observed under 
restricted glucose conditions (Fig. 3.4 and 3.6.). NOR glucose had higher 
expression of MYHC 1, 4 and 7 suggesting that there was no real 
modification in myotube composition under LOW and MED conditions, 
instead there was just a reduced expression possibly due to the reduction 
in myotube size and number. There was no significant difference between 
any of the glucose concentration in the atrophic gene expression, which is 
in a direct conflict of the morphological and biochemical data. This may 
suggest that the reduction in myogenic gene expression drives the 
reduction in differentiation observed. There was however a reduction in 
ID3 following in NOR glucose after 0 h which may have given rise to the 
increase in MyoD observed at the same time points. Although, in 
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opposition to NOR conditions MyoD was reduced in LOW glucose (Fig 
3.5.) there was no significant increase in ID3 (Fig 3.10) which would be 
indicative of an ID3 mediated increase in MyoD.  
 
As myotube formation was greatest in the NOR condition and there was a 
reduction observed in SIRT1 it would be most logical to suggest that this 
reduction may be required for differentiation to take place, especially given 
that MED glucose conditions display an impaired differentiation and 
myotube maturation while the reduction in SIRT1 is delayed. Alternatively, 
based on our groups previous findings, in which an increase in SIRT1 
under stress environments is a survival mechanism stress aiding 
improvements in differentiation (Saini et al., 2012). In this instance this 
data may be interpreted that under NOR glucose conditions appropriate 
differentiation is occurring and as such no survival mechanism is required, 
thus SIRT1 is not increased.  
 
3.5. Conclusion 
We can conclude from this data that we have been able to establish a 
model to investigate the impact of glucose concentration on muscle cell 
differentiation. The two concentrations we performed in depth 
morphological, biochemical and gene expression investigations on are 
models of reduced (MED) and impaired (LOW) differentiation which also 
provide an in vitro representation of both glucose conditions under normo-
caloric and restricted levels respectively. Finally, as we observed similar 
results to those previously documented in the presence of TNF-α, in which 
SIRT1 is increased under stress. If indeed an increase in SIRT1 under 
stress environments is a survival mechanism, further activation of SIRT1 
than produced by stressed cells may promote successful survival and 
improvements in myotube differentiation (Saini et al., 2012). Before this 
can be performed however an optimum SIRT1 activation must first be 
established.  
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4. The activation of SIRT1 in 
myoblasts in response to a 
pharmacological administration 
of resveratrol and EX-527. 
4.1. Introduction 
The antioxidant resveratrol (RES) has been used widely as a mimetic of 
dietary restriction (DR) due to its ability to increase cell survival in budding 
yeast (Howitz et al., 2003) and its purported role in the extension of 
lifespan in mice consuming high calorie diets (Baur et al., 2006). Found 
predominately in the skin of red grapes, this polyphenol was originally 
determined to activate Sir2 in yeast and more recently the Sir2 
mammalian homologue SIRT1 (Vinciguerra et al., 2010, Zu et al., 2010). 
Although most frequently studied in relation to SIRT1 activation RES also 
increases, which may be responsible for some of the many discrepancies 
observed within the literature (Gertz et al., 2012). SIRT1 activation via 
RES administration, can also regulate AMPK activity and mitochondrial 
function (Price et al., 2012). Calorie restriction has previously been 
documented to evoke an increase in SIRT1 activity as a potential survival 
mechanism (Chen et al., 2008) while Fulco et al. (2008) suggest that the 
increase in SIRT1 is the mechanism that instigates the loss in muscle 
mass under this nutritional stress.  
 
Previous literature has administered RES to assess growth, differentiation 
and migration in murine skeletal muscle cells (Fröjdö et al., 2011, 
Kaminski et al., 2012), and has been used to treat parental C2 (Saini et al., 
2012) and daughter C2C12 cells (Deane and Sharples et al, Unpublished) 
It was shown to enable the maintenance of differentiation in the presence 
of increased inflammation (Saini et al., 2012), with other groups also 
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suggesting that resveratrol can improve myoblast migration following 
oxidative stress (Bosutti and Degens, 2015). Therefore, the use of RES to 
activate SIRT1 in muscle cells may enable us to elucidate the role of 
SIRT1 activation and the impact of blocked/impaired muscle cell 
differentiation/myotube hypertrophy under nutrient/glucose restriction 
(chapter 3) in future chapters (chapter 5 and 6). Although the 
aforementioned studies used resveratrol, these studies have only 
characterised the total protein and/or mRNA of SIRT1 (or neither) and 
have not characterised SIRT1 activity (phosphorylation) in response to 
resveratrol administration in muscle cells. Therefore we aim to elucidate 
the changes in SIRT1 activation (phosphorylation) following resveratrol 
administration in skeletal muscle cells in a dose responsive fashion.  
 
Inhibition of SIRT1 activation will be implemented in order to act as 
relevant negative control opposing increases in SIRT1 activity in the 
presence of low glucose conditions later documented in chapters 5 and 6..  
SIRT1 inhibition at the gene expression level has been performed in 
previous studies using siRNA (Rodgers et al., 2005a, Saini et al., 2012). 
Alternatively, selective SIRT1 inhibitors have also been utilized, EX-527 is 
one such SIRT1 inhibitor able to reduce SIRT1 activity in a wide variety of 
cells including; astrocytes (Kauppinen et al., 2013), human embryonic 
kidney and fibrosarcoma cell lines (Yang et al., 2007). However to the 
authors’ knowledge, there are no studies using EX-527 in myoblasts that 
assess the impact of this treatment on SIRT1 activation.  
 
This group have previously administered C2C12 cells with concentrations 
of RES at 30 and 60 μM however these doses compromised cell viability 
(Deane and Sharples et al., 2015 unpublished). Cell death has also been 
observed at these doses by other groups in C2C12’s (Bosutti and Degens, 
2015). We therefore undertook a dose response of resveratrol at 5, 10 and 
15 M and investigate the impact on SIRT1 activation. Additionally recent 
evidence suggests that 10 M is beneficial in C2C12 myoblasts 
remodelling under oxidative stress and as such has potential to be 
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beneficial under an alternative stress environment (DR) (Bosutti and 
Degens, 2015). We also aimed to undertake dosing of muscle cells with 
the SIRT1 inhibitor (EX-527) at both 30 and 60 µM. We hypothesised that 
SIRT1 activity would increase and decrease following RES/ EX-527 
administration respectively in a dose responsive manner. The ultimate aim 
was to establish whether activation/inactivation of SIRT1 can ameliorate 
the nutrient restriction induced block in muscle cell differentiation observed 
in low glucose (mimicking muscle interstitium glucose during DR) and the 
reduced differentiation in medium glucose (circulatory glucose during DR) 
respectively. 
 
4.2. Methods 
4.2.1. Cell culture 
6Well plates were pre-treated with 0.2% porcine gelatine for 10 min at 
room temperature (RT) and 10 min in a humidified, 37°C with 5% CO2. 
The excess gelatine was aspirated and cells were seeded at 8 × 104 
cells/ml in 2 ml of GM per well, these were then incubated until 80% 
confluence. Cells were washed in PBS and transferred into 2 ml of DM in 
37°C with 5% CO2 for up to 7 days (7D). Time point of extraction was as 
described in the methods section 2.2.2. i.e. 15 min following administration 
of the SIRT1 activator/ inhibitor. In order to determine the optimum 
concentration to increase expression of SIRT1 cells were incubated with 
either: 5 μM, 10 μM or 15 μM of RES (5RES, 10RES and 15RES 
respectively). Inhibition of SIRT1 expression was initially assessed via 
incubation of 30 or 60 μM and then subsequently lower doses of 100 nM 
or 200 nM of EX-527. All SIRT1 activation and inhibition experiments for 
this dose response study were performed in the same reconstituted 
differentiation media as discussed in chapter 3 at a glucose concentration 
of 4.5 g/L (NOR condition). Further information of cell culture methods can 
be found in section 2.2.1 in chapter 2.  
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4.2.2. Total protein content 
Protein was measured using BCA™ (Pierce, Rockfored, IL) according to 
instructions and detected using CLARIOstar® plate reader (BMG labtech, 
Germany) at a wavelength of 540-590 mM to quantify total protein 
concentrations prior to relative comparison of CK samples (See general 
methods chapter 2, section 2.2.8.). 
 
4.2.3. SDS-PAGE and immunoblotting 
Full methods can be found in in chapter 2, section 2.2.10. Briefly, western 
blot analysis via SDS-PAGE and immunoblotting was carried out on 10% 
resolving gels using 30 μg of protein per sample. Semidry transfer was 
utilized and immunoblotting for total and phosphorylated SIRT1 was 
carried out using catalogue number 07-131 from Merck Millipore 
(Darmstadt, Germany) and catalogue number 2314L (Cell Signalling 
Technology, MA, USA) respectively. Additionally, GAPDH 5174 (Cell 
Signalling Technology, MA, USA) was implemented as a loading control, 
further information on protocol and the antibody concentrations used 
factors can be found in chapter 2, section 2.2.10.  
 
4.2.4. Statistical analysis 
All data was performed using three separate cell populations thus 
performed N=3. Analysis was then carried out using Minitab® 17 (Minitab 
Ltd, Coventry U.K). Outliers where removed using Grubbs outlier test. All 
data was parametric, assessed using the Anderson-Darling test for 
normality. General linear models where carried out for the initial RES 
analysis (4 x 1) for RES concentration (DM, 5, 10,15 μM) and for the 
selected time point, this analysis was carried out for timepoints (15 min, 30 
min, 2 h and 24 h). Time course analysis for 10 and 15RES were carried 
out using a (2 x 4) general linear model for RES concentration (10, 15 μM) 
and time (15 min, 30 min, 2 h and 24 h). The timecourse, which compared 
DM to 10 and 15 RES, implemented a general linear model (3 x 4) for 
RES concentration (DM, 10 and 15 μM) and timepoint (15 min, 30 min, 2 h 
and 24 h). The SIRT1 inhibitor (EX-527) analysis was performed via a 
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general linear model (2 x 4) for RES concentration (DM, 100 nM) and 
timepoint (15 min, 30 min, 2 h and 24 h). Post hoc tests were performed 
using Fisher, Bonferroni and Tukey. The results produced through the 
Bonferroni tests are reported throughout results unless otherwise stated. 
 
4.3. Results 
4.3.1. Initial resveratrol dose response. 
A dose response investigation was implemented to study whether 
resveratrol (RES) administration could be used to effectively activate 
SIRT1. Our first objective was to establish the optimal dose of resveratrol 
in activating SIRT1 via western blot analysis of phosphorylated SIRT1 
concomitantly with any changes in total SIRT1 protein levels. Based on 
our unpublished results that 30 and 60 uM resveratrol reduces myoblast 
cell viability, as observed by others (Bosutti and Degens, 2015). We 
undertook a dose response for resveratrol of 5, 10, 15 μM. There was an 
average increase observed for 5, 10 and 15 μM in comparison to the DM 
condition following 30 min in which 10RES appeared to possess a higher 
average activity rate (30 min: 5RES vs. 10RES: 1.27 ± 0.48 vs. 1.34 ± 
0.01, p > 0.05, Fig. 4.1.). As this was non-significant to establish whether 
RES increased over time, therefore we carried out a timecourse analysis 
over a longer period e.g. 15, 30 mins, 2 h and 24 h. During this analysis 
we did not carry forward the 5RES as the activation was slightly less 
favorable than the higher dose of 10 μM (5Res vs. 10RES: 1.27 ± 0.48 vs. 
1.34 ± 0.01, p > 0.05). 
 
4.3.2. Effect of 10 μM RES on SIRT1 activation 
We observed significant increases in SIRT1 activity following 10RES 
supplementation following 15 min and 24 h with an increase suggested 
following 30 min (DM 15 min: 1.00 ± 0.00 vs. 10RES 15 min: 16.34 ± 4.26, 
p = 0.021 vs. 10RES 24 h: 15.65 ± 7.70, p = 0.026, 10RES 2 h: 11.22 ± 
5.54, p = 0.088, (all fisher comparisons) Fig. 4.1.). Similarly, 15RES also 
increased significantly from the 15 min DM at 2 h and 24 h (DM 15 min: 
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vs. 15RES 24 h: 17.50 ± 10.86, p = 0.014, 15RES 2 h: 13.72 ± 8.51, p = 
0.047(all fisher comparisons) Fig 4.1), 15RES also increased significantly 
after 30 min but not 15 min (DM 15 min: 1.00 ± 0.00 vs. 15RES 30 min: 
13.78 ± 6.41, p = 0.046 (fisher) Fig 4.1.). SIRT1 activity was therefore 
increased in both 10RES and 15RES. As there was still no observable 
difference between these two concentrations therefore to save additional 
reagent costs at higher concentrations the use of the lower concentration 
10RES was taken forward. Especially given recent evidence that 10 M is 
beneficial in C2C12 myoblasts remodelling under oxidative stress (Bosutti 
and Degens, 2015).  
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4.3.2. The Effect of the SIRT1 inhibitor (EX-527) at a concentration of 
30 μM and 60 μM on SIRT1 activation 
We also undertook a dose response study of SIRT1 inhibitor (EX-527). 
Initially we carried this out using 30 μM and 60 μM concentrations as this 
inhibitor at 30 μM has been previously shown to inhibit SIRT1 at these 
Fig.4.1. Control corrected, Phosphorylated SIRT1 relative to Total SIRT1 across the 
time course, relative to the loading control, GAPDH. Both 10 and 15RES displayed an 
increase in SIRT1 in comparison to DM. Significant difference (p < 0.05) is denoted 
using a *. 
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concentrations in C2C12 cells (Price et al., 2012). We however discovered 
no significant differences in p-SIRT at 15 min, 30 min nor 2 h (All 
comparisons, p > 0.05, Fig.4.2.). Indeed, in some instances there was 
increased SIRT1 activity with EX-527 administration (Fig. 4.2). A lower 
doses of 100 nM was consequently carried out, as the lower concentration 
of 100 nM had been previous shown to inhibit SIRT1 in other non-muscle 
cell types (Solomon et al., 2006).  
 
Fig.4.2. Phosphorylated SIRT1 relative to Total SIRT1 at 15 min (A), 30 min (B) and 2 
h (C) displayed no significant differences for any experimental conditions. 
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4.3.3. The Effect of the SIRT1 inhibitor (EX-527) at a concentration of 
100 nM on SIRT1 activation  
We observed an average decrease of 71% in SIRT1 activity following 24 h 
in the presence of 100 nM of EX-527 in comparison to the DM control at 
15 min, an observation that approached significance (DM 15 min vs. EX-
527 24 h: 1.00 ± 0.54 vs. 0.29 ± 0.13, p = 0.062 (fisher), Fig. 4.3.) 
compared to only a 50% reduction after 24 h in SIRT1 phosphorylation 
without EX-527 administration (DM 15 min vs. DM 24 h: 1.00 ± 0.54 vs. 
0.48 ± 0.34, p > 0.05). This suggested that on average there was a 20% 
larger reduction in SIRT1 by 24 h with the addition of EX-527 vs. 15 min 
SIRT1 expression in DM (Fig 4.3.). Additionally, EX-527 at a concentration 
of 100 nM at 2 and 24 h was also reduced by an average of 20 and 40% 
respectively in comparison to DM at the same time points although this did 
not achieve statistical significance (2 h, DM vs. EX-527: 0.48 ± 0.32 vs. 
0.40 ± 0.31, 24 h, DM vs. EX-527: 0.48 ± 0.34 vs. 0.29 ± 0.13, p > 0.05).    
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4.4. Summary 
To establish whether SIRT1 activation/inhibition would improve growth and 
differentiation in muscle cells in glucose restricted environments we 
needed to establish SIRT1 phosphorylation in the absence or presence of 
commercially available SIRT1 activator/inhibitor, resveratrol and EX-527 
respectively. We observed a significant increase in SIRT1 activity with 
Fig.4.3. Phosphorylated SIRT1 relative to Total SIRT1 across the time course. A 
larger mean decrease in SIRT1 activity was observed between 15 min DM and 24 h 
following EX-527 at 100 nM. Significant difference (p < 0.05) is denoted using a *. If 
approaching significance p value is stated. 
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both 10 and 15 uM RES. Activation seemed more consistently elevated 
over the time course of 15 min, 30 min, 2, and 24 h with 10 uM RES, with 
the largest increase in SIRT1 Phosphorylation at 15 min with RES 10 uM. 
There was also no significant difference between 10 or 15 uM of RES. 
Therefore, these results and in order to save additional reagent costs at 
higher concentrations the use of the lower concentration 10RES was 
taken forward to chapter 5 and 6. Especially given recent evidence that 10 
M is beneficial in C2C12 myoblasts remodelling under oxidative stress 
(Bosutti and Degens, 2015). Furthermore, it is worth bearing in mind that 
oral resveratrol treatment is financially expensive and in-vivo resveratrol 
may have poor bioavailability through the gut (Walle et al., 2004), low 
concentration may only be available to skeletal muscle tissue, 
subsequently if lower concentrations were able to affect the block/reduced 
differentiation/ observed in chapter 3 during glucose restriction this would 
potentially reduce the amount of resveratrol required to pass through the 
gut and be available to skeletal muscle tissue (Walle et al., 2004). 
 
On average EX-527 reduced SIRT1 across the timecourse to the greatest 
extent following administration of 100 nM EX527, although this was not to 
as greater extent as we had previously anticipated. Indeed, initially higher 
doses of 30 and 60 uM did not decrease SIRT1 activity and in some 
instances paradoxically increased SIRT1 activation. There was no 
explanation as to why these higher doses may increase SIRT1 activation, 
however doses of 48-100 nM have previously been shown to inhibit SIRT1 
by approximately 50% (Solomon et al., 2006, Napper et al., 2005, Zhao et 
al., 2013). Inhibition in these instances was measured via vitro Fluor de 
Lys deacetylation assays in embryonic kidney cells to assess SIRT1s 
deacetylation activity and not phosphorylation (Solomon et al., 2006). 
Reductions in phosphorylation have been associated with reduced 
deacetylation activity of SIRT1. Therefore despite the poorer than 
anticipated reduction in SIRT1 phosphorylation following 100 nM of EX-
527 we suggest that the deacetylation may have decreased accordingly or 
to a greater extent within the C2C12 cells.  
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In the next chapter the objective was to implement these concentrations of 
SIRT1 activator/ inhibitor in the presence or absence of low glucose 
conditions as characterised in the previous chapter (3). This would enable 
us to determine whether the activation/inhibition of SIRT1 was able to alter 
the block/reduction of differentiation observed in low/ medium glucose 
concentrations respectively that mimic circulatory (MED) and interstitial 
glucose levels (LOW) observed during DR in rodents (observed in chapter 
3).  
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Chapter 5 
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5. SIRT1 activation and 
inhibition in myoblasts under 
reduced glucose conditions. 
5.1. Introduction 
In chapter 3 we provided evidence for a model of reduced (MED glucose) 
and blocked (LOW glucose) muscle cell differentiation with glucose 
concentrations that were physiologically relevant to dietary restricted 
circulatory blood levels (MED 1.13 g/L or 6.25 mM) and that of the 
interstitium (LOW 0.56 g/L or 3.12 mM) in rodents. Furthermore, in chapter 
3, we also observed increased SIRT1 gene expression where myotube 
formation was completely blocked in LOW glucose conditions. Because 
the SIRT1 activator, resveratrol, has been previously observed to improve 
differentiation, where differentiation was blocked due to TNF- 
administration (Saini et al., 2012). We suggested that SIRT1 activation via 
resveratrol treatment may improve differentiation and myotube maturation 
in skeletal muscle cells under reduced glucose conditions. Furthermore, in 
chapter 4 we determined the concentrations of RES and EX-527 for the 
activation and suppression respectively of SIRT1 activity in myoblasts. 
Therefore these data from chapter 3 and 4 combined to allow us to 
determine whether SIRT1 activation or inhibition would affect the loss of 
differentiation in LOW glucose conditions and the impaired differentiation 
observed in MED glucose conditions. We aimed to activate or inhibit 
SIRT1 activity under MED, LOW and NOR glucose conditions in 
differentiating myoblasts. We hypothesised that SIRT1 activation may 
ameliorate the blocked and reduced differentiation capacity observed 
under LOW and MED conditions respectively.  
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5.2. Methods 
5.2.1. Cell culture 
C2C12 murine myoblasts (Blau et al., 1985) at passage 12 were incubated 
in separate T75 flasks in a humidified, 37°C with 5% CO2 Growth media 
(GM) containing: Dulbecco’s Modified Eagle Serum (DMEM) (D6429-6, 
Sigma-Aldrich, UK), 1% Penicillin Streptomycin (Pen Strep), 10% New 
born calf serum (NBCS) and 10% Fetal Bovine Serum (FBS) until 80% 
confluency was attained. 
 
Experiments were initiated by removing GM (as described in the general  
methods, chapter 2, section 2.2.2), washing once with phosphate buffered 
saline (PBS) followed by the addition of powdered differentiation media 
(DM). The chosen powered DMEM was reconstituted according to 
manufactures instructions (8.3 g/L of DMEM) supplemented with 0.5840 
g/L L-Glutamine; 3.7000 g/L Sodium Bicarbonate; 0.1100 g/L, Sodium 
Pyruvate; 0.0159 g/L Phenol red and either 0 g/L or 4.5 g/L D-Glucose in 
order for the composition to match that of the more generally used liquid 
DMEM. This media was also supplemented with 2% HS and 1% PS. The 
powdered DM supplemented with glucose was compared to the liquid 
DMEM in section 3.3.1, thus making this powdered DMEM a relevant 
control as well as being used to produce the dosing conditions described 
below under section 3.2.2. The reduction in serum content, causing the 
C2C12 myoblasts to undergo spontaneous differentiation without requiring 
the addition of growth factors to initiate the process (Blau et al., 1985). 
Cells were seeded following trypsinization of the adherent cells, counts 
where performed using haemocytometer in the presence of Trypan Blue 
dye as described in general methods (section 2.2.3).  
5.2.2. Cell dosing 
6 Well plates where pre-treated with 0.2% porcine gelatine for 10 min at 
room temperature (RT) and 10 min in a humidified, 37°C with 5% CO2. 
The excess gelatine was aspirated and cells were seeded at 8 X 104 
cells/ml in 2 ml of GM, these were then incubated until 80% confluence. 
  
106 
Cells were washed in PBS and transferred into 2 ml of DM in 37°C with 
5% CO2 for up to 7 days (7D). Time point zero was defined as an 
incubation of 30 min after transfer to DM and is denoted as 0 hours (0 h). 
To assess the effect of SIRT1 manipulation under a glucose restricted 
environment in myoblasts the cells where incubated in reconstituted 
powdered media as described above and originally in chapter 2, section 
2.2.5.1 with either 25.00 mM (NOR), 6.25 mM (MED), or 3.12 mM (LOW) 
glucose. Resveratrol and EX-527 where also reconstituted as described in 
chapter 2, section 2.2.5.1. RES was used at a concentration of 10 μM and 
EX-527 at 100 nM. 
 
5.2.3. Morphology 
Myotube parameters including; number, diameter and size were assessed 
using a live imaging light microscope (AF600 modular system, Leica, 
Germany) cell imaging system at x 20 magnification at time points; 0, 72 h 
and 7D post transfer into DM. Per experiment, each time point and 
experimental condition was performed in duplicate with 12 images taken 
per well providing a total of 24 images per condition per timepoint. 
Experiments were then repeated n = 3. Analysis was performed on the 
images acquired at 0 h, 72 h and 7D using ImageJ software (NIH, USA) 
(See general methods chapter 2, section 2.2.6.) 
 
5.2.4. Total protein content 
Protein was measured using BCA™ (Pierce, Rockfored, IL) according to 
instructions and detected using CLARIOstar® plate reader (BMG labtech, 
Germany) at a wavelength of 540-590 mM to quantify total protein 
concentrations prior to relative comparison of CK samples (See general 
methods chapter 2, section 2.2.8.). 
 
5.2.5. Creatine Kinase  
Assessment of creatine kinase activity was measured using assay kit 
(Catachem, Inc, Connecticut, NE) according to manufactures instructions 
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and detected using a CLARIOstar® plate reader (BMG labtech, Germany) 
at a wave length of 340 nm. See general methods chapter 2, section 2.2.9. 
 
5.2.6. RNA Extraction and analysis 
RNA extraction was performed using the TRIzol method (See method 
chapter 2, section 2.2.11.), following the manufactures instructions 
(Invitrogen, Life technologies, Carlsbad, CA). RNA purity and 
concentration was assessed using 1μl of sample on a NanoDrop 2000c, 
UV-Vis (Ultraviolet–visible spectroscopy) spectrophotometer (Thermo 
Fisher Scientific, MA, USA) using ODs of 260 and 280 nm. A ratio of these 
OD value was calculated for each sample with all samples possessing 
260/280 ratios of between 1.8-2.2 and therefore accepted as high RNA 
quality. 
 
5.2.7. Primer design 
Identification of target sequences were carried out via Gene 
(http://www.ncbi.nlm.nih.gov/gene). Primers (Chapter 2, section 2.2.12.4.- 
table 2.2) were designed using Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
 
5.2.8. RT-PCR and analysis 
RT-PCR was carried out using Quantifast SYBR green RT-PCR kit 
(Qiagen, Manchester, UK) on a Rotor-Gene® (Qiagen, Manchester, UK) 
supported by Rotor-Gene® Q Software, version 2.1.0.9 (Qiagen, 
Manchester, UK). The RT-PCR cycles consisted of; 48°C, 30 min (reverse 
transcription/ synthesis of cDNA), 95°C, 10 min (transcriptase inactivation 
and initial denaturation) followed by 40 cycles of 95°C, 15 sec 
(denaturation), 60°C, 1 min (annealing and extension in 1 step). 
Disassociation melt-curve analysis was performed to reveal and therefore 
exclude non-specific amplification and primer dimer issues. All out gene 
products yielding on single melt peak/temperature suggesting one product 
was amplified. Relative gene expression analysis was carried out using 
ΔΔCt equation, otherwise known as the Livak method (Schmittgen and 
  
108 
Livak, 2008), this is to establish normalised expression ratios, where the 
relative expression is calculated as 2-ΔΔCt and Ct represents the threshold 
cycle. RPIIβ was extremely stable between experimental conditions (mean 
Ct 15.62 ± 0.11) and therefore used as the housekeeping gene in all RT-
PCR assays and the pooled mean used in the ΔΔCt calculations. All RT-
PCR figures are presented as a relative gene expression in comparison to 
the 0 h cell incubated in “Normal” glucose (4.5g/L or 25 mM). This sample 
was used as a calibrator condition in the subsequent equations in order to 
compare expression values across glucose concentrations. 
 
5.2.9. Statistical analysis 
All data was performed using three separate cell populations thus 
performed N=3. Analysis was then carried out using Minitab® 17 (Minitab 
Ltd, Coventry U.K). Outliers where removed using Grubbs outlier test. All 
data was parametric, assessed using the Anderson-Darling test for 
normality. General linear models (3 x 3 x 3) for time (0, 72h, 7D), glucose 
concentration (LOW, MED, NOR) and SIRT1 activation/inhibition (DM, 
RES, EX-527) where carried out for morphological analysis of myotube 
number and CK activity and a general linear model (4 x 3 x 3) for time (0, 
24, 72h, 7D), glucose concentration (LOW, MED, NOR) and SIRT1 
activation/inhibition (DM, RES, EX-527) gene expression. (Post hoc tests 
were performed using Bonferroni, Tukey and Fisher). The results 
produced through the Bonferroni tests are reported throughout results 
unless otherwise stated. 
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5.3. Results
 
Fig. 5.1. Representative images for 72 h and 7D of myoblast culture in LOW, MED 
and NOR glucose alone and with the addition of RES or EX-527. 
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5.3.1. Effect of EX-527 administration on myotube number under 
Myotube number displayed a significant interaction for time, glucose 
concentration and SIRT1 manipulation (F(8, 868) = 12.32, p < 0.001), There 
was also a significant interaction between glucose concentration and 
SIRT1 (F(4, 868) = 20.62, p < 0.001), glucose and time (F(4, 868) = 58.29, p < 
0.001. There were significant main effects also present for glucose (F(2, 868) 
= 114.82, p < 0.001) and time (F(2, 868) = 135.41, p < 0.005) but not SIRT1 
activation/inhibition alone (F(2, 868) = 0.87 p > 0.05). As readily observed in 
Figure 5.1.  
 
In the presence of the SIRT1 inhibitor measurable myotubes were 
produced in LOW glucose conditions following 7D. This condition was the 
only LOW glucose condition to produce observable myotubes. Despite this, 
there was no significant difference between the SIRT1 inhibitor and the 
LOW glucose alone (LOW EX-527 vs. LOW: 0.03 ± 0.17 vs. 0.00 ± 0.00, p 
> 0.05, Fig. 5.2.). Therefore SIRT1 activation/inhibition via RES and EX-
527 respectively had little or no effect on restoring blocked differentiation 
observed when no increase was detected in myotube number in LOW 
glucose conditions at either 72 h or 7D. 
 
At 72 h there was no significance difference in myotube number following 
administration of RES or EX-527 within either the MED or NOR glucose 
concentrations. At 7D however, surprisingly under NOR conditions 
myotube number was significantly reduced when SIRT1 was activated 
under RES administration (NOR vs. NOR RES: 4.92 ± 3.30 vs. 3.67 ± 2.99, 
p = 0.009, Fig. 5.2.). SIRT inhibition via EX-527 administration in NOR 
glucose further reduced myotube number at 7D vs. NOR alone (NOR vs. 
NOR EX-527: 4.92 ± 3.30 vs. 2.03 ± 2.75, p < 0.001, Fig. 5.2.). Importantly, 
EX-527 administration in NOR glucose produced the lowest number of 
myotubes that were also significantly reduced vs. RES in NOR glucose at 
7D (p < 0.001). In MED glucose concentrations at 7D, there was a non-
significant increase in myotube number in the presence of RES (MED 
RES 0.59 ± 0.33 vs. MED 0.60  ± 0.21, p > 0.05). There was however a 
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significant increase in myotube number in MED glucose conditions in the 
presence of EX-527 in comparison to both MED glucose alone and MED 
glucose in the presence of resveratrol (MED EX-527 vs. MED: 3.04 ± 3.11 
vs. 0.13 ± 0.34, p < 0.001 and vs. MED RES: 0.79 ± 1.32, p < 0.001, Fig. 
5.2.).  
 
 
 
5.3.2. Resveratrol increases creatine kinase activity at 7D in LOW 
glucose conditions despite no increase in myotube formation and 
reduces CK activity with SIRT1 inhibition in normal glucose 
conditions.  
To confirm myotube number morphology as a measure of 
differentiation/fusion, biochemical activity of differentiation marker creatine 
kinase was assessed and produced a significant main effect for glucose 
(F(2,293) = 76.72, p  0.001) and time (F(2,293) = 4.80, p < 0.005). Additionally, 
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Fig. 5.2. Myotube number is reduced in cells undergoing MED glucose restriction, 
regardless of SIRT1 manipulation. No myotubes were observed in any LOW glucose 
conditions at any timepoint. Formation of myotubes under NOR conditions is impaired 
following the addition of RES at 7D and further impaired following the addition of EX-
527. Significant difference (p < 0.05) is denoted using a *. 
  
112 
a significant interaction was observed between time, glucose 
concentration and SIRT1 activation/inhibition (F(2,293) = 4.80, p= 0.009). As 
suggested in chapter 3 and confirmed here the LOW glucose condition 
had significantly lower CK activity across the time points in comparison to 
NOR glucose conditions (LOW vs. NOR; 48 h: 26.47  18.39 vs. 98.68  
29.56 mU.mg.ml-1, p < 0.001 (fisher), 72 h: 38.1  73.3 vs. 98.91  32.39, 
p = 0.003 (fisher), 7D: 16.82  15.95 vs. 139.56  22.17 mU.mg.ml-1, p < 
0.001). The same trend was also present for MED when compared to 
NOR glucose (MED vs. NOR; 48 h: 60.09  21.36 vs. 98.68  29.56, p = 
0.056 (fisher), 72 h : 21.71  17.93 vs. 98.91  32.39, p = 0.055, 7D: 44.4 
 27.14 vs. 139.56  22.17 mU.mg.ml-1, p < 0.001). There was however no 
significant difference between LOW and MED across time points (LOW vs. 
MED; 48 h: 26.47  18.39 vs. 60.09  21.36, p = 0.997, 72 h: 38.1  73.3 
vs. 21.71  17.93, p > 0.05, 7D: 16.82  15.95 vs. 44.4  27.14 mU.mg.ml-
1, p > 0.05). Again this morphology and CK activity data confirms the data 
in chapter 3 and suggests within the present chapter these data were 
relevant control conditions to elucidate any additional changes in the 
presence of absence of SIRT1 activation/inhibition. There was however, 
no significant differences in CK activity in the presence of RES on a 
background of LOW glucose at either 48 h (LOW vs. LOW RES: 26.47  
18.39 vs. 16.0  46.8 mU.mg.ml-1, p > 0.05), or 72 h (LOW vs. LOW RES: 
38.1  73.3 vs. 14.0  34.8 mU.mg.ml-1, p > 0.05). There was however an 
average increase at 7D that approached significance using fisher 
comparisons where RES administration was responsible for an increase in 
CK activity under LOW glucose conditions (LOW vs. LOW RES: 16.82  
15.95 vs. 54.4  44.7 mU.mg.ml-1, p = 0.069). CK values were however, 
still significantly lower under LOW conditions with the administration of 
RES than values observed in the NOR glucose condition at the same time 
point (LOW RES vs. NOR: 54.4  44.7 vs. 139.56  30.08, p = 0.016), 
therefore while SIRT1 activation was able to somewhat improve CK 
activity via resveratrol administration under LOW conditions these levels 
did not reach those observed under NOR conditions nor did we detect any 
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improvement in morphological differentiation via myotube number analysis, 
discussed above. There was also no significant difference present 
following the administration of EX-527 compared to LOW glucose alone 
conditions at 48 h (LOW EX-527 vs. LOW: 38.87  25.25 vs. 26.47  
18.39, p > 0.05) or 7D (LOW EX-527 vs. LOW: 22.1  10.1 vs. 16.82  
15.95, p > 0.05). At 72 h, however there was a significant reduction in CK 
under the EX-527 conditions (LOW EX-527 vs. LOW: 22.1  10.1 vs. 
16.82  15.95, p = 0.019 (fisher)). This is indicative of a complete loss of 
differentiation under EX-527 administration following 72 h. SIRT activation 
improved CK activity at 7 days. These findings confirm a role for SIRT1 in 
differentiation in the presence of nutrient stress, albeit SIRT1 activation 
was unable to return differentiation back to control levels.  
 
We observed no significant differences when resveratrol was administered 
in the presence of MED glucose alone at any of the time points analysed 
(MED RES vs. MED; 48 h: 60.09  21.36 vs. 54.65  30.00, p > 0.05, 72 h: 
39.83  22.20 vs. 21.71  17.93, p > 0.05, 7D: 14.4  79.6 vs. 44.4  27.14, 
p > 0.05). Nor was there any significance present following EX-527 
administration under MED conditions (MED vs. MED EX-527: 48 h: 60.09 
 21.36 vs. 61.08  23.85, p > 0.05, 72 h: 21.71  17.93 vs. 43.6  42.2, p 
> 0.05, 7D: 44.4  27.14 vs. 69.3  12.3, p > 0.05). As with the MED 
glucose alone condition there was also no significant difference present 
under NOR conditions at any time point when supplemented with either 
RES (NOR vs. NOR RES; 48 h: 98.68  29.56 vs. 92.8  42.8, p > 0.05, 
72 h: 98.91  32.39 vs. 88.8  36.7, p > 0.05, 7D: 139.56  22.17 vs. 132.9 
 30.08, p > 0.05) or EX-527 (NOR vs. NOR EX-527; 48 h: 98.68  29.56 
vs. 99.2  49.8, p > 0.05, 72 h: 98.91  32.39 vs. 85.2  43.3, p > 0.05, 7D: 
139.56  22.17 vs. 110.1  48.8, p > 0.05).  
 
Therefore overall, while there was increased CK activity in LOW glucose 
conditions in the presence of RES (Fig. 5.3), there was no increase in 
morphological differentiation/myotube number in these conditions (Fig 
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5.1.). This may suggest that CK may not be a relevant marker of 
differentiation in this instance and may perhaps be more a marker of 
potential differentiation when in a larger cell population. If this is the case it 
would suggest that SIRT1 activation via resveratrol administration maybe 
increasing CK activity in an attempt to initiate differentiation in LOW 
glucose, without leading to successful forming myotubes observable at the 
morphological level. However, SIRT inhibition via EX-527 administration in 
low glucose conditions at 72 h did lead to a complete loss of CK activity vs. 
low glucose alone and RES conditions. Finally, SIRT1 activation via 
resveratrol seems to be unable to improve reduced differentiation 
observed in MED glucose conditions and surprisingly both activation and 
inhibition of SIRT1 via resveratrol and EX-527 administration was actually 
detrimental to myotube formation/number and CK activity in normal 
glucose conditions (albeit lowest myotube formation was observed with 
SIRT1 inhibition vs. RES MED glucose alone).  
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5.3.3 Myotube size increased with resveratrol administration in NOR 
glucose conditions.  
There was no significant difference present for myotube size at 72 h for 
any condition within MED and NOR glucose conditions, readily observed 
in figure 5.4. Additionally, there was no significant difference following 7D 
in either MED or NOR conditions following the addition of EX-527 (All 
comparisons, p > 0.05). Myotubes were however significantly larger under 
NOR conditions with the addition of RES compared to the addition of EX-
527 (5718.00 ± 3532.00 vs. 4142.00 ± 1873.00, p = 0.021) and compared 
Fig 5.3. CK measurements of myoblasts undergoing differentiation under three different 
glucose conditions, with and without SIRT1 manipulation. As expected NOR glucose was 
significantly higher CK activity than the LOW and MED glucose concentrations at all time 
points. SIRT1 significantly increased CK activity in LOW glucose conditions at 7D, 
however this was without an increase in morphological myotube formation (Figure above 
5.1). Means and SD displayed. p < 0.05 is depicted by *. If approaching significance p 
value is stated. 
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to NOR glucose alone (NOR RES vs. NOR: 5718.00 ± 3532.00 vs. 
4551.00 ± 2836.00, p = 0.044, Fig 5.4.).  
 
Myotube diameter displayed a significant main effect for glucose condition 
(F(1, 281) = 18.01, p < 0.005), but no other main effect or interaction was 
present. Additionally, there was no significant change in diameter following 
the addition of either RES or EX-527 in either MED or NOR glucose 
conditions. As there were no observable myotubes in low glucose 
conditions as previously suggested this analysis was unavailable in these 
conditions.  
 
Therefore, although there were reductions in myotube number (Fig 5.2) 
and CK activity (Fig. 5.3) in the presence of RES in normal glucose 
conditions suggesting that RES actually impaired differentiation/myotube 
formation in these conditions (Fig. 5.4.). Resveratrol treatment actually 
increased myotube hypertrophy in normal glucose conditions shown by 
increases in myotube size, but not diameter, suggesting that while RES 
reduced myotube formation it increased the size of myotubes that were 
still present, potentially due to an increased length of myotubes (given that 
diameter did not increase and overall size did increase) (Fig. 5.4.). 
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Fig. 5.4. Graph A: Myotube area was significantly increased following the 
administration of RES in the NOR condition compared to NOR alone and EX-527 
supplementation. Additionally NOR RES also increased over time from 72 h and 7D. 
Graph B: No change was observed in myotube diameter. Significant difference (p < 
0.05) is denoted using a *. 
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5.3.4. MRF’s are unaltered following SIRT1 activation via resveratrol 
administration 
In order to elucidate the molecular mechanisms for the 
increased/decreased differentiation/ CK activity we examined the role of 
myogenin (differentiation/myotube formation) and MRF4 (late myotube 
differentiation/myotube maturation). Myogenin had a significant main effect 
for both time (F(3,54) = 29.31, p < 0.001) and glucose (F(3,54) = 36.87, p < 
0.001) as well as an interaction between the two (F(6,54) = 12.42, p = 0.004, 
Figure 5.4). However, the addition of RES or EX-527 did not significantly 
effect myogenin expression at any time point for both the glucose 
restricted conditions; MED (all comparisons p > 0.05, Fig 5.4). In NOR 
glucose conditions however, the addition of both EX-527 and RES 
significantly decreased the expression of myogenin at 72 h (NOR vs. NOR 
RES: 29.68  4.71 vs. 16.80  20.80, p = 0.007 (fisher), NOR vs. NOR EX-
527: 29.68  4.71 vs. 18.45  6.46, p = 0.017 (fisher)). This reduction in 
myogenin (Fig. 5.5.) corresponded with later reductions in myotube 
number by 7D (Fig 5.2) in these conditions. However, there was also an 
increase in myogenin in the presence of EX-527 at 7D, in which 
expression was significantly increased compared to NOR glucose alone at 
this time point (NOR vs. NOR EX-527: 21.60  18.70 vs. 33.36  0.33, p = 
0.013 (fisher)). RES however, induced no change in NOR conditions 
following 7D. Additionally NOR glucose with the addition of EX-527 also 
significantly increased over time, where expression was higher at 7D than 
at 72 h (7D vs. 72 h: 33.36  0.33 vs. 18.45  6.46, p = 0.002 (fisher)). 
Overall however the myogenic regulatory factor, myogenin does not seem 
to be involved in the improvements in CK activity and differentiation with 
the addition of resveratrol in the low glucose conditions at 7D or increases 
in myotube size with RES in normal glucose conditions.  
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There were also no significant differences in MRF4 expression with the 
addition of RES or EX-527 at any glucose concentration at 24 h and 72 h 
(all comparisons p > 0.05; Fig 5.6). Following 7D there was also no 
significant difference when SIRT1 was manipulated via resveratrol 
treatment in the NOR and the LOW conditions (all comparisons p > 0.05., 
Fig. 5.6.). The addition of EX-527 in MED conditions did not significantly 
Fig. 5.5. Graph depicting means and SD’s for gene expression for Myogenin. 
Myogenin in NOR glucose conditions in the presence of both RES and EX-527 was 
significantly decreased in comparison to NOR glucose alone at 72 h. Significant 
difference (p < 0.05) is denoted using a * . 
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change MRF4 expression following 7D (MED vs. MED EX-527: 1.02  
1.38 vs. 5.70  4.83, p > 0.05). Unexpectedly, MRF4 in MED glucose 
conditions was however increased under RES conditions in comparison to 
MED glucose alone (MED vs. MED RES: 1.02  1.38 vs. 58.70  79.30, p 
< 0.001 (fisher)), however, large standard deviations were observed in this 
condition and is therefore unlikely to be an accurate representation of 
expression in this condition. 
 
Fig. 5.6 Graph depicting means and SD’s for gene expression for MRF4. Significant 
difference (p < 0.05) is denoted using a * . 
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5.3.5. Resveratrol administration increased MYHC7 and MYHC4 gene 
expression in NOR glucose conditions. 
With an increase in myotube hypertrophy/size with resveratrol in normal 
glucose conditions and after observing a reduction in MYHCs with 
myotube atrophy under MED and LOW glucose concentrations in Chapter 
3. The gene expression of MYHC’s was assessed in order to analyse 
whether there was potentially increased contractile protein mRNA being 
transcribed in RES conditions that would subsequently lead to increased 
myotube protein content and hypertrophy and if there was a preference of 
either slow or fast MYHC’s. Gene expression of the MYHC’s within the 
muscle cells changed over time, suggested via a significant main effect for 
time for all MYHC measured including: MYHC7 (transcript coding for slow 
type I protein isoform) (F(3,51) = 8.95, p < 0.001),  MYHC2 (IIa) (F(3,59) = 
9.32, p < 0.001), MYHC4 (IIb) (F(3,57) = 23.90, p< 0.001), MYHC1 (IIx) 
(F(3,63) = 33.83, p < 0.001). 
 
Following 72 h there was no significant difference in MYH7 (slow type I) 
gene expression in any glucose dose condition supplemented with either 
RES or EX-527 (all comparisons p > 0.05, Fig. 5.7). The 7D time point 
revealed similar results for the LOW glucose condition in which there was 
no significant difference with the addition of RES or EX-527 (all 
comparisons p > 0.05, Fig. 5.6). The SIRT1 inhibitor however, significantly 
reduced the MYHC7 gene expression within the MED glucose condition at 
the same time point (MED vs. MED EX-527: 58.90  69.20 vs. 14.30  
18.40, p = 0.019 (fisher)). EX-527 did not however, significantly affect the 
MYHC7 expression under NOR glucose conditions (p > 0.05.). Importantly, 
the only significant increase in expression following RES administration 
was observed under the NOR glucose condition (NOR vs. NOR RES: 
10.53  9.84 vs. 77.50  102.40, p = 0.002 (fisher)) suggesting an 
increase in MYHC7 slow type I gene expression was present under these 
conditions that corresponded with an increase in myotube 
area/hypertrophy under these conditions at 7D. As described in chapter 3,  
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MYHC2 (type IIa) showed no significant differences in any condition (all 
comparisons, p > 0.05. (Fig. 5.8.). 
  
 
Fig. 5.7. Graph depicting means and SD’s for gene expression for: MYHC7. Gene 
expression under NOR RES conditions was significantly increased in comparison to 
NOR alone at 7D. Significant difference (p < 0.05) is denoted using a *.  
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In addition to the above reported significant main effect for time, MYHC4 
(type IIb) also displayed a significant main effect for glucose (F(2,57) = 4.77, 
p= 0.012) as well as a significant interaction between time and glucose 
(F(6,57) = 4.38, p = 0.001). There were no significant individual differences 
between any of the glucose conditions and the addition of RES or EX-527 
at 24 h or 72 h (all comparisons p > 0.05, Fig. 5.9).  In LOW and MED 
Fig. 5.8.  Graph depicting means and SD’s for gene expression for: MYHC2., in 
which no significant interactions were observed 
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glucose conditions no significant differences were observed following 7D 
conditions following the addition of resveratrol. In LOW glucose conditions 
the addition of EX-527 was also non- significant (all comparisons p > 0.05). 
There was a significant increase in MYHC4 expression with EX-527 
supplementation in MED conditions at 7D (MED vs. MED EX-527: 36.20  
42.20 vs. 79.90  51.10, p = 0.048 (fisher)). This confirms the morphology 
findings in which myotube number was increased in MED EX-527 in 
comparison to MED alone. Myotube number was also reduced in MED 
RES in comparison to MED EX-527, again MYHC4 expression mirrored 
these findings (29.60  32.80 vs. 79.90  51.10, p = 0.024). Contrary to 
the findings observed for MED glucose the NOR condition displays no 
significance with the addition of EX-527 (p > 0.05). However, MYHC4 
expression was increased in NOR RES conditions in comparison to NOR 
EX-527 (172.40  111.80 vs. 87.70  123.90, p = 0.002 (fisher)), these 
findings complement those observed in morphological data in which area 
was also increased under the supplementation of RES in comparison to 
EX-527 supplementation. MYHC4 expression in NOR conditions 
supplemented with RES is also significantly increased in the presence of 
NOR glucose (NOR vs. NOR RES: 67.90  19.20 vs. 172.40  111.80, p < 
0.001 (fisher)). These findings corroborate the morphological findings in 
which myotube area was increased following RES administration in NOR 
glucose.  
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Similarly to the MYHC4 data above there was a significant main effect for 
glucose dose (F(2,63) = 22.74, p < 0.001) present for MYHC1 (type IIx), as 
well as a significant interaction between time and glucose dose (F(6,63) = 
Fig. 5.9. Graph depicting means and SD’s for gene expression for: MYHC4. RES in 
NORM glucose conditions was significantly increased compared to NOR alone and 
vs. NOR with the addition of EX-527 at 7D. Significant difference (p < 0.05) is denoted 
using a *. 
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12.24, p < 0.001; Fig. 5.9). Comparisons of individual experimental 
conditions revealed no significant differences with the addition of RES or 
EX-527 for 24 h and 72 h (all comparisons p > 0.05, Fig. 5.10.). Following 
7D there was also no significant differences in MYHC1 between MED or 
LOW glucose conditions (all comparisons p > 0.05). Resveratrol increased 
MYHC1 on average in NOR glucose conditions however, they were not 
significant different to NOR alone (NOR vs. NOR RES: 212.40  120.40 vs. 
242.20  57.00, p > 0.05). There was however, a significant reduction in 
MHYC1 with EX-527 in NOR glucose conditions (NOR vs. NOR EX527: 
212.40  120.40 vs. 123.00  174.00, p = 0.008 (fisher)). 
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These data suggest that the activation of SIRT1 via RES administration in 
NOR glucose conditions perhaps evokes increases in both MYHC7 and 
MYHC4 gene transcripts coding for slow type 1 and fast IIb protein MYHC 
Fig. 5.10. Graph depicting means and SD’s for gene expression for: MYHC1. Gene 
expression under NOR EX-527 conditions was significantly reduced in comparison to 
NOR alone and NOR RES at 7D. Significant difference (p < 0.05) is denoted using a *. 
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isoforms in order to improve myotube hypertrophy as observed here by an 
increase in myotube size. Furthermore, SIRT inhibitor conditions suggest 
that MYHC1 gene transcript coding for fast IIx protein MYHC isoforms is 
reduced and therefore normal SIRT activity is perhaps important to 
maintain adequate fast IIx isoform gene expression. Having said this, 
MYHC changes do not seem to be involved in the improved 
differentiation/CK activity observed with resveratrol administration in LOW 
glucose conditions at 7 days.  
 
5.3.6. SIRT1 is reduced in all conditions following 7D and GCN5 
remains unchanged under most experimental conditions. 
SIRT1 gene expression possessed a significant interaction for time, 
glucose concentration and SIRT1 manipulation (F(12,50 = 1.83, p = 0.069). 
Additionally, a significant interaction was present between time and 
glucose (F(6,50) = 3.58, p = 0.005) and a significant main effect for time 
alone (F(3,50) = 31.02, p < 0.001; Fig 5.10). Interestingly, in NOR, MED and 
LOW conditions there was a drop in SIRT1 gene expression over the 
timecourse (observed by a significant main effect of time). Further, EX-527 
reduced SIRT1 gene expression in NOR and MED conditions over time 
(NOR EX-527: 24 h vs. 72 h: 0.72  0.05 vs. 0.18  0.04, p = 0.028 (fisher) 
and DM 0 h vs. MED EX-527 24 h: 1.01  0.04 vs. 0.47  0.31, p = 0.012 
(fisher). Where, MED EX-527 glucose conditions demonstrated the lowest 
reduction at 72hrs vs. NOR EX-527 (0.77  0.09 vs. 0.21  0.00). There 
was however no observed effect of SIRT1 activation or inhibition via 
resveratrol and EX-527 administration respectively in normal or MED 
glucose conditions within time points of 24 h, 72 h and 7d (All comparisons 
p > 0.05, Fig 5.11).  
  
Finally, as observed in chapter 3 in LOW glucose conditions alone there 
was an average increase vs. NOR and MED glucose alone conditions 
across the timecourse (24 h: LOW: 0.56   0.23 vs. MED:  0.60  0.21 vs. 
NOR:  1.00  0.53,  72 h: LOW : 1.34  1.06 vs. MED: 0.75  0.38 vs. 
NOR:  0.39  0.14,   7D: LOW :  0.18  0.00 vs. MED: 0.09  0.01 vs. 
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NOR:  0.11  0.00, all comparisons, p > 0.05), however the data presented 
here failed to reach significance due to large standard deviations in the 
LOW glucose condition. Furthermore, there was no difference in SIRT1 
gene expression in LOW glucose conditions with the addition of RES or 
EX-527 at 24 h, 72h and 7D (all comparisons, p > 0.05). Overall, therefore 
the supplementation of RES or EX-527 did not significantly change SIRT1 
expression values for NOR, MED or LOW glucose.  
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Fig. 5.11. Graph depicting means and SD’s for gene expression for SIRT1. Significant 
difference (p < 0.05) is denoted using a *. 
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5.4.Summary 
In this chapter we aimed to activate or inhibit SIRT1 activity under MED, 
LOW and NOR glucose conditions in differentiating myoblasts. We 
hypothesised that SIRT1 activation (Chapter 4) may ameliorate the 
blocked and reduced differentiation capacity observed under LOW and 
MED conditions respectively (observed in chapter 3). Overall, we partially 
rejected our hypothesis in that while there was increased CK activity 
indicative of increased differentiation in LOW glucose conditions in the 
presence of resveratrol, the SIRT1 activator was unable to prevent the 
block on morphological differentiation in low glucose conditions. This 
suggested that SIRT1 activation via resveratrol administration maybe 
increasing CK activity in an attempt to initiate differentiation in LOW 
glucose. Due to the small number of viable cells however, there is a lack 
of proximity to allow fusion to take place thus this increase in CK does not 
lead to the successful myotube formation observable at the morphological 
level.  
 
It is worth mentioning that SIRT inhibition via EX-527 administration in low 
glucose conditions at 72 h did lead to a complete loss of CK activity vs. 
low glucose alone and RES conditions. NOR glucose conditions SIRT1 
inhibition produced the lowest number of myotubes vs. resveratrol and 
control conditions at 7D, suggesting that normal SIRT1 activity was 
required to enable normal CK activity in low glucose conditions and basal 
myotube formation in normal glucose conditions. Furthermore, SIRT1 
activation via resveratrol was unable to improve the impaired 
differentiation observed in MED glucose conditions (therefore rejecting the 
original hypothesis). Both activation and inhibition of SIRT1 via resveratrol 
and EX-527 respectively was detrimental to myotube formation/number, 
CK activity in normal glucose conditions (albeit lowest absolute myotube 
formation was observed with SIRT1 inhibition vs. RES/MED glucose 
alone). Surprisingly, inhibition of SIRT1 via EX-527 caused an increase in 
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myotube number, a finding that was unexpected and warrants future 
investigation.  
 
The most unexpected and important finding in this study was that while the 
addition of both RES and EX-527 impaired CK activity, myogenin 
expression and formation of myotubes in NOR glucose conditions, in the 
myotubes that were still present resveratrol evoked an increase in 
myotube size/hypertrophy. This observation also corresponded with an 
increase in MYHC7 gene expression MYHC4 coding for the slow type I 
and fast IIb MYHC protein isoforms respectively. These data suggest that 
this adaptation following increased SIRT1 activity via resveratrol 
administration is perhaps responsible for the increased myotube size 
observed via the increased laying down of these contractile proteins. 
Furthermore, SIRT inhibitor conditions suggest that MYHC1 coding for the 
fast IIx MYHC protein isoform is reduced in normal glucose conditions and 
therefore suggests that normal SIRT activity is perhaps important to 
maintain adequate fast isoform gene expression. Having said this, MYHC 
changes do not seem to be involved in the improved differentiation/CK 
activity observed in LOW glucose conditions at 7D, which is partly 
expected as despite increases in CK activity this did not result in increased 
myotube formation.  
 
5.4.1. Future directions for chapter 6 
RES did not improve differentiation as we had previously hypothesized. 
There was however a beneficial increase in CK activity appears to be an 
indicator of differentiation potential rather than a quantifier of differentiation. 
As such regardless of this increase improvement in differentiation under 
LOW glucose conditions was present. This is potentially due to the limited 
cell population still present not being in close proximity to each other 
making fusion difficult. Therefore, in the next chapter we wished to 
examine the role of SIRT1 activation/inhibition in LOW and NORM glucose 
conditions on existing myotube cultures. The reasons for this were 
threefold; 1) because low glucose completely blocks myotube formation 
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(chapter 3), yet resveratrol does drive increases in CK activity despite no 
improvement in myotube formation in these conditions it is feasible that in 
the presence of existing myotubes, resveratrol may prevent myotube 
atrophy; 2) myotube cultures are perhaps more indicative of in-vivo tissue 
where myofibres already exist rather than differentiating myoblasts 
creating primary myotubes which more closely mimics 
development/regeneration; 3) and we would like to ascertain whether the 
increases in myotube hypertrophy are also observed in existing myotubes. 
In addition SIRT1 activation via resveratrol treatment in normal glucose 
concentrations increased myotube hypertrophy together with elevated 
slow type 1 MYHC (7) and type IIb MYHC4 gene expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
134 
 
 
 
 
 
Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
135 
6. Resveratrol reduces acute 
myotube atrophy with glucose 
restriction 
6.1. Introduction 
In the previous chapter we determined the advantageous affects present 
following SIRT1 activation via resveratrol administration in LOW glucose 
conditions. This consisted of an increase in CK activity despite an inability 
to ameliorate the lack of differentiation capacity under LOW glucose 
observed in chapter 3. In addition to these findings we also observed an 
increase in myotube hypertrophy in NOR glucose conditions which was 
coupled with an elevation in slow type 1, MYHC7 and type IIb MYHC4 
gene expression. We therefore aimed in the following chapter to ascertain 
the role of SIRT1 activation/ inhibition in LOW and NOR glucose 
conditions on mature myotubes. We hypothesised that activation of SIRT1 
may reduce myotube atrophy observed in nutrient (LOW glucose) 
restricted conditions and that resveratrol may accentuate hypertrophy 
myotubes in normal glucose conditions.  
 
6.2. Methods 
6.2.1. Cell culture and treatments  
6well plates where pre-treated with 0.2% porcine gelatine for 10 min at 
room temperature (RT) and 10 min in a humidified, 37°C with 5% CO2. 
The excess gelatine was aspirated and cells were seeded at 8 x 104 
cells/ml in 2 ml of GM per well, these were then incubated until 80% 
confluence. Cells were washed in PBS and transferred into 2 ml of normal 
glucose DM in 37°C at 5% CO2 for 7D in order to differentiate. Once 
existing myotubes had been formed over 7D in DM, cells were dosed in 
the below experimental conditions for a further 72 h (total 10 days in 
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culture) to assess the impact of the activation/inhibition of SIRT1 in 
nutrient restriction on existing myotubes: LOW (0.5 g/L glucose); NOR (4.5 
g/L glucose); LOW + Resveratrol (RES) (0.5 g/L glucose + 10 μM RES), 
MED + RES (1.125 g/L glucose + 10 μM RES), NOR + RES (4.5 g/L 
glucose + 10 μM RES); LOW + SIRT1 inhibitor (EX-527) (0.5 g/L glucose 
+ 100 nM EX-527); MED + EX-527 (1.125 g/L glucose + 100 nM EX-527) 
or NOR + EX-527 (4.5 g/L glucose + 100 nM EX-527). Morphological 
analysis of myotube number, diameter and area were both performed at 0 
and 72 h initially and then at 24 and 48 h for additional analysis (see 
results section). For these experiments the 0 hours baseline control 
condition was 30 minutes in NOR glucose (DM 0 h). Protein activity of 
AMPK and p70s6K were completed at 0, 15 min, 30 min, 2 h and 24 h 
time points after dosing in order to investigate energy sensing vs. protein 
synthetic/growth associated cellular signalling in myotubes. Gene 
expression for later differentiation and myotube maturation (MRF4, 
MYHC1, 2, 4, 7) and genes associated with myotube hypertrophy (IGF-I, 
IGF-IR, IGF-II, IGF-IIR, IGFBP2, mTOR) and myotube atrophy (TNF-, 
myostatin, MuRF, MAFbx, MUSA1, FOXO1, 3, NF-kB, p53) as well as 
SIRT1 gene expression were completed at 0, 72hrs, with targeted gene 
expression based on the results from 72 h data were followed up to 
investigate changes at 24 h (see results below). Precise methods for 
morphological analysis, gene expression (RT-PCR) and cell signalling 
(western blotting) can be located in the methods section in chapter 2.  
 
6.2.2. Statistical analysis 
All data was performed using three separate cell populations thus 
performed N=3. Analysis was then carried out using Minitab® 17 (Minitab 
Ltd, Coventry U.K). Outliers where removed using Grubbs outlier test. All 
data was parametric, assessed using the Anderson-Darling test for 
normality. General linear models (2 x 2 x 3) for time (0, 72 h), glucose 
concentration (LOW, NOR) and SIRT1 activation/inhibition (DM, RES, EX-
527) were carried out for morphological analysis of myotube number, area 
and diameter for the 72 h data. Morphological analysis for the additional 
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24 and 48 h data was also performed using a general linear model (2 x 3 x 
3) for time (0, 24 and 48 h), glucose concentration (LOW, NORM) and 
SIRT1 activation/inhibition (DM, RES, EX-527). Gene expression data for 
both the 72 h and 24 h data was performed using a general linear model 
(2 x 2 x 3) for time (0, 72 h or 0, 24 h), glucose concentration (LOW, NOR) 
and SIRT1 activation/inhibition (DM, RES, EX-527). A general linear 
model for glucose (LOW , NOR) and SIRT1 activation/inhibition (DM, RES, 
EX-527) was performed for protein activity. Post hoc tests were performed 
using Bonferroni, Tukey and Fisher. The results produced through the 
Bonferroni tests are reported throughout results unless otherwise stated. 
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6.3. Results 
6.3.7. Myotube diameter and area were increased in LOW glucose 
conditions at 24 h after resveratrol supplementation.  
Following myotube imaging (Fig 6.1.) further analysis observed reduced 
myotube number under EX-527 supplementation following 24 and 48 h (24 
h: NOR vs. NOR EX-527: 10.69  3.81 vs. 8.58  3.71, p = 0.004 (fisher), 
48 h: NOR vs. NOR EX-527: 10.95  3.15 vs. 9.48  2.68, p = 0.046 
Fig. 6.1. Representative images following 24 h in LOW and NOR glucose alone and 
with the addition of RES or EX-527. 
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(fisher)). Resveratrol was unable to improve myotube number in any NOR 
glucose condition or timepoint, as well as any LOW glucose condition (p > 
0.005) (Fig. 6.2.). Following 48 h in NOR conditions RES supplementation 
not only did not improve number but it produced a negative affect in which 
myotube number was reduced (NOR vs. NOR RES: 10.95  3.15 vs. 9.43 
 2.90, p = 0.039 (fisher)).   
 
Myotube diameter remained unaffected at 24 h and 48 h in NOR 
conditions following the supplementation of both RES and EX-527. 
Resveratrol had no effect at the later time point on LOW glucose at 48 h 
(LOW vs. LOW RES: 13.48  4.11 vs. 13.50  4.75 μM, p > 0.05. EX-527 
also had no significant effect on myotube diameter at 48 h and at 24 h in 
either NOR nor LOW glucose conditions (p > 0.05) (Fig 6.3.). Importantly, 
at 24 h RES significantly increased myotube diameter in LOW glucose 
condition (LOW RES vs. LOW: 13.23  4.12 vs. 12.47  4.05 μM, p = 
0.022 (fisher)). 
Fig. 6.2. Mean and SD of Myotube number is represented above. Myotube number 
declined in NOR conditions due to the supplementation of EX-527. No improvements 
in myotube number were observed following RES administration. Significant 
difference (p < 0.05) is denoted using  *. 
 
 
 
Significant difference (p < 0.05) is denoted using a *. 
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Importantly, under both LOW and NOR conditions at the 24 h timepoint 
the supplementation of RES significantly increased myotube area (LOW 
vs. LOW RES: 2635  1524 vs. 3474  2235 μM2, p < 0.001, NOR vs. 
NOR RES: 2835  1959 vs. 3454  2110 μM2, p = 0.009). As with the 
diameter data above, RES did not improve area at 48 h in low glucose 
conditions (Fig. 6.4.). Also, as with the data presented above at the 72 h 
timepoint, RES administration also increased myotube size in NOR 
glucose conditions at 48 h (NOR vs. NOR RES: 2835.20  1959.40 vs. 
3858.00  2800.00 μM2, p = 0.023 (fisher)) (Fig. 6.4.). The addition of EX-
527 had no significant affect on myotube area following 24 h and 48 h for 
NOR nor LOW glucose conditions (p > 0.05). 
 
Fig. 6.3. Myotube diameter increased over time, however only RES supplementation 
increase diameter at 24 h whereas EX-527 decreased myotube diameter. Significant 
difference (p < 0.05) is denoted using  *. 
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These data suggest that RES administration in LOW glucose does not 
improve myotube diameter or area at the later, 48 and 72 h timepoints. 
Following 24 h however resveratrol did ameliorate the myotube atrophy 
observed under LOW glucose conditions. This suggests that the low 
glucose conditions over a period of 3 days is driving considerable atrophy 
and that a single dose of RES may be sufficient to return myotubes to 
normal growth over the first 24 h, yet perhaps repeated doses would be 
required when low glucose conditions are maintained over 48-72 h.  
 
Following RES administration in NOR glucose conditions MYHC7 gene 
expression increased in differentiating myoblasts, documented in chapter 
5. Both MYHC7 and IGF-I gene expression were increased in mature 
myotubes following a 72 h incubation also following RES administration in 
NOR glucose conditions. As a result we next wished to assess these 
genes in resveratrol treated low glucose conditions at 24 h where we 
Fig. 6.4 Myotube area is increase by the supplementation of RES in NOR conditions 
at both 24 and 48 h whereas this increase was only observed at 24 h when in LOW 
glucose conditions. Supplementation of EX-527 did not differ from DM when RES 
increased area however it was significantly reduced in comparison to the RES 
condition. SD’s represented as error bars. Significant difference (p < 0.05) is denoted 
using a *. 
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observed an improvement in myotube size. Furthermore, as we found 
reduced gene expression of protein degradative Ub ligase MUSA1 in RES 
treated low glucose conditions at 72 h, without improvements in 
morphology at 72 h, we also sought to investigate these genes for their 
role in the improvements in myotube diameter and size observed in low 
glucose with RES at 24 hrs.  
 
6.3.8. Resveratrol increased MYHC7 expression in NOR conditions 
after 24 h but not in LOW glucose conditions. 
MYHC7 displayed a significant main effect for time (F(1, 20) = 19.79, p < 
0.001). Gene expression for MYHC7 was increased in NOR glucose 
conditions supplemented with RES over time vs. 0 h (NOR RES vs. 0 h: 
3.85  0.60 vs. 9.77  1.24, p = 0.048 (fisher). However, there were no 
significant differences present for either glucose condition following the 
activation or inhibition of SIRT1 at 24 h (Fig 6.5.).  
 
A significant main effect for time was observed for IGF-I (F(1, 20) = 174.82, 
p < 0.001). However, there was no significant difference following SIRT1 
activation/inhibition in either NOR or LOW glucose conditions at 24 h (Fig 
6.5.).   
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6.3.9. MRF4 increased after 24 h with resveratrol supplementation in 
LOW glucose  
Without changes in MYHC’s or IGF-I at 24h in low glucose with RES 
treatment to support the improved myotube size in the conditions at this 
timepoint. We therefore decided to investigate MRF4 gene expression as 
this is expressed temporally before adult MYHC’s in the stages of myotube 
maturation and hypertrophy. We observed a significant increase in MRF4 
gene expression with the administration of RES in LOW glucose 
conditions at 24 h, however, surprisingly the SIRT1 inhibitor also 
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Fig. 6.5. As significant increase in MYH7 (A) expression from 0 h was observed in 
LOW glucose alone and following the addition of EX-527 but not in RES. NOR RES 
was significantly increased in 24 h compared to 0 h but not in either of the other NOR 
conditions. IGF-I (B) expression was significantly higher in 0 h than any other 
condition at 24 h.  SD’s represented as error bars. Significant difference (p < 0.05) is 
denoted using a *. 
 
 
  
144 
increased MRF4 gene expression at this time point (LOW vs. LOW RES: 
1.43  0.25 vs. 21.5  24.2, p = 0.048 (fisher), LOW vs. LOW EX-527: 1.43 
 0.25 vs. 25.6  20.3, p = 0.020 (fisher), LOW RES vs. LOW EX-527:  
21.5  24.2 vs. 25.60  20.30, p = 0.638).  
 
6.3.10. No significant changes were present in MUSA1 gene 
expression following the activation/ inhibition of SIRT1.  
MUSA1, a ubiquitin ligase involved in protein degradation, was reduced at 
72 h in low glucose conditions in the presence of RES, yet morphological 
findings suggested there was no change in myotube size at this timepoint. 
We therefore investigated MUSA1 expression at 24 h where an 
improvement in myotube diameter and size were observed with RES 
treatment in low glucose conditions. Following 24 h MUSA1 displayed a 
significant main effect for time (F(1,18) = 320.00, p < 0.001) (Fig 6.6.). All 
experimental conditions are significantly reduced in comparison to the 0 h 
control (0 h: 0.99  0.09 vs. LOW: 0.29  0.13, p < 0.001 vs. LOW RES: 
0.25  0.00, p < 0.001, 0 h vs. LOW EX-527: 0.30  0.06, p < 0.001 0 h vs. 
NOR: 0.19  0.00, p < 0.001, 0 h vs. NOR RES: 0.27  0.14, p < 0.001, 0 
h vs. NOR EX-527: 0.24  0.08, p < 0.001). MUSA1 however, displayed 
no significance was present for LOW or NOR glucose after the addition of 
either RES or EX-527 (Fig 6.6.).  
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Finally, despite no changes in gene expression at 24 h timepoint, we 
hypothesised that cell signalling would be temporally more immediate than 
gene expression changes over the first 24 h and may indicate the potential 
mechanisms of RES/SIRT1 activation induced improvements in myotube 
size vs. low alone conditions. We therefore investigated energy sensing 
Fig. 6.6. Both graphs depict average changes using mean values and error bars 
represent SD’s. MRF4 (A)  was significantly increased in LOW glucose following both 
the addition of RES and EX-527.  MUSA1 (B) was significantly reduced from 0 h to 24 
h in all conditions, however SIRT1 manipulation did not instigate any significant 
changes. Significant difference (p < 0.05) is denoted using  *.  
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(AMPK) vs. protein synthetic signalling (p70S6K) across a range of 
timepoints over the first 24 h (0, 15, 30 min, 2 and 24 h) (Alterations in 
AMPK with starvation have previously been associated with reductions in 
mTOR/p70s6K via TSC1/2 (Inoki et al., 2003)). A significant interaction 
was present for AMPK protein activity between glucose and SIRT1 
manipulation (F(2,35) = 3.13, p = 0.056 (Fig. 6.7)). Following 15 min there 
was a trend toward a significant increase in AMPK activity following the 
administration of EX-527 in LOW glucose compared to LOW with the 
addition of RES (LOW RES vs. LOW EX-527: 0.95 ± 0.41 vs. 2.01 ± 1.11, 
p = 0.055 (fisher)). Individual differences between glucose concentration 
or the activation/ inhibition of SIRT1 were observed. 
 
Once incubated for 30 min the addition of EX-527 to NOR glucose 
increased AMPK in comparison to NOR glucose alone (Fig 6.8.) (2.63 ± 
1.66 vs. 1.00 ± 0.63, p = 0.066 (fisher)) and when NOR glucose was 
supplemented with RES (2.63 ± 1.66 vs. 1.00 ± 0.63, p = 0.066 (fisher)). A 
trend for AMPK activity to increase was also observed in the presence of 
EX-527 under NOR glucose conditions in comparison to NOR glucose 
alone at both 2 h (NOR vs. NOR EX-527: 1.00 ± 0.36 vs. 2.24 ± 1.45, p = 
0.086 (fisher)) (Fig 6.9.) and 24 h (NOR vs. NOR EX-527: 1.00 ± 0.43 vs. 
2.61 ± 0.75, p = 0.069 (fisher)) (Fig 6.10.). Increases in AMPK with EX-527 
in NOR glucose conditions also reduced protein activity for p70S6K at 15 
min (Fig 6.11.) and 30 min (Fig 6.12.) vs. NOR alone, although this was 
not significantly different (15min, NOR vs. NOR EX-527: 1.30 ± 0.02 vs. 
0.94 ± 0.20, 30 min, NOR vs. NOR EX-527: 1.30 ± 0.02 vs. 0.94 ± 0.20, p 
> 0.05). There were no significant difference over 2 h (Fig 6.13.) or 24 h 
(Fig 6.14.) for NOR glucose conditions. There were also no significant 
differences in AMPK or P70S6K in low glucose conditions in the absence 
or presence of SIRT1 activation/ inhibition (see figures 6.7- 6.14 below). 
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Fig. 6.7. Phosphorylated AMPK (p-AMPK) relative to Total AMPK and calibrated to 
NOR glucose at 15 min., this timepoint was additionally compared to GAPDH as 
there was a significant difference present between loading values. A trend towards 
significance was present for LOW RES vs. LOW EX-527.  Significant difference (p < 
0.05) is denoted using  *. P values approaching significance are displayed. 
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Fig. 6.8. Phosphorylated AMPK (p-AMPK) relative to Total AMPK and calibrated to NOR 
glucose at 30 min. 30 min incubation saw an increase in AMPK protein activity for NOR 
EX-527 compared to NOR, NOR RES and LOW EX-527. Significant difference (p < 
0.05) is denoted using  *. P values approaching significance are displayed. 
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Fig. 6.9. Phosphorylated AMPK (p-AMPK) relative to Total AMPK at 2 h and 
calibrated to NOR glucose at 2h. A trend was present at the 2 h timepoint 
suggesting NOR EX-527 increased AMPK activity compared to NOR and LOW EX-
527. Significant difference (p < 0.05) is denoted using  *. P values approaching 
significance are displayed. 
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Fig. 6.10. Phosphorylated AMPK (p-AMPK) relative to Total AMPK at 24 h and 
calibrated to NOR glucose at 24h.  The addition of EX-527 significantly increased 
AMPK content compared to LOW EX-527 and NOR glucose alone. Significant 
difference (p < 0.05) is denoted using a *. P values approaching significance are 
displayed. 
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Fig. 6.11. Phosphorylated p70S6K (p-p70S6K) relative to Total p70S6K at 15 
min and calibrated to NOR glucose at 15 min displayed no significant differences 
for any experimental conditions. 
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Fig. 6.12. Phosphorylated p70S6K (p-p70S6K) relative to Total p70S6K at 30 min and 
calibrated to NOR glucose at 30 min displayed no significant differences for any 
experimental conditions. 
 
 
 
  
153 
 
Fig. 6.13. Phosphorylated p70S6K (p-p70S6K) relative to Total p70S6K at 2 h and calibrated to 
NOR glucose at 2 h displayed no significant differences for any experimental conditions. 
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When the time points were extended to 72 h changes in myotube number 
and size were observed NOR glucose following manipulation of SIRT1, 
despite this genes associated with skeletal muscle atrophy and protein 
degradation appear to be unchanged. (All data presented in Appendix 1). 
Under LOW glucose conditions there appeared to be a reduction in 
atrophy/protein degradative genes such as myostatin and MUSA1, despite 
no increases in myotube size or number with RES treatment. This could 
be a continued compensatory drive to restore the atrophy observed under 
low glucose, although unsuccessful. 
Fig. 6.14. Phosphorylated p70S6K (p-p70S6K) relative to Total p70S6K at 24 h and 
calibrated to NOR glucose at 24 h displayed no significant differences for any 
experimental conditions. 
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6.4. Summary 
RES was able to increase both myotube area and diameter acutely over a 
24 h time point. This was accompanied by increases in MRF4 (as perhaps 
would be expected given that MRF4 is an early driver of myotube 
maturation). This data suggests that the LOW glucose conditions over a 
period of 3 days is impairing growth and that a single dose of resveratrol 
may be sufficient to return myotubes to normal growth over the first 24 h. 
We observed that RES does not improve myotube diameter or area/ size 
in LOW glucose at the later time points of; 48 and 72 h (appendix 1) that 
repeated doses of RES when glucose conditions are restricted may 
maintain this increase over 48- 72h. 
 
Area but not diameter was also increased following RES administration in 
NOR glucose conditions, however this was accompanied with a reduction 
in myotube number. These myotubes did not significantly differ from the 
other NOR glucose conditions, however compared to the 0 h timepoint 
they increased in the slow twitch myosin isoform (MYHC7). When the data 
was extended to the later 72 h timepoint however MYHC7 was 
significantly increased following RES supplementation in comparison to 
NOR glucose alone (appendix1). At this time point myotube number is no 
longer significantly reduced whereas myotube area is still increased in 
comparison to no RES supplementation. This is suggestive of a potential 
switch towards a greater number of oxidative fibres which is driving the 
myotubes enlarged size.  
 
Inhibition of SIRT1 via EX-527 supplementation reduced myotube number 
in NOR conditions and reduced diameter within LOW conditions. As these 
findings do not directly oppose those observed with RES supplementation 
there is clearly a more complex relationship between SIRT1 and  
differentiation. 
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Despite the investigation of energy sensing pathways (AMPK) sensitive to 
changes in energy status have previously been shown to supress growth 
signalling (p70s6k) under starvation (Inoki et al., 2003). We observed a 
trend towards increased AMPK with SIRT1 inhibition (EX-527 
administration) approaching significance in normal glucose conditions 
together with non-significant reductions in p70S6K where in this condition 
there was a corresponding suppression of myotube hypertrophy. 
Furthermore, we observed increased AMPK with SIRT1 inhibition at 15 
minutes in low glucose conditions in comparison with resveratrol 
conditions, yet the increase was not significant versus control conditions 
and no corresponding changes in p70S6K were observed at this timepoint. 
However, there were no other alterations in low glucose conditions at any 
other time points with the activation or inhibition of SIRT1. No changes in 
myotube hypertrophy were observed in normal glucose at 24 and 72h in 
the presence of increased SIRT1 activity via RES administration. This 
suggested that only SIRT1 inhibition was able to increase AMPK activity in 
both glucose conditions however this only resulted in non-significant 
reductions in p70S6k in normal glucose conditions. Despite this it is 
unlikely that, alterations in energy status impacted on protein synthetic 
signalling in the presence of RES and therefore not associated with the 
increased myotube hypertrophy at 24 h in low glucose and 24-72 h in 
normal glucose.  
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Chapter 7 
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7. Discussion 
7.1. Relevant physiological model of glucose restriction 
Within chapter 3 we presented two models of glucose restriction. Where 
under medium (MED) and low (LOW) glucose we observed a reduction 
and blocking (LOW glucose) in differentiation and myotube hypertrophy 
respectively assessed via morphological, biochemical and gene 
expression analysis. By using the two glucose concentrations we 
attempted to model physiologically similar glucose concentrations 
observed after dietary restriction (DR) in vivo. Where the MED condition 
possessed a glucose concentration of 1.13 g/L or 6.25 mM, similar to the 
average 1 g/L (5.6 mM), which has been previously observed in the 
circulation of rodents during DR (Cartee et al., 1994, Walford et al., 1992). 
Additionally, this concentration was similar to the concentration used in 
previous in vitro studies utilizing models of nutrient restriction (Elkalaf et al., 
2013, Khodabukus and Baar, 2015), therefore also allowing for more 
accurate comparisons to be made between studies. Furthermore, based 
on the work of Aussedat et al. (2000) and Maggs et al. (1995) the 
concentration of glucose was observed to be approximately 30% lower in 
the interstitium than those levels found in circulating blood, as such the 
LOW glucose concentration was therefore in line with these levels at a 
concentration of 0.56 g/L or 3.12 mM, therefore making MED and LOW 
concentrations physiologically relevant to both circulatory and  interstitial 
levels respectively following DR in vivo.  
 
Accompanying the aforementioned morphological analysis, reductions in 
differentiation and myotube formation observed in these models was 
associated with a reduction in biochemical differentiation (reduced CK), as 
well as gene expression of important myogenic regulatory factors (MRF’s). 
MyoD underpin the lineage determination of myoblasts and the onset of 
fusion (Buckingham et al., 2003, Cooper et al., 1999), whereas myogenin 
regulates formation and promotes terminal differentiation (Berkes and 
Tapscott, 2005). The reductions in these MRF’s confirm reductions in 
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differentiation observed in these restricted glucose conditions. This data is 
in line with previous research that suggests starvation in myoblasts during 
differentiation reduced these MRFs and indeed that overexpression of 
MyoD can help restore differentiation in the presence of starvation, albeit 
starvation in this instance was removal of serum, amino acids and glucose 
(Lagirand-Cantaloube et al., 2009).  
 
Furthermore, the reduction in myotube hypertrophy at 7 days in glucose-
restricted conditions resulted in a reduction in gene expression of MYHC’s 
1,4 and 7, which code for the myosin heavy chain protein isoforms of type 
IIx, IIb and slow twitch fibers respectively. With respect to LOW glucose 
the expression of MYHC’s was almost completely abolished as a 
consequence of no myotubes being formed in this condition. Whereas, the 
MED glucose condition there was impaired yet not completely blocked 
myotube formation the expression of MYHC was not completely abolished, 
however there was a significant reduction in the expression in comparison 
to the control. A reduction in total MYHC protein in C2C12 cells has 
previously been reported under low glucose conditions, therefore 
suggesting again that we possess a suitable model of impaired 
differentiation and myotube atrophy in MED glucose and blocked 
differentiation in LOW glucose conditions (Fulco et al., 2008).  
 
Notably, we observed an increase in SIRT1 gene expression in the lowest 
glucose condition. Activation of SIRT1 (phosphorylation) has been 
previously observed in C2C12 muscle cells under low glucose conditions 
(Fulco et al., 2008). Upregulation of SIRT1 gene expression has also been 
observed to also take place in the presence of the inflammatory cytokine, 
TNF-α in C2 myoblasts (Saini et al., 2012). Within this model of 
inflammation gene silencing of SIRT1 increased cell death in the presence 
of TNF-α whereas activation of SIRT1 via resveratrol (RES) administration 
ameliorated the inflammatory induced increase in cell death and reduction 
in differentiation. Suggesting that resveratrol is an important in survival 
and differentiation in myoblasts under stress.  Inferring from the previous 
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literature (Fulco et al., 2008), although it was demonstrated that  SIRT1 
increased at the gene expression level in the presence of TNF-α, that 
perhaps this was a precursor for increased SIRT1 protein levels available 
for subsequent increases in SIRT activity. We therefore suggested that 
this increase may not have caused the reduction in differentiation rather 
was a unsuccessful attempt to improve survival and perhaps 
enable/initiate differentiation under nutrient stress. As such we 
hypothesised that similarly to the findings observed under inflammation 
that SIRT1 activation via resveratrol treatment may improve differentiation 
and myotube maturation in skeletal muscle cells under reduced glucose 
conditions.  
 
7.2. Dose response for SIRT1 activation and inhibition 
Before the manipulation of SIRT1 activation would be possible under 
reduced glucose conditions, we first aimed to optimise the dosing of 
resveratrol and the SIRT1 inhibitor (EX-527) in chapter 4.  Previously, we 
have administered C2C12 cells with 30 and 60 μM of RES, however cell 
viability was compromised at these doses (Deane and Sharples et al, 
2015, unpublished). Decreased cell viability has also been observed in 
C2C12 at doses of 20 M and higher (Higashida et al., 2013, Bosutti and 
Degens, 2015). Despite Higashida et al. (2013) observing no change in 
total PGC-1α (a downstream protein modulated by SIRT1 (Rodgers et al., 
2005b)) following 5 and 10 μM after a 24 h incubation, recent evidence 
has suggested that 10 μM was beneficial in C2C12 myoblast remodeling 
under oxidative stress (Bosutti and Degens, 2015). We therefore 
performed a dose response of RES at 5, 10 and 15 μM. The impact of 
SIRT1 activation was investigated (phosphorylation via western blotting) in 
which a significant increase in SIRT1 activity was observed in both 10 and 
15 μM. Activation seemed more consistently elevated over the time course 
of 15 min, 30 min, 2 h, and 24 h with 10 M RES, with the largest increase 
in SIRT1 phosphorylation at 15 min with a resveratrol concentration of 10 
M. Indeed, there are limited studies characterising SIRT1 activity 
(phosphorylation) with RES administration in myoblasts. Studies that have 
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measured this previously have focused on SIRT1 mRNA (Saini et al., 
2012) or SIRT1 total protein levels (Fröjdö et al., 2011). Due to SIRT1 
being a histone deacetylase its function is determined both by total protein 
and its deacetylase activity. Phosphorylation of SIRT1 is required however 
to enable increases in deacetylase activity (Sasaki et al., 2008).  
 
As mentioned above we also aimed to ascertain the optimal concentration 
of the commercially available SIRT1 inhibitor EX-527. Initially we observed 
SIRT1 activity following administration of 30 and 60 M of EX-527. SIRT1 
activity did not significantly reduce activity under these concentrations and 
unexpectedly increased in some instances. EX-527 has an IC50 (inhibitory 
concentration 50%) of 98 nM for SIRT1 inhibition (Carafa et al., 2016) and 
as such has been previously documented to reduce SIRT1 activation by 
approximately 50% at concentrations between 48 and 100 nM. However, 
inhibition in these studies was measured via vitro Fluor de Lys 
deacetylation assays in embryonic kidney cells to assess SIRT1s 
deacetylation activity and not phosphorylation per se (Solomon et al., 
2006). We also observed average reductions in SIRT1 activity following 24 
h at a concentration of 100 nM, however this was analyzed via 
phosphorylation and not deacetylation. From this data it could be 
suggested that deacetylation activity would also be reduced as a result, 
given that phosphorylation of SIRT1 is required however to enable 
deacetylase activity (Sasaki et al., 2008). However was not tested as 
deacetylation assays were unavailable in the labs at the time of data 
collection. This would be important to establish in future studies.  
 
7.3. SIRT1 activation and inhibition in restricted and normal glucose 
conditions 
The objective for chapter 5 was to manipulate SIRT1 activity using the 
concentrations characterised in chapter 4 on a background of restricted 
glucose previously established in chapter 3. By combining the findings 
from chapters 3 and 4 we were able to establish whether SIRT1 activation/ 
inhibition could attenuate the reduction in differentiation and myotube 
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hypertrophy observed in the MED glucose conditions and prevent the 
complete depletion of myotubes observed in the LOW glucose condition. 
We hypothesised that SIRT1 activation via resveratrol would ameliorate 
the diminished and reduced differentiation observed under LOW and MED 
glucose conditions respectively. Despite observed improvements in 
creatine kinase activity in the lowest glucose condition following SIRT1 
activation, we did however reject this hypothesis. Generally, RES was 
unable to prevent the loss of morphological differentiation in either glucose 
condition.  
 
It is worth noting however that SIRT inhibition produced absolutely no CK 
activity in LOW conditions at 72 h and the corresponding lowest number of 
myotubes in comparison to the other NOR glucose conditions. This 
suggests that normal SIRT1 activity was required for normal CK and basal 
myotube formation to take place in LOW and NOR conditions respectively. 
The opposite was however true for MED glucose conditions in which 
SIRT1 inhibition implemented an increase in myotube number following 
SIRT inhibition. The findings in MED glucose are similar to those 
previously observed by Fulco et al. (2008) in which the reduction of SIRT1 
via a retrovirus expressing short hairpin targeting SIRT1 mRNA (shSIRT1) 
was able to rescue differentiation under glucose restriction. The inference 
of which is that SIRT1 is required for the loss of differentiation observed 
under glucose-restricted conditions to take place. The glucose 
concentration administered in the Fulco et al. (2008) study was very 
similar the MED glucose condition (5.00 vs. 6.25 mM) which may be one 
such reason for the similarities. Although this glucose concentration was 
previously deemed to be physiologically similar to values available for DR 
in vivo it may also be more physiologically similar to non DR glucose 
concentrations than the NOR glucose control. As previously discussed 
NOR glucose condition is super physiological and may provide a model 
closer to hyperglycemia than NOR glucose in vivo. As such the reason 
that LOW and NOR observe improvements under SIRT1 increases may 
be due to their roles as physiological stress environments, whereas MED 
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glucose is not a true nutritional stress.  As our findings under NOR and 
LOW glucose however oppose these findings in which inhibition of SIRT1 
following 72 h abolished CK activity in LOW conditions. This could 
potentially suggest than when translated to whole organism populations 
that SIRT1 increases are only need under a nutritional stress and a 
reduction in SIRT1 may improve muscle growth under normocaloric 
environments due to the lack of stress present. 
 
Following administration of both EX-527 and RES in NOR glucose 
conditions there was an impairment in CK activity and myogenin 
expression as well as formation of myotubes. Despite this and possibly 
most importantly we observed an increase in myotube size in the 
remaining myotubes following the supplementation of resveratrol in normal 
glucose conditions. This observation was coupled with an increase in 
MYHC 7 and MYHC 4 gene expression, which code for the slow type I and 
fast type IIb MYHC protein isoforms respectively. These findings 
suggested that the adaptation observed following RES administration 
might be responsible for the increase in myotube size via an increase in 
the genes coding for contractile proteins. Indeed, these findings are in line 
with those previously observed by both Montesano et al. (2013) and 
Kaminski et al. (2012) in which total MYHC protein is increased in normal 
glucose conditions in the presence of RES. Montesano et al. (2013) did 
not measure myotube area, however they did observe significant 
increases in both myotube diameter and length following RES 
administration, suggesting that overall size would indeed be increased. 
Our measurements in myotube diameter however displayed no significant 
changes in any of our experimental conditions. Bosutti and Degens (2015) 
found that a RES concentration of 10 M (the same as we utilized) was 
the only concentration to enhance the percentage of cells in the G0-G1 
phase and this was not the case in a similar concentration to that used in 
the Montesano et al. (2013) study (20 M). It may be proposed therefore 
that the increase in myotube area observed under these conditions was 
due to earlier cell cycle exit. It is interesting, however that an increase in 
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area was also observed by Montesano et al. (2013) as they observed no 
increase in p21 protein content (associated with cell cycle exit and early 
differentiation) with the administration of RES in comparison to the DM 
conditions alone. Despite these findings Bosutti and Degens (2015) did 
not observe inhibition of this cell cycle arrest until much higher 
concentrations (40 - 60 M) therefore increases in myotube size may 
indeed be due to early exit of the cell cycle leading to earlier initiation of 
differentiation and subsequently allowing more time for myotube 
maturation and hypertrophy. Unfortunately, Montesano et al. (2013) did 
not measure myotube number therefore our proposal that RES 
administration increases myotube size without an increase in myotube 
number contributes to advancing understanding in these conditions. 
Additionally, this previous study did not measure activation or expression 
of SIRT1 and as such our data extends this work by suggesting a positive 
role for SIRT1 activation in myotube hypertrophy in normal glucose 
conditions.  
 
Although not measured within this study, resveratrol has been suggested 
to improve myoblast migration but not the impaired fusion induced by 
oxidative stress (Bosutti and Degens, 2015). The present study, albeit 
under the stress environment induced by low glucose, also suggested that 
resveratrol cannot improve fusion/ differentiation of myoblasts. Additionally, 
the present study also identified that the SIRT inhibitor (EX-527) evoked 
reductions in MYHC1 coding for the fast IIx MYHC protein in normal 
glucose conditions and therefore suggested that normal SIRT activity was 
perhaps important to maintain adequate fast isoform gene expression. A 
finding that to the authors knowledge has not been shown before. 
Moreover, future studies may wish to investigate the role of SIRT1 
activation/ inhibition on Nuclear factor of activated T-cells (NFAT) activity 
in skeletal muscle cells. As this transcription factor, regulates activation of 
muscle fiber genes associated with characterization of ‘slow’ and ‘fast’ 
myofibres (Chin et al., 1998) and is known to be transcriptionally 
suppressed by SIRT1 (Jia et al., 2014). Future studies may wish to 
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investigate the role of SIRT1 activation/inhibition on NFAT activity in 
skeletal muscle cells. Overall, chapter 5, SIRT1 activation lead to 
increases in myotube hypertrophy and SIRT1 inactivation a slowing of the 
myotube contractile apparatus in normal glucose conditions.  
 
Due to the interesting findings observed in chapter 5 in which RES 
treatment increased myotube hypertrophy in NOR glucose conditions and 
although resveratrol was unsuccessful in improving morphological 
measures, CK was increased in LOW glucose conditions following RES 
administration. We therefore examined the role of SIRT1 inhibition/ 
activation in both LOW and NOR glucose conditions on existing myotube 
cultures. Where in the previous chapter we observed changes in 
differentiating myoblasts and their ability to produce myotubes this chapter 
involved the use of mature myotubes, which could be suggested as more 
indicative of in-vivo tissue. As resveratrol was observed to increase 
myotube size in NOR glucose following 7D, we chose to administer RES 
following 7D in culture in which myoblasts had already differentiated into 
myotubes. In addition, in chapter 5 RES supplementation in LOW glucose 
conditions following 7D did drive increases in CK, despite no improvement 
in myotube formation. It is therefore feasible that in the presence of 
existing myotubes, resveratrol may prevent myotube atrophy evoked by 
LOW glucose conditions. We therefore hypothesised that activation of 
SIRT1 may reduce myotube atrophy observed in nutrient (LOW glucose) 
restricted conditions and that resveratrol may further induce myotube 
hypertrophy in normal glucose conditions. 
 
As observed in the myoblasts study from chapter 5, the inhibition of SIRT1 
via EX-527 reduced myotube number. In addition to this myotube size was 
also negatively affected and the activation of SIRT1 via resveratrol 
increased myotube area at 72 h after dosing on to myotubes. Again MYHC 
expression was altered corresponding with this data, however in the 
myotubes studies these alterations consisted of reductions in MYHC 1, 2 
and 4 following SIRT1 inhibition, coding for IIx, IIa, IIb isoforms 
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respectively and an increase in MYHC7 (slow twitch isoform) following 
SIRT1 activation. These findings suggest that increases in SIRT1 activity 
mediated an increase in slow fiber type isoform gene expression and a 
decrease in SIRT activity reduces fast fiber type isoform gene expression. 
A finding that consolidated observations made in chapter 5 where SIRT1 
inhibition reduced fast MYHC’s in differentiating myoblasts. These findings 
taken together with the corresponding increases in myotube size observed 
in normal glucose conditions following RES supplementation, suggest that 
the observed hypertrophy is resultant from the increase in the gene coding 
for increasing slow fiber type protein isoforms. As such despite possessing 
larger myotubes they may have a slower contractile potential. Resveratrol 
supplementation however little effect on myotubes in low glucose 
conditions at this 72 h timepoint. 
 
In addition to the regulation of MYHC expression observed at 72 h the 
increase in myotube number and size observed in NOR glucose following 
resveratrol treatment corresponded with increases in the expression of 
growth related genes IGF-I but not IGF-IR, IGF-II and IGF-IIR. IGF-I has 
previously been associated with increased differentiation; myotube 
hypertrophy and increases in muscle size in vivo (Scimè and Rudnicki, 
2006, Stewart and Rotwein, 1996, Jacquemin et al., 2004, Quinn et al., 
2007, Sharples et al., 2011, Sharples et al., 2010) and as such this 
observation may provide insight into the mechanisms underpinning the 
increase in myotube hypertrophy following RES supplementation after 72 
h. An increase in IGFBP2 gene expression was associated with the 
reduction in myotube size observed during the inhibition of SIRT1. IGFBP2 
is a known inhibitor of differentiation and myotube hypertrophy when 
protein levels are altered in differentiating myoblasts (Sharples et al., 2010, 
Sharples et al., 2013b), however within myotube studies its role is yet to 
be defined. However, overexpression of IGFBP2 in mice results in a 
reduction in muscle size (Rehfeldt et al., 2010). SIRT1 may thereby 
regulate IGFBP2 expression and subsequent reduction observed with EX-
527 in NOR glucose conditions.  
  
167 
 
Interestingly in low glucose conditions, despite no observable increases 
present in myotube size following 72 h with resveratrol treatment there 
was a reduction in myostatin, a negative regulator of muscle mass, 
myostatin (Mcpherron and Lee, 1997) and protein degradative gene 
MUSA1 (Milan et al., 2015). Similarly to the increase in CK, observed in 
LOW glucose in differentiating myoblasts (chapter 5) this may have been a 
compensatory mechanism attempting to restore the observed atrophy 
within this experimental condition. However this was unsuccessful in 
rescuing atrophy observed at 72 h.  
 
Most importantly within the final data chapter (6) resveratrol improved 
myotube area and diameter in LOW glucose at a more acute timepoint of 
24 h. This finding was observed despite no changes being observed at 48 
or 72 h.  These findings, however, were not driven by changes in MYHC 
as was the case for changes in NOR glucose in both myoblasts and 
mature myotubes. Improvements in myotube area and diameter where 
instead associated with increased MRF4 (myf6) which to our knowledge 
has not previously been associated with resveratrol in skeletal muscle. 
MRF4 is involved in the transition between differentiated and mature 
myotubes and therefore may be expected to be upregulated at the earlier 
timepoint of 24 h over MYHC expression (Ropka-Molik et al., 2011). From 
these findings we can infer that the muscle atrophy experienced under 
LOW glucose conditions may be attenuated following a single dose of 
resveratrol over a 24 h time period. Unfortunately, as these positive 
findings where not observed at later timepoints it suggests that a repeated 
dose may be required to main myotube hypertrophy over a longer time 
scale in low glucose conditions and therefore this warrants further 
investigation.  
 
It has previously been observed that glucose deprivation in skeletal 
muscle increases both AMPK and SIRT1 and that the AMPK- nampt- 
SIRT1 pathway allows the cell to respond to nutrient deprivation and adapt 
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accordingly in both muscle cells (Fulco et al., 2008) and animal models. 
Furthermore AMPK has been observed to suppress growth related 
signaling of p70S6K via TSC2 inhibition of mTOR (Inoki et al., 2003). 
Under normal glucose conditions with resveratrol treatment we observed 
increases in IGF-I gene expression and subsequent increases in myotube 
hypertrophy. Therefore, it may be expected that we would observe 
alterations in downstream p70S6K the translation initiator for protein 
synthesis from mRNA in the ribosome, thus enabling increased myotube 
hypertrophy (Rommel et al., 2001). We observed a trend towards 
increased AMPK with SIRT1 inhibition (EX-527 administration) 
approaching significance in normal glucose conditions together with 
average but non-significant reductions in p70S6K where in this condition 
there was a corresponding suppression of myotube hypertrophy. 
Furthermore, we observed increased AMPK with SIRT1 inhibition at 15 
minutes in LOW glucose conditions in comparison with resveratrol 
conditions, yet the increase was not significantly increased versus control 
conditions and no corresponding changes in p70S6K were observed at 
this timepoint. However, there were no other alterations in LOW glucose 
conditions at any other time points with the activation or inhibition of SIRT1. 
Additionally, no alterations where we observed myotube hypertrophy in 
normal glucose (observed at 24 and 72h) in the presence of increased 
SIRT1 activity via resveratrol administration. Suggesting that only SIRT1 
inhibition was able to increase AMPK activity in both glucose conditions 
however this only resulted in reductions (albeit non-significant) in p70S6k 
in normal glucose conditions. Suggesting that perhaps normal SIRT1 
activity was required for adequate AMPK activity to prevent the 
suppression of p70S6K and the corresponding reductions in myotube size 
observed in SIRT1 inhibitor conditions. Despite this the mechanisms 
responsible for the increased myotube hypertrophy following RES 
administration at 24 h in low glucose and 24- 72 h in normal glucose 
conditions are unlikely to be attributable to alterations in energy sensing 
signalling and/or protein synthetic signalling. 
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If there was significant changes present in the AMPK p70S6K pathway it 
would suggest that RES would be actively initiating hypertrophy, however 
as the morphological results following RES administration in LOW glucose 
condition do not significantly exceed NOR conditions it could be suggested 
that a reduction in atrogenes such as MuRF1 and MaFbx and not 
hypertrophic response per se. One such mechanism could be via 
modifications in FoXOs, previously suggested in skeletal muscle overload 
(Koltai et al., 2017).  
 
7.4. Conclusions 
Despite the initial hypothesis suggesting that resveratrol would improve 
the loss of differentiation observed under glucose restriction we rejected 
this hypothesis in differentiating myoblasts as little effect was observed 
under these conditions. Resveratrol did however evoke increases in 
myotube hypertrophy under normal glucose conditions and enable 
improved myotube hypertrophy over an acute 24 h period when 
administered to existing myotubes in LOW glucose. If this finding 
translates to whole organisms and human populations it could provide 
healthspan improvements in individuals undergoing diretary restriction. 
Unfortunately, after the 24 h period the myotubes continued to undergo 
atrophy, which is suggestive of the requirement for dosing every 24 h. In 
the LOW glucose condition SIRT1 activation increased MRF4 gene 
expression and was associated with the improved myotube size at 24 h in 
this condition. Whereas SIRT1 activation in normal glucose conditions 
modulated increased gene expression coding for slow MYHC isoforms 
while inhibition of SIRT1 lead to reductions in gene expression coding for 
fast MYHCs. This finding may be particularly usefully when concidering 
dieatary interventions in fed individuals who partake in aerobic activities, 
potentially providing a greater number of slow twitch fibres for 
improvements in aerobic economy.  While SIRT activation did modulate 
increases IGF-I gene expression, it did not appear to modulate energy 
sensing vs. growth related signaling pathways. However, SIRT1 inhibition 
(EX-527) did reduce AMPK activity in low and normal glucose conditions 
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with corresponding mean reductions in P70S6K in normal glucose 
conditions. In low glucose induced myotube atrophy resveratrol did 
however impair the negative regulator of muscle mass, myostatin, and 
protein degradative ubiquitin ligase enzyme, MUSA1. Overall, SIRT1 
activation via a single dose of resveratrol appears to have a role in acutely 
negating the effect of myotube atrophy in low glucose conditions and 
promoting hypertrophy when normal levels of glucose are available.  
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9. Appendix 1
 
 
6.3.1. Low glucose reduces myotube number and promotes myotube 
atrophy  
Following image collection (Fig A1.1) myotube number was analysed at 72 
h over time in comparison to a 0 h control, following this incubation a 
significant interaction between timepoint, glucose concentration and 
SIRT1 manipulation was observed (F(2, 466) = 6.55, p = 0.002) as well as 
between timepoint and glucose concentration (F(1, 466) = 16.89, p < 0.001). 
Additionally, all variables: glucose (F(1, 466) = 9.20, p = 0.003), time (F(1, 466) 
Fig. A1.1. Representative images following 72 h in LOW and NOR glucose alone and 
with the addition of RES or EX-527. 
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= 36.81, p < 0.001) and SIRT1 manipulation (F(1, 466) = 7.89, p < 0.001) 
displayed a significant main effect. No change in myotube area was 
observed from the 0 h control to 72 h in NOR glucose conditions. There 
was no change in myotubes grown in NOR conditions with the 
administration of RES compared with 0 h baseline control myotubes (0 h: 
8.25  2.85 vs. NOR: 9.00  2.59, p > 0.05, vs. NOR RES: 8.33  2.74, p > 
0.05). By supplementing NOR glucose conditions with SIRT1 inhibitor (EX-
527) a reduction in myotube number was observed from 0 h to 72 h (0h vs. 
NOR EX-527: 9.00  2.59 vs. 5.62  2.94, p < 0.001, Fig 6.2.). All LOW 
glucose conditions had a significantly reduced number of myotubes 
following 72 h versus the 0 h control (0 h: 8.25  2.85 vs. LOW: vs. 5.38  
2.28, p < 0.001, vs. LOW RES: 5.73  2.97, p < 0.001, vs. LOW EX-527: 
5.62  2.94, p < 0.001). However, there was no significant difference 
observed for this glucose concentration when SIRT1 activity was 
manipulated (LOW vs. LOW RES: 5.38  2.28 vs. 5.73  2.97, p > 0.05, 
LOW vs. LOW EX-527: 5.38  2.28 vs. 5.62  2.94, p > 0.05, LOW RES vs. 
LOW EX-527: 5.38  2.28 vs. 5.62  2.94, p > 0.05).  
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Fig. A1.2. Myotube number following the addition of EX-527 in NOR conditions in 
comparison to the 0 h control. All LOW glucose conditions where also reduced in 
comparison to the 0 h control. Significant difference (p < 0.05) is denoted using  *. 
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Myotube diameter displayed a significant main effect for time following 
comparisons between 0 h control and 72 h incubation (F(1, 3661) = 13.68, p 
< 0.001) and glucose concentration (F(1, 3661) = 138.24, p < 0.001) as well 
as a significant interaction for time x glucose concentration (F(1, 3661) = 
116.42, p < 0.001). There was also a significant increase in diameter for 
all NOR glucose conditions in comparison to the 0 h control (0 h: 12.86  
4.40 vs. NOR: 15.53  5.37 μm, p < 0.001, vs. NOR RES: 15.08  5.32 μm, 
p < 0.001, vs. NOR EX-527: 15.23  5.30 μm, p < 0.001). Whereas, in 
LOW glucose there was a significant decrease in diameter from the 0 h 
control across all conditions (0 h: 12.86  4.40 vs. LOW: 12.01  4.25 μm, 
p = 0.033 (fisher), vs. LOW RES: 11.79  4.32 μm, p = 0.007 (fisher), vs. 
LOW EX-527: 11.71  4.20 μm, p = 0.004 (fisher)). There were no 
significant differences observed at 72 h in low glucose conditions with 
Fig. A1.3. Myotube diameter is reduced in all LOW glucose conditions in comparison to the 0 h 
control whereas All NOR glucose conditions are significantly increased in comparison o the 0 h 
control. Repeated measures analysis carried out using 36 images per experimental condition 
provided significant values between the small changes observed between NOR and LOW 
glucose.  Significant difference (p < 0.05) is denoted using  *. 
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activation or inhibition of SIRT1 (All comparisons p > 0.05, Fig 6.3.).  
 
Significant interactions were present for myotube area again following a 72 
h incubation in comparison to a 0 h control: Timepoint x glucose 
concentration (F(1, 3723) = 51.43, p < 0.001), timepoint x SIRT1 
manipulation (F(2, 3723) = 4.28, p = 0.014), and SIRT1 manipulation x 
glucose (F(2, 3723) = 3.31, p = 0.037). Significant main effects were also 
observed for time (F(1, 3723) = 14.07, p < 0.001), glucose (F(1, 3723) = 55.86, p 
< 0.001) and SIRT1 manipulation (F(2, 3723) = 12.36, p < 0.001). Myotube 
area increased from 0 h in all NOR conditions (0 h: 2876  1628 vs. NOR: 
3785  2542 μm2, p < 0.001, vs. NOR RES: 4088  2728 μm2, p < 0.001, 
vs. NOR EX-527: 3433  2394 μm2, p < 0.001). However, there was no 
change from 0 h to 72 h in LOW glucose conditions (0 h: 2876  1628 vs. 
LOW: 2862  1947 μm2, p > 0.05 vs. LOW RES: 2816  2207 μm2 p = 
0.442, vs. LOW EX-527: 2643  1743 μm2, p = 0.250). At 72 h, although 
there were no increases in myotube size following RES administration in 
the LOW glucose condition, there was an increase with RES in NOR 
glucose (LOW vs. LOW RES: vs. 2816  2207 μm2, p > 0.05, NOR vs. 
NOR RES: 3785  2542 vs. 4088  2728 μm2, p = 0.052 (fisher)). 
Additionally, there was a reduction in myotube size with the addition of the 
SIRT1 inhibitor (EX-527) in NOR conditions; however this reduction was 
not observed in LOW glucose conditions at 72 h (NOR vs. NOR EX-527: 
3785  2542 vs. 3433  2394 μm2, p = 0.026 (fisher), LOW vs. LOW EX-
527: 2862  1947 vs. 2643  1743 μm2, p > 0.05, Fig. 6.4.).  
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Unlike SIRT1 activation via resveratrol administration improving 
differentiation at 7D in differentiating myoblasts, altering SIRT1 activity 
with resveratrol was unable to improve myotube survival/loss or myotube 
atrophy in low glucose conditions when administered to existing myotube 
cultures. Importantly however, SIRT1 inhibition (EX-527) reduced myotube 
number and myotube size and, SIRT1 activation via resveratrol increased 
myotube area in normal glucose conditions. As such we next wished to 
assess the impact on important regulators of late differentiation/ myotube 
maturation such as MRF4 and adult myosin heavy chains (MYHC) 1, 2, 4 
and 7 gene expression that would be involved laying contractile proteins 
for myotube maturation/hypertrophy. 
 
Fig. A1.4. Myotube area is increased in all NOR glucose conditions in comparison to 
the 0 h control. In NOR glucose RES increases whereas EX-527 decreased area. 
Significant difference (p < 0.05) is denoted using  *. 
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6.3.2. MRF4 was unchanged with resveratrol or SIRT1 inhibitor 
As with the morphological data the following gene expression analysis was 
carried out following a 72 h incubation. Following this 72 h incubation on 
existing myotubes there were no significant interactions for MRF4 in either 
of the previous myoblast studies in chapters 3 and 5. MRF4 is involved in 
late differentiation/early myotube maturation, as such in mature myotubes 
a significant interaction between glucose and time was observed (F(1, 36) = 
4.86, p = 0.034). There was also a significant main effect for glucose 
dosing (F(1, 36) = 4.86, p = 0.034), and time (F(1, 36) = 64.35, p < 0.001). All 
conditions were significantly reduced following 72 h compared to the 0 h 
control (0 h: 1.01 ± 0.19 vs. NOR: 0.48 ± 0.09, p = 0.006, vs. NOR RES: 
0.52 ± 0.10, p = 0.015, vs. NOR EX-527: 0.53 ± 0.09, p = 0.039, vs. LOW 
RES: 0.68 ± 0.20, p = 0.008 (fisher), vs. LOW EX-527: 0.68 ± 0.14, p = 
0.005 (fisher)). This was perhaps because myotubes were already formed 
for 7 days in the 0h control and the peak MRF4 expression occurred 
earlier in myotube formation vs. 72hrs (total 10 days in differentiation). 
This reduction in MRF4 at 72 h in all conditions was with the exception of 
LOW glucose alone, where this did not significantly drop vs. 0h (0 h vs. 
LOW: 1.01 ± 0.19 vs. 0.83 ± 0.22, p > 0.05). These data suggest a 
prolonged MRF4 expression in low glucose alone. There were no 
significant differences with the addition of either of the SIRT1 
activation/inhibition within LOW conditions at 72 h (LOW vs. LOW RES: 
0.83 ± 0.22 vs. 0.68 ± 0.20, p > 0.05, LOW vs. LOW EX-527: 0.83 ± 0.22 
vs. 0.68 ± 0.14, p > 0.05). No significance was observed under SIRT1 
manipulations in NOR glucose conditions either. This data reflected the 
previous observations in myoblast studies (NOR vs. NOR RES: 0.48 ± 
0.09 vs. 0.52 ± 0.10, p > 0.05, NOR vs. NOR EX-527: 0.48 ± 0.09 vs. 0.53 
± 0.09, p > 0.05). There was however, significantly delayed reductions in 
MRF4 in LOW vs. NOR conditions without the supplementation of RES or 
EX-527 in which no significance was observed (LOW vs. NOR: 0.83  
0.22 vs. 0.48  0.09, p = 0.007 (fisher), LOW RES vs. NOR RES: 0.68  
0.20 vs. 0.52  0.10, p > 0.05, LOW EX-527 vs. NOR EX-527: 0.68  0.14 
vs. 0.53  0.09, p > 0.05), again suggesting that perhaps LOW may be 
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attempting to improve their delayed impaired differentiation by keeping 
MRF4 expression higher than NOR conditions. However, RES/SIRT1 
inhibitor did not significantly improve MRF4 in low glucose conditions.  
 
 
 
Fig. A1.5. Graph depicting means and SD’s for gene expression for MRF4 at 72 h 
compared to the 0 h control. All experimental conditions where significantly reduced in 
comparison to the 0 h control except LOW glucose alone. Significant difference (p < 
0.05) is denoted using  *. 
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6.3.3. MYHC 7 expression is increased with SIRT1 activator 
resveratrol and MYHC 1,2,4 reduced with SIRT1 inhibitor EX-527 in 
normal glucose conditions.  
Significant main effects were observed for glucose dosing (F(1, 35) = 60.28, 
p < 0.001), SIRT1 manipulation (F(2, 35) = 4.39, p = 0.020) and time (F(1, 35) 
= 69.24, p < 0.001) for MYHC7 gene expression. Significant interactions 
were also present between time and both glucose (F(1, 35) = 60.28, p < 
0.001) and SIRT1 manipulation (F(2, 35) = 4.39, p = 0.020). The 
manipulation of SIRT1 did not significantly affect the LOW glucose 
conditions (LOW vs. LOW RES: 1.04 ± 0.22 vs. 1.29 ± 0.49, p > 0.05, 
LOW vs. LOW EX-527: 1.04 ± EX-527 0.22 vs. 1.39 ± 0.84, p > 0.05). 
Although there was an average reduction, there was no significant effect 
on MYHC7 expression in the NOR condition upon the administration of 
EX-527 (3.08 ± 0.81 vs. 2.52 ± 0.66, p > 0.05). There was however, a 
significant increase in MYCH7 expression following the addition of SIRT 
activator, RES in NOR conditions (3.08 ± 0.81 vs. 4.20 ± 0.82, p = 0.002 
(fisher)).  
 
  
204 
 
For MYHC2 gene expression, a significant main effect was present for 
time (F(1, 29) = 10.32, p = 0.003) and glucose concentration (F(1, 29) = 
156.49, p < 0.001). There was also a significant interaction between time x 
glucose concentration (F(1, 29) = 156.49, p < 0.001). As with MYHC1 there 
was no significant difference found following SIRT1 manipulation in the 
LOW glucose conditions (LOW vs. LOW RES: 0.37 ± 0.05 vs. 0.32 ± 0.11, 
p > 0.05, LOW vs. LOW EX-527: 0.37 ± 0.05 vs. 0.71 ± 0.83, p > 0.05). In 
the NOR condition RES did not affect MYHC2 expression (NOR vs. NOR 
Fig. A1.6. Graph depicting means and SD’s for gene expression for MYHC7 at 72 h 
compared to the 0 h control. RES significantly increased MYHC7 expression in NOR 
conditions. Significant difference (p < 0.05) is denoted using  *. 
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RES: 1.86 ± 0.41 vs. 1.89 ± 0.34, p > 0.05). In the NOR glucose conditions, 
the SIRT1 inhibitor EX-527 significantly reduced MYHC2 expression (NOR 
vs. NOR EX-527: 1.86 ± 0.41 vs. 1.55 ± 0.08, p = 0.034 (fisher)). 
 
MYHC4 displayed a significant main effect for glucose concentration (F(1, 
35) = 25.91, p < 0.001), time (F(1, 35) = 19.98, p < 0.001) as well as a 
significant interaction between glucose concentration and time (F(1, 35) = 
25.91, p < 0.001). In NOR glucose conditions, expression of MYHC4 was 
Fig. A1.7. Graph depicting means and SD’s for gene expression for MYHC2 at 72 h 
compared to the 0 h control. NOR glucose was significantly increased in comparison 
to NOR EX-527. Significant difference (p < 0.05) is denoted using  *. 
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significantly increased following 72 h in comparison to LOW glucose 
conditions (4.52 ± 2.83 vs. 0.92 ± 0.35, p = 0.011). SIRT1 
activation/inhibition had no effect on MYHC4 expression in LOW glucose 
conditions (LOW vs. LOW RES: 0.92 ± 0.35 vs. 0.60 ± 0.22, p > 0.05, 
LOW vs. LOW EX-527: 0.92 ± 0.35 vs. 2.02 ± 2.50, p > 0.05). There were 
also no significant differences following RES administration in NOR 
glucose conditions (NOR vs. NOR RES: 4.52 ± 2.83 vs. 5.95 ± 2.80, p > 
0.05). Again, as with MYHC2, there was a reduction in MYHC4 expression 
following SIRT1 inhibition via EX-527 administration (NOR vs. NOR EX-
527: 4.52 ± 2.83 vs. 2.72 ± 0.74, p = 0.058 (fisher)).  
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Similar to myoblast studies, MYHC1 displayed significant interactions 
between glucose concentration and time (F(1, 35) = 23.83, p < 0.001). There 
was also an individual main effects for glucose (F(1, 35) = 23.83, p < 0.001) 
and time (F(1, 35) = 23.09, p < 0.001). MYHC1 expression was significantly 
increased in NOR in comparison to LOW glucose conditions (3.39 ± 1.38 
vs. 1.20 ± 0.30, p = 0.007). There was however, no significant difference 
following the administration of RES in either NOR (NOR vs. NOR RES: 
3.39 ± 1.38 vs. 3.61 ± 1.61, p = 1.000) or LOW glucose conditions (LOW 
vs. LOW RES: 1.20 ± 0.30 vs. 1.05 ± 0.35, p > 0.05). There was also no 
significant difference following EX-527 administration in LOW glucose 
(LOW vs. LOW EX-527: 1.20 ± 0.30 vs. 1.63 ± 0.14, p > 0.05) or NOR 
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Fig. A1.8. Graph depicting means and SD’s for gene expression for MYHC4 at 72 h 
compared to the 0 h control. EX-527 reduced MYHC4 expression in NOR conditions. 
Significant difference (p < 0.05) is denoted using  *. 
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glucose, (NOR vs. NOR EX-527: 3.39 ± 1.38 vs. 2.26 ± 0.69, p = 0.094 
(fisher)), however there was a trend that was approaching significance.  
 
 
Overall, the inhibition (EX-527) of SIRT1 reduced myotube number and 
myotube size, The activation of SIRT1 via RES increased myotube area in 
normal glucose conditions. These findings corresponded with reductions in 
IIx, IIa, IIb coding MYHC isoforms (1,2,4 respectively) following SIRT1 
Fig. A1.9. Graph depicting means and SD’s for gene expression for MYHC1 at 72 h 
compared to the 0 h control. EX-527 significantly reduced MYHC1 expression in NOR 
conditions even when RES was supplemented. Significant difference (p < 0.05) is 
denoted using  *. 
 
NOR LOW LOW RES LOW EX-527 NOR NOR RES NOR EX-527
0
2
4
6
M
Y
H
C
1
 Δ
Δ
C
T
 e
x
p
re
s
s
io
n
 v
a
lu
e
0 h 72 h
*
*
*
  
209 
inhibition and increases in slow isoform coding MHYC7 gene expression 
with SIRT1 activation. Suggesting that changes in SIRT1 activity mediates 
gene expression of these important genes coding for increasing contractile 
protein isoforms. There are also associated with increased myotube 
maturation and hypertrophy observed in normal glucose conditions in the 
presence of SIRT1 activator, RES. However, SIRT1 activation had little 
effect on myotubes in low glucose conditions at this timepoint (72 h). 
 
Because of this interesting finding, we then wished to investigate some of 
the other important gene regulatory targets of altered SIRT1 activity 
following the same 72 h timepoint. Including genes associated with 
myotube growth/hypertrophy (IGF-I, IGF-IR, IGF-II, IGF-IIR, IGFBP2, 
mTOR) and myotube atrophy (TNF-, MuRF, MAFbx, MUSA1, p53, 
GADD45a and b, FOXO1 and 3, NF-kB), as well as SIRT1 gene 
expression. 
 
6.3.4. Myotube growth/hypertrophy 
Increased IGF-I has previously been observed with advancing 
differentiation and myotube hypertrophy in-vitro (Sharples et al., 2010, 
Sharples et al., 2011). This group has shown that a reduction in calories 
has been shown to reduce IGF-I expression (Sharples et al., 2015). The 
manipulation of SIRT1 during glucose restriction in mature myotubes 
displayed a significant interaction for glucose x time (F(2, 29) = 233.98, p < 
0.001) as well as a significant main effect for glucose alone (F(2, 29) = 
233.98, p < 0.001). Under all NOR glucose conditions there was an 
increase in IGF-I expression over time from 0 h to 72 h (0 h: 1.03 ± 0.01 vs. 
NOR: 1.61 ± 0.40, p = 0.024, vs. NOR RES: 2.12 ± 0.20, p < 0.001, vs. 
NOR EX-527: 1.79 ± 0.45, p = 0.002), whereas from 0 to 72 h LOW 
glucose decreased IGF-I expression in all conditions (0 h: 1.03 ± 0.01 vs. 
LOW: 0.05 ± 0.01, p < 0.001, vs. LOW RES: 0.05 ± 0.01, p < 0.001, 0 h vs. 
LOW EX-527: 0.46  0.01 p < 0.001). This resulted in gene expression for 
IGF-I being significantly lower in LOW versus NOR glucose conditions 
(LOW vs. NOR: 0.05 ± 0.01 vs. 1.61 ± 0.40, p < 0.001). SIRT1 inhibitor 
  
210 
EX-527 did not affect IGF-I under NOR (NOR vs. NOR EX-527: 1.61 ± 
0.40 vs. 1.79 ± 0.45, p > 0.05) or LOW conditions (LOW vs. LOW EX-527: 
0.05 ± 0.01 vs. 0.46 ± 0.01, p > 0.05). RES conditions significantly 
increase IGF-I expression in NOR (NOR vs. NOR RES: 1.61 ± 0.40 vs. 
2.12 ± 0.20, p < 0.033) conditions but not in LOW (LOW vs. LOW RES: 
0.05 ± 0.01 vs. 0.05 ± 0.01, p > 0.05 (Fig 5.9.)).  
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Fig. A1.10. Graph depicting means and SD’s for gene expression for IGF-I at 72 h 
compared to the 0 h control. RES significantly increased IGF-I expression in NOR 
conditions following RES administration. Significant difference (p < 0.05) is denoted 
using a *. 
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A significant interaction was present for IGF-IR gene expression between 
time, SIRT1 manipulation (F(2, 36) = 4.79, p = 0.014) and glucose 
concentration (F(1, 36) = 76.60, p < 0.001). Time (F(1, 36) = 73.40, p < 0.001), 
SIRT1 manipulation (F(2, 36) = 4.79, p = 0.014) and glucose concentration 
(F(1, 36) = 76.60, p < 0.001) were also significant main effects. All LOW 
glucose conditions at 72 h were significantly reduced IGF-IR expression in 
comparison to 0 h (0 h: 1.15 ± 0.04 vs. LOW: 0.74 ± 0.05, p < 0.001, vs. 
LOW RES: 0.66 ± 0.05, p < 0.001, vs. LOW EX-527: 0.79 ± 0.16, p < 
0.001 (Fig. 6.11)). NOR glucose remained unchanged overtime from 0 h to 
72 hrs (0 h vs. NOR: 1.15 ± 0.04 vs. 1.11 ± 0.13, p > 0.05), as did NOR 
RES (0 h vs. NOR RES: 1.15 ± 0.04 vs. 1.05 ± 0.05, p > 0.05). At 72 h In 
NOR glucose conditions supplemented with SIRT1 inhibitor, EX-527 
significantly increased IGF-IR expression in comparison to 0 h (0 h vs. 
NOR EX-527: 1.15 ± 0.04 vs. 1.29 ± 0.11, p = 0.034 (fisher)). NOR EX-
527 was also increased in comparison to NOR alone at 72 h (NOR vs. 
NOR EX-527: 1.11 ± 0.13 vs. 1.29 ± 0.11, p = 0.010 (fisher)). No other 
significant differences were detected in either glucose condition following 
the activation/inhibition of SIRT1 at 72 h (LOW vs. LOW RES: 0.74 ± 0.05 
vs. 0.66 ± 0.05, p > 0.05, LOW vs. LOW EX-527: 0.74 ± 0.05 vs. 0.79 ± 
0.16, p > 0.05, NOR vs. NOR EX-527: 1.11 ± 0.13 vs. 1.29 ± 0.11, p = 
0.667).  
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There was no significant interaction or main effect present for IGF-II 
expression. There was also no significant differences observed following 
post hoc tests (Fig. 6.12).  
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Fig. A1.12. Graph depicting means and SD’s for gene expression for IGF-II at 72 h 
compared to the 0 h control, in which no significant differences were observed. 
Significant difference (p < 0.05) is denoted using  *. 
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Fig. A1.11. Graph depicting means and SD’s for gene expression for IGF-IR at 72 h 
compared to the 0 h control. LOW conditions all displayed a reduced expression of 
IGF-IR following 72 h. No significant difference was observed from the control 
condition in NOR glucose until EX-527 was supplemented. Significant difference (p < 
0.05) is denoted using a *. 
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IGF-IIR had a significant main effect for glucose (F(1, 35) = 8.22, p = 0.007) 
and time point (F(1, 35) = 87.10, p < 0.001) and a significant interaction 
between the two (F(1, 35) = 8.22, p = 0.007). The two glucose conditions did 
not express significantly different IGF-IIR expression values at 72 h (LOW 
vs. NOR: 0.86 ± 0.09 vs. 0.79 ± 0.04, p = 1.000). All experimental 
conditions significantly reduced IGF-IIR expression compared to the 0 h 
control (0 h: 1.00 ± 0.05 vs. NOR: 0.79 ± 0.04, p  = 0.005, vs. NOR RES: 
0.78 ± 0.09, p = 0.003, vs. NOR EX-527: 0.72 ± 0.10, p < 0.001, vs. LOW: 
0.86 ± 0.09, p = 0.004 (fisher), vs. LOW EX-527: 0.86 ± 0.11, p < 0.001) 
except LOW glucose with RES supplementation at 72 h that was 
maintained at a similar level to 0 h control (0 h vs. LOW RES: 1.00 ± 0.05 
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vs. 0.95 ± 0.11, p = 1.000). As a result, at 72 h gene expression of IGF-IIR 
with RES administration under LOW conditions was higher than LOW 
alone (LOW vs. LOW RES: 0.86 ± 0.09 vs. 0.95 ± 0.11, p = 0.054 (fisher)). 
 
 
A significant interaction between glucose concentration and time was 
present for IGFBP2 gene expression (F(1, 24) = 2.12, p < 0.001) in addition 
to significant main effects for time and glucose concentration respectively 
(F(1, 24) = 2.12, p < 0.001), (F(1, 24) = 11.01, p = 0.003). IGFBP2 gene 
Fig. A1.13. Graph depicting means and SD’s for gene expression for IGF-IIR at 72 h 
compared to the 0 h control. RES significantly increased IGF-IIR in LOW conditions. 
Significant difference (p < 0.05) is denoted using  *. 
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expression in all NOR glucose conditions with or without supplementation 
or SIRT1 activator or inhibitor at 72 h is similar to 0 h control (0 h: 1.21 ± 
0.00 vs. NOR: 1.20 ± 0.55, p = 1.000, vs. NOR RES: 1.37 ± 0.27, p = 
1.000, vs. NOR EX-527: 1.65 ± 0.45, p = 1.000). LOW glucose on the 
other hand, significantly reduced IGFBP2 expression at 72 h in 
comparison to 0 h (0 h: 1.21 ± 0.00 vs. LOW: 0.44 ± 0.12, p = 0.003 
(fisher), vs. LOW RES: 0.22 ± 0.03, p = 0.022, vs. LOW EX-527: 0.46 ± 
0.25, p = 0.003 (fisher)). As such there was a significant difference 
between NOR and LOW glucose at 72 h (NOR vs. LOW: 1.20 ± 0.55 vs. 
0.44 ± 0.12, p = 0.042), as previously observed in myoblast studies in 
chapter 5. SIRT1 activation via RES supplementation did not affect either 
glucose concentration significantly at 72 h (NOR vs. NOR RES: 1.20 ± 
0.55 vs. 1.37 ± 0.27, p = 1.000, LOW vs. LOW RES: 0.44 ± 0.12 vs. 0.22 ± 
0.03, p = 1.000). SIRT1 inhibition via EX-527 administration increased 
IGFBP2 expression in NOR (NOR vs. NOR EX-527: 1.20 ± 0.55 vs. 1.65 ± 
0.45, p = 0.043 (fisher)) but not LOW glucose concentrations at 72 h (LOW 
vs. LOW EX-527: 0.44 ± 0.12 vs. 0.46 ± 0.25, p = 1.000).  
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There was no significant interaction or main effect for any of the variables 
analysed for mTOR expression. Additionally, there were no significant 
individual differences present between any experimental conditions 
following pairwise comparison analysis.  
 
Fig. A1.14. Graph depicting means and SD’s for gene expression for IGF-BP2 at 72 h 
compared to the 0 h control. LOW glucose conditions displayed a reduced expression 
of IGFBP2 after 72 h  whereas NOR conditions did not in fact EX-527 further 
increased IGFBP2 levels from the 0h control. Significant difference (p < 0.05) is 
denoted using a *. 
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With respect to genes associated with myotube growth, where there were 
increased number of myotubes and myotube hypertrophy with RES 
administration in normal glucose conditions there were corresponding 
increases in IGF-I but not IGF-IR, IGF-II, IGF-IIR. There were reductions in 
IGFBP2 (a known inhibitor of differentiation when at high levels (Sharples 
et al., 2013)) with RES in LOW glucose conditions and increases with 
SIRT1 inhibitor EX-527 in normal glucose conditions. The reductions in 
myotube size associated with SIRT1 inhibition corresponded with 
increased in IGFBP2 expression in normal glucose a known inhibitor of 
differentiation in myoblasts. Therefore, these changes in IGFBP2 may 
Fig. A1.15. Graph depicting means and SD’s for gene expression for mTOR at 72 h 
compared to the 0 h control. mTOR remained unchanged following 72 h 
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have been important in the myotube atrophy seen in normal glucose with 
SIRT1 inhibition, however, as yet there is an undefined role for IGFBP2 in 
myotubes. Somewhat, paradoxically SIRT1 inhibition increased IGF-IR 
expression perhaps as a compensatory drive, albeit unsuccessful in 
rescuing growth observed morphologically. In low glucose conditions, 
although no improvements in myotube growth were observed at 72 h with 
RES administration, RES was able to somewhat maintain normal IGF-IIR 
expression at 72 h. 
 
6.3.5. Genes associated with myotube atrophy and protein 
degradation: 
TNF-α displayed a significant main effect for time (F(1, 36) = 5.81, p = 0.021). 
There were however, no significant differences in TNF-α expression with 
SIRT1 manipulation.  
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TNFRSF1β (TNF-alpha soluble receptor) gene expression analysis revealed 
both a significant interaction (F(1, 35) = 92.48, p <0.001) and significant 
main effects were for glucose concentration (F(1, 35) = 92.48, p <0.001) and 
time (F(1, 35) = 4.30, p = 0.046). All LOW glucose conditions at 72 h where 
significantly increased in comparison to the 0 h control (0 h: 1.00 ± 0.13 vs. 
LOW: 0.56 ± 0.08, p < 0.001, vs. LOW RES: 0.65 ± 0.08, p = 0.009, vs. 
LOW EX-527: 0.73 ± 0.30, p = 0.001). Both NOR alone and NOR RES 
where significantly lower than the 0 h control (0 h: 1.00 ± 0.13 vs. NOR: 
1.32 ± 0.04, p = 0.039, vs. NOR RES: 1.33 ± 0.16, p = 0.023). The only 
condition that was not significant in comparison to the 0 h control was 
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Fig. A1.16. Graph depicting means and SD’s for gene expression for TNF-α at 72 h 
compared to the 0 h control. No experimental control elicited a change in TNF-
α.Significant difference (p < 0.05) is denoted using  *. 
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NOR glucose supplemented with SIRT1 inhibitor, EX-527 at 72 h (0 h vs. 
NOR EX-527: 1.00 ± 0.13 vs. 1.14 ± 0.16, p = 1.000). As a result, NOR 
glucose conditions with SIRT 1 inhibitor, EX-527 had a significantly lower 
expression than NOR RES at 72 h (NOR EX-527 vs. NOR RES: 1.14 ± 
0.16 vs. 1.33 ± 0.16, p = 0.039 (fisher)) and versus NOR glucose alone at 
72 h (NOR vs. NOR EX-527: 1.32 ± 0.04 vs. 1.14 ± 0.16, p = 0.055 
(fisher)). No significance was present between the three LOW conditions 
at 72 h (LOW vs. LOW RES: 0.56 ± 0.08 vs. 0.65 ± 0.08, p = 1.000, LOW 
vs. LOW EX-527: 0.56 ± 0.08 vs. 0.73 ± 0.30, p = 1.000).  
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Fig. A1.17. Graph depicting means and SD’s for gene expression for TNFRSF1β at 
72 h compared to the 0 h control. A change over time was observed for TNFRSF1β, in 
addition to decreases in NOR following both RES and EX-527 supplementation. 
Significant difference (p < 0.05) is denoted using  *. p values approaching significance 
are displayed. 
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There was a significant main effect for time for myostatin gene expression 
(F(1,28) = 19.43, p < 0.001). NOR glucose alone and with the addition of 
EX-527 at 72 h were not significantly changed in comparison to the 0 h 
baseline control (0 h: 0.71 ± 0.17 vs. NOR: 1.27 ± 0.65, p = 1.000, vs. 
NOR EX-527: 1.58 ± 0.49, p = 1.000). Myostatin expression under NOR 
conditions with the addition of RES was significantly increased in 
comparison the 0 h control (0 h vs. NOR RES: 0.71 ± 0.17 vs. 1.99 ± 0.81, 
p = 0.007 (fisher)). This condition was also significantly increased in 
comparison to NOR glucose alone at 72 h alone (NOR vs. NOR RES: 1.27 
± 0.65 vs. 1.99 ± 0.81, p = 0.027(fisher)). Under LOW conditions alone 
there was a significant increase in myostatin expression over time (0 h vs. 
LOW: 0.71 ± 0.17 vs. 2.12 ± 1.33, p = 0.004 (fisher)). Despite no 
improvement in myotube number or size with RES addition in LOW 
glucose conditions, at 72 h in the addition of RES to LOW glucose 
significantly reduced the gene expression of the negative muscle mass 
regulator, myostatin (LOW vs. LOW RES: 2.12 ± 1.33 vs. 1.41 ± 0.70, p = 
0.024 (fisher)). 
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6.3.6. Ubiquitin Ligases: MAFbx, MuRF1 and MUSA1  
As discussed in the previous chapter (5) both muscle ring finger1 (MuRF1) 
and muscle atrophy F-box (MAFbx) and muscle ubiquitin ligase of SCF 
complex in atrophy 1 (MUSA1) have been identified as important 
regulators of skeletal muscle atrophy (Bodine and Baehr, 2014). There 
was a main significant effect for time for MuRF1 (F(1, 36) = 39.60, p < 0.001). 
There was a decrease over time in MuRF1 from 0 to 72 h in both the NOR 
and LOW glucose conditions (0 h: 1.03 ± 0.30 vs. NOR: 0.63 ± 0.20, p = 
0.011, vs. NOR RES: 0.72  0.17, p = 0.070 vs. NOR EX-527: 0.57  0.01, 
p = 0.016 vs. LOW: 0.58 ± 0.11, p = 0.022, vs. LOW RES: 0.47  0.10, p = 
0.002, vs. LOW EX-527: 0.61  0.17, p = 0.012 (all significance was 
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Fig. A1.18. Graph depicting means and SD’s for gene expression for myostatin at 72 
h compared to the 0 h control. RES decreased myostatin in LOW and increased in 
NOR. Significant difference (p < 0.05) is denoted using *. 
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observed following fisher comparisons, Fig 6.10.). However, there was no 
significant difference between these two conditions at 72 h (LOW vs. NOR: 
0.58 ± 0.11 vs. 0.63 ± 0.20, p = 1.000). Additionally, there were no 
significance differences present at 72 h when SIRT1 was activated or 
inhibited in either of the two glucose conditions investigated.  
 
Similarly to MuRF1, MAFbx also displayed a significant main effect for 
time (F(1, 35) = 34.05, p < 0.001). Compared to 0 h there was no significant 
reduction present when the glucose concentration was reduced at the 72 h 
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Fig. A1.19. Graph depicting means and SD’s for gene expression for MuRF1 at 72 h 
compared to the 0 h control, in which the 0 h control possessed a higher gene 
expresseion than all other experiemental conditions. Significant difference (p < 0.05) is 
denoted using *. 
 
Significant difference (p < 0.05) is denoted using a *. 
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(LOW vs. 0 h: 0.92 ± 0.20 vs. 1.01 ± 0.19, p = 1.000, Fig. 6.20). Under 
NOR conditions there was a significant reduction in MAFbx compared to 0 
h (0 h vs. NOR: 1.01 ± 0.19 vs. 0.69 ± 0.06, p = 0.006 (fisher)). 
Additionally, at 72 h there was a significant increase present in LOW vs. 
NOR glucose conditions (NOR vs. LOW: 0.69 ± 0.06 vs. 0.92 ± 0.20, p = 
0.044 (fisher)). The addition of RES or EX-527 had no effect on the NOR 
glucose conditions (NOR vs. NOR RES: 0.69 ± 0.06 vs. 0.72 ± 0.07, p = 
1.000, NOR vs. NOR EX-527: 0.69 ± 0.06 vs. 0.70 ± 0.02, p = 1.000). EX-
527 also had no effect on MAFbx gene expression in the LOW glucose 
conditions at 72 h (LOW vs. LOW EX-527: 0.92 ± 0.20 vs. 0.81 ± 0.13, p = 
1.000). There was however an average reduction in MuRF1 when RES 
was administered to LOW glucose condition (LOW vs. LOW RES: 0.92 ± 
0.20 vs. 0.71 ± 0.08, p = 0.064 (fisher)), despite no increase in myotube 
number or area in this condition.  
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MUSA1 increases in expression following denervation induced muscle 
atrophy where knockdown can attenuate the loss of muscle mass (Milan et 
al., 2015). A significant main effect was present for glucose (F(2, 35) = 9.13, 
p = 0.005) and time (F(1, 35) = 21.79, p < 0.001), as well as a significant 
interaction between these factors (F(2, 35) = 9.13, p = 0.005). In low glucose 
conditions LOW glucose expression of MUSA1 was significantly higher 
than the NOR glucose condition (LOW vs. NOR: 1.09 ± 0.16 vs. 0.74 ± 
0.05, p = 0.013). NOR glucose remains unchanged when SIRT1 was 
activated or inhibited (NOR vs. NOR RES: 0.74 ± 0.05 vs. 0.71 ± 0.10, p = 
1.000, NOR vs. NOR EX-527: 0.74 ± 0.05 vs. 0.74 ± 0.03, p = 1.000). The 
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Fig. A1.20. Graph depicting means and SD’s for gene expression for Mafbx at 72 h 
compared to the 0 h control. LOW glucose produced significantly higher expression of 
Mafbx in comparison to NOR, this was reduced following RES supplementation. 
Significant difference (p < 0.05) is denoted using a *. p values approaching 
significance are displayed. 
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increase in MUSA1 expression experienced under LOW glucose 
conditions alone was reduced following treatment with RES (LOW vs. 
LOW RES: 1.09 ± 0.16 vs. 0.77 ± 0.21, p = 0.023 (fisher)). However, these 
reductions were also observed with the SIRT1 Inhibitor, EX-527 (LOW vs. 
LOW EX-527: 1.09 ± 0.16 vs. 0.86 ± 0.28, p = 0.006 (fisher)).  
 
Fig. A1.21. Graph depicting means and SD’s for gene expression for MUSA1 at 72 h 
compared to the 0 h control. Decreases in LOW glucose following both RES and EX-
527 supplementation. Significant difference (p < 0.05) is denoted using  *. 
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SIRT1 expression did not possess any significant main or interactional 
effects. Unlike myoblasts studies (where there were increases in SIRT1 in 
low glucose conditions) but there were no significant pairwise comparisons 
between any experimental conditions for SIRT1 gene expression (Figure 
6.22). 
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Fig. A1.22. Graph depicting means and SD’s for gene expression forSIRT1 at 72 h 
compared to the 0 h control, in which no significant difference was observed.  
 
 
